<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD000219.pub4" GROUP_ID="ARI" ID="144599081614131606" MERGED_FROM="" MODIFIED="2015-06-22 23:12:40 +0100" MODIFIED_BY="Liz Dooley" REVIEW_NO="A010" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="17.0">
<COVER_SHEET MODIFIED="2015-06-22 23:12:40 +0100" MODIFIED_BY="Liz Dooley">
<TITLE MODIFIED="2012-11-23 15:21:49 +1000" MODIFIED_BY="Liz Dooley">Antibiotics for acute otitis media in children</TITLE>
<CONTACT MODIFIED="2015-06-22 23:12:40 +0100" MODIFIED_BY="Liz Dooley"><PERSON ID="12462205442426823266100401013025" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Roderick</FIRST_NAME><MIDDLE_INITIALS>P</MIDDLE_INITIALS><LAST_NAME>Venekamp</LAST_NAME><SUFFIX>MD, PhD</SUFFIX><POSITION>Postdoctoral Researcher</POSITION><EMAIL_1>R.P.Venekamp@umcutrecht.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of Otorhinolaryngology &amp; Julius Center for Health Sciences and Primary Care</DEPARTMENT><ORGANISATION>University Medical Center Utrecht</ORGANISATION><ADDRESS_1>Heidelberglaan 100</ADDRESS_1><CITY>Utrecht</CITY><ZIP>3508 GA</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 6 1336 3481</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2015-06-22 23:12:40 +0100" MODIFIED_BY="Liz Dooley"><PERSON ID="12462205442426823266100401013025" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Roderick</FIRST_NAME><MIDDLE_INITIALS>P</MIDDLE_INITIALS><LAST_NAME>Venekamp</LAST_NAME><SUFFIX>MD, PhD</SUFFIX><POSITION>Postdoctoral Researcher</POSITION><EMAIL_1>R.P.Venekamp@umcutrecht.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of Otorhinolaryngology &amp; Julius Center for Health Sciences and Primary Care</DEPARTMENT><ORGANISATION>University Medical Center Utrecht</ORGANISATION><ADDRESS_1>Heidelberglaan 100</ADDRESS_1><CITY>Utrecht</CITY><ZIP>3508 GA</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 6 1336 3481</PHONE_1></ADDRESS></PERSON><PERSON ID="z1501190037585896094087801756936" ROLE="AUTHOR"><FIRST_NAME>Sharon</FIRST_NAME><MIDDLE_INITIALS>L</MIDDLE_INITIALS><LAST_NAME>Sanders</LAST_NAME><EMAIL_1>ssanders@bond.edu.au</EMAIL_1><EMAIL_2>ssanders@bond.edu.au</EMAIL_2><ADDRESS><DEPARTMENT>Centre for Research in Evidence-Based Practice (CREBP)</DEPARTMENT><ORGANISATION>Bond University</ORGANISATION><ADDRESS_1>University Drive</ADDRESS_1><ADDRESS_2>Robina</ADDRESS_2><CITY>Gold Coast</CITY><ZIP>4229</ZIP><REGION>Queensland</REGION><COUNTRY CODE="AU">Australia</COUNTRY></ADDRESS></PERSON><PERSON ID="4655" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Paul</FIRST_NAME><MIDDLE_INITIALS>P</MIDDLE_INITIALS><LAST_NAME>Glasziou</LAST_NAME><POSITION>Professor</POSITION><EMAIL_1>pglaszio@bond.edu.au</EMAIL_1><ADDRESS><DEPARTMENT>Centre for Research in Evidence-Based Practice (CREBP)</DEPARTMENT><ORGANISATION>Bond University</ORGANISATION><ADDRESS_1>University Drive</ADDRESS_1><CITY>Gold Coast</CITY><ZIP>4229</ZIP><REGION>Queensland</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 7 5595 4482</PHONE_1><FAX_1>+61 7 5595 1652</FAX_1></ADDRESS></PERSON><PERSON ID="12249" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Chris</FIRST_NAME><MIDDLE_INITIALS>B</MIDDLE_INITIALS><LAST_NAME>Del Mar</LAST_NAME><SUFFIX>MA MB BChir MD FRACGP FAFPHM</SUFFIX><POSITION>Professor</POSITION><EMAIL_1>cdelmar@bond.edu.au</EMAIL_1><URL>http://ari.cochrane.org</URL><MOBILE_PHONE>+61 403 220080</MOBILE_PHONE><ADDRESS><DEPARTMENT>Centre for Research in Evidence-Based Practice (CREBP)</DEPARTMENT><ORGANISATION>Bond University</ORGANISATION><ADDRESS_1>University Drive</ADDRESS_1><CITY>Gold Coast</CITY><ZIP>4229</ZIP><REGION>Queensland</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 7 5595 2504</PHONE_1><FAX_1>+61 7 5595 1652</FAX_1><FAX_2>+61 7 5595 1271</FAX_2></ADDRESS></PERSON><PERSON ID="11975" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Maroeska</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Rovers</LAST_NAME><POSITION>Epidemiologist</POSITION><EMAIL_1>Maroeska.Rovers@radboudumc.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of Operating Rooms</DEPARTMENT><ORGANISATION>Radboud University Nijmegen Medical Centre</ORGANISATION><ADDRESS_1>Hp 630, route 631</ADDRESS_1><ADDRESS_2>PO Box 9101</ADDRESS_2><CITY>Nijmegen</CITY><ZIP>6500 HB</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2015-05-11 20:41:44 +1000" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="26" MONTH="4" YEAR="2015"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="26" MONTH="4" YEAR="2015"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="26" MONTH="4" YEAR="2017"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="1995"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="1996"/>
<LAST_CITATION_ISSUE ISSUE="6" YEAR="2015"/>
</DATES>
<WHATS_NEW MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2015-05-11 20:42:01 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="26" MONTH="4" YEAR="2015"/>
<DESCRIPTION>
<P>The conclusions regarding the effectiveness and safety of antibiotics have essentially not changed, except for some new outcomes (e.g. long-term effects on AOM recurrences) and minor changes to the risk of bias.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="26" MONTH="4" YEAR="2015"/>
<DESCRIPTION>
<P>We updated the searches in April 2015.</P>
<P>In this updated review, we now provide outcome data on:</P>
<UL>
<LI>pain at 24 hours, two to three days, four to seven days and 10 to 14 days (in earlier versions outcome data on pain were presented at 24 hours, two to three days and four to seven days);</LI>
<LI>abnormal tympanometry findings at two to four weeks, six to eight weeks and three months (in earlier versions outcome data on abnormal tympanometry findings were presented at four to six weeks and three months);</LI>
<LI>long-term effects including number of parent-reported AOM-symptom episodes, antibiotic prescriptions, health care utilisation as assessed at least one year after randomisation (in earlier versions no data on long-term effects were presented).</LI>
</UL>
<P>The outcome 'Adverse effects likely to be related to the use of antibiotics such as vomiting, diarrhoea or rash' has been added to primary outcomes (in earlier versions this outcome was listed as a secondary outcome) according to the recommendations described in Chapter 5.4.2 of the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>("the primary outcomes should include at least one desirable and at least one undesirable outcome") (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
<P>One new trial was identified for the review of antibiotics against placebo (<LINK REF="STD-Tapiainen-2014" TYPE="STUDY">Tapiainen 2014</LINK>). This study included children aged between six months and 15 years and provided data on pain at days four to seven, adverse effects likely to be related to the use of antibiotics, abnormal tympanometry findings at two to four weeks and six to eight weeks, tympanic membrane perforation and serious complications.</P>
<P>New data were added to the review from previously included trials.</P>
<P>For the review of antibiotics against placebo:</P>
<UL>
<LI>data on pain at 10 to 12 days (<LINK REF="STD-Hoberman-2011" TYPE="STUDY">Hoberman 2011</LINK>);</LI>
<LI>data on abnormal tympanometry findings at two to four weeks (<LINK REF="STD-Kaleida-1991" TYPE="STUDY">Kaleida 1991</LINK>);</LI>
<LI>data on long-term effects (<LINK REF="STD-Burke-1991" TYPE="STUDY">Burke 1991</LINK>; <LINK REF="STD-Damoiseaux-2000" TYPE="STUDY">Damoiseaux 2000</LINK>).</LI>
</UL>
<P>For the review of immediate antibiotics against expectant observation:</P>
<UL>
<LI>data on pain at 11 to 14 days (<LINK REF="STD-Spiro-2006" TYPE="STUDY">Spiro 2006</LINK>);</LI>
<LI>data on abnormal tympanometry findings at two to four weeks (<LINK REF="STD-McCormick-2005" TYPE="STUDY">McCormick 2005</LINK>);</LI>
<LI>data on long-term effects (<LINK REF="STD-Little-2001" TYPE="STUDY">Little 2001</LINK>).</LI>
</UL>
<P>We identified one ongoing trial (<LINK REF="STD-ACTRN12608000424303" TYPE="STUDY">ACTRN12608000424303</LINK>). The objective of this double-blind, placebo-controlled randomised clinical trial is to assess the effectiveness of azithromycin for seven days in aboriginal children with asymptomatic AOM, defined as a bulging tympanic membrane without associated symptoms at the time of diagnosis. The primary outcome is the proportion of children with a bulging tympanic membrane or ear discharge or withdrawn due to complications or side effects at 14 days.</P>
<P>Quality of evidence is now described based on the GRADE framework.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2015-06-19 18:58:24 +1000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="8" MONTH="11" YEAR="2012"/>
<DESCRIPTION>
<P>A new review author joined the team to update this review. We updated the searches in November 2012. Two new trials were identified for the review of antibiotics against placebo (<LINK REF="STD-Hoberman-2011" TYPE="STUDY">Hoberman 2011</LINK>; <LINK REF="STD-T_x00e4_htinen-2011" TYPE="STUDY">Tähtinen 2011</LINK>). These studies included children &lt; 35 months of age and provided data on pain (<LINK REF="STD-T_x00e4_htinen-2011" TYPE="STUDY">Tähtinen 2011</LINK>), contralateral otitis, late recurrences (<LINK REF="STD-Hoberman-2011" TYPE="STUDY">Hoberman 2011</LINK>), perforation and adverse events (<LINK REF="STD-Hoberman-2011" TYPE="STUDY">Hoberman 2011</LINK>; <LINK REF="STD-T_x00e4_htinen-2011" TYPE="STUDY">Tähtinen 2011</LINK>).</P>
<P>The <LINK REF="STD-Laxdal-1970" TYPE="STUDY">Laxdal 1970</LINK> trial has been removed from the review of antibiotics against placebo and added to the review of immediate antibiotics versus expectant observation.</P>
<P>No new trials were identified for the review of immediate antibiotics compared with expectant observation. Furthermore, we did not identify ongoing trials.</P>
<P>In this updated review, we now provide outcome data for pain at 24 hours, two to three days and four to seven days (in earlier versions outcome data for pain were presented at 24 hours and two to seven days).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-06-19 18:55:52 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="8" MONTH="11" YEAR="2012"/>
<DESCRIPTION>
<P>The general conclusions and recommendations regarding the effectiveness of antibiotics on pain and adverse events remained unchanged.</P>
<P>Antibiotic treatment led to a statistically significant reduction of children with AOM experiencing pain at two to seven days compared with placebo, but since most children (82%) settle spontaneously, about 20 children must be treated to prevent one suffering from ear pain at two to three and four to seven days. (In the previous version the number needed to treat to benefit (NNTB) was 16). However, in this updated review antibiotic treatment appeared to have a statistically significant beneficial effect on the number of tympanic membrane perforations (risk ratio (RR) 0.37, 95% confidence interval (CI) 0.18 to 0.76; NNTB 33) and contralateral acute otitis media (AOM) episodes (RR 0.49, 95% CI 0.25 to 0.95; NNTB 11) compared with placebo.</P>
<P>For every 14 children treated with antibiotics one child experienced an adverse event (such as vomiting, diarrhoea or rash) that would not have been occurred if antibiotics were withheld. (In the previous version the number needed to treat to harm (NNTH) was 24).</P>
<P>Antibiotics are most useful in children under two years of age with bilateral AOM, or with both AOM and otorrhoea. For most other children with mild disease, an expectant observational approach seems justified. We have no data on populations with higher risks of complications.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="19" MONTH="6" YEAR="2012"/>
<DESCRIPTION>
<P>Feedback added to review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2015-06-19 18:57:17 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="2" MONTH="9" YEAR="2009"/>
<DESCRIPTION>
<P>95% confidence intervals corrected for the outcome pain at two to seven days and adverse events stated in the abstract and body of the review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-06-19 18:58:24 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="2" MONTH="7" YEAR="2008"/>
<DESCRIPTION>
<P>The search was updated in July 2008. Four new trials were identified and included in the review (<LINK REF="STD-Le-Saux-2005" TYPE="STUDY">Le Saux 2005</LINK>; <LINK REF="STD-McCormick-2005" TYPE="STUDY">McCormick 2005</LINK>; <LINK REF="STD-Neumark-2007" TYPE="STUDY">Neumark 2007</LINK>; <LINK REF="STD-Spiro-2006" TYPE="STUDY">Spiro 2006</LINK>). One of these trials compared antibiotics with placebo (<LINK REF="STD-Le-Saux-2005" TYPE="STUDY">Le Saux 2005</LINK>). For the outcome pain at 24 hours and two to seven days, inclusion of this trial did not alter the overall conclusions of the primary analysis. The three other new trials compared immediate antibiotics with various observational approaches (<LINK REF="STD-McCormick-2005" TYPE="STUDY">McCormick 2005</LINK>; <LINK REF="STD-Neumark-2007" TYPE="STUDY">Neumark 2007</LINK>; <LINK REF="STD-Spiro-2006" TYPE="STUDY">Spiro 2006</LINK>). One of the new trials compared immediate antibiotics with delayed prescribing (<LINK REF="STD-Spiro-2006" TYPE="STUDY">Spiro 2006</LINK>). The other trials compared immediate antibiotics with 'watchful waiting', in which no prescription was supplied but advice on when to seek treatment was provided (<LINK REF="STD-McCormick-2005" TYPE="STUDY">McCormick 2005</LINK>; <LINK REF="STD-Neumark-2007" TYPE="STUDY">Neumark 2007</LINK>). Outcome data on pain at three to seven days from these trials were analysed with data from another trial of immediate versus delayed prescription (<LINK REF="STD-Little-2001" TYPE="STUDY">Little 2001</LINK>). In earlier versions of the review data from the Little trial had been included in a sensitivity analysis (<LINK REF="STD-Little-2001" TYPE="STUDY">Little 2001</LINK>). In this update, data from the four trials comparing immediate versus observational management strategies have been included in the main analysis. Information on subgroups of children who are most likely to benefit from treatment with antibiotics, obtained from a meta-analysis of individual patient data, has been included in this review (<LINK REF="REF-Rovers-2006" TYPE="REFERENCE">Rovers 2006</LINK>). Methods of the IPD meta-analysis, conducted by two authors on this review (and others) are also included. Survival curves from the IPD meta-analysis showing the pattern of recovery from acute otitis media over time has been included as an extra figure. Two ongoing trials comparing antibiotics with placebo in children &lt; 35 months have been identified.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-12-07 14:09:29 +1000" MODIFIED_BY="Liz Dooley">
<DATE DAY="17" MONTH="1" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2008-07-01 10:39:10 +1000" MODIFIED_BY="Liz Dooley">
<DATE DAY="4" MONTH="9" YEAR="2007"/>
<DESCRIPTION>
<P>Feedback added.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2009-02-02 07:43:46 +1000" MODIFIED_BY="Liz Dooley">
<DATE DAY="18" MONTH="2" YEAR="2005"/>
<DESCRIPTION>
<P>Feedback and reply added.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-12-07 15:04:03 +1000" MODIFIED_BY="Liz Dooley">
<DATE DAY="24" MONTH="3" YEAR="2003"/>
<DESCRIPTION>
<P>Searches conducted.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2008-07-01 10:40:12 +1000" MODIFIED_BY="Liz Dooley">
<DATE DAY="24" MONTH="8" YEAR="2002"/>
<DESCRIPTION>
<P>Feedback added.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2008-07-01 10:41:58 +1000" MODIFIED_BY="Liz Dooley">
<DATE DAY="17" MONTH="2" YEAR="2002"/>
<DESCRIPTION>
<P>Feedback added.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2008-07-01 10:42:53 +1000" MODIFIED_BY="Liz Dooley">
<DATE DAY="20" MONTH="11" YEAR="2000"/>
<DESCRIPTION>
<P>Feedback comments and replies added.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-07-01 11:09:18 +1000" MODIFIED_BY="Liz Dooley">
<DATE DAY="3" MONTH="2" YEAR="2000"/>
<DESCRIPTION>
<P>Searches conducted.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2008-12-07 14:09:48 +1000" MODIFIED_BY="Liz Dooley">
<DATE DAY="3" MONTH="2" YEAR="2000"/>
<DESCRIPTION>
<P>Conclusions changed.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-07-01 11:10:00 +1000" MODIFIED_BY="Liz Dooley">
<DATE DAY="30" MONTH="12" YEAR="1998"/>
<DESCRIPTION>
<P>Searches conducted.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-12-07 14:09:35 +1000" MODIFIED_BY="Liz Dooley">
<DATE DAY="30" MONTH="7" YEAR="1994"/>
<DESCRIPTION>
<P>Searches conducted.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2015-06-20 08:35:19 +1000" MODIFIED_BY="Liz Dooley">
<SUMMARY MODIFIED="2015-06-19 18:50:50 +1000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">Antibiotics for acute middle ear infection (acute otitis media) in children</TITLE>
<SUMMARY_BODY MODIFIED="2015-06-19 18:50:50 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Review questions</B>
</P>
<P>This review compared 1) the clinical effectiveness and safety of antibiotics against placebo in children with an acute middle ear infection (acute otitis media (AOM)) and 2) the clinical effectiveness and safety of antibiotics against expectant observation (observational approaches in which prescriptions may or may not be provided) in children with AOM.</P>
<P>
<B>Background</B>
</P>
<P>AOM is one of the most common infections in early infancy and childhood, causing pain and general symptoms of illness such as fever, irritability and problems feeding and sleeping. By three years of age, most children have had at least one AOM episode. Though AOM usually resolves without treatment, it is often treated with antibiotics.</P>
<P>
<B>Study characteristics</B>
</P>
<P>The evidence in this review is current to 26 April 2015.</P>
<P>For the review of antibiotics against placebo we included 13 trials (3401 children aged between two months and 15 years) from high-income countries with generally low risk of bias. Three trials were performed in a general practice (GP) setting, six in an outpatient hospital setting and four in both settings.</P>
<P>For the review of antibiotics against expectant observation, five trials (1149 children) from high-income countries were eligible with low to moderate risk of bias. Two trials were performed in a GP setting and three in an outpatient hospital setting. Four trials (1007 children) reported outcome data that could be used for this review.</P>
<P>
<B>Key results</B>
</P>
<P>We found that antibiotics were not very useful for most children with AOM; antibiotics did not decrease the number of children with pain at 24 hours (when 60% of children were better anyway), only slightly reduced the number of children with pain in the days following and did not reduce the number of children with late AOM recurrences and hearing loss (that can last several weeks) at three months compared with placebo. However, antibiotics did slightly reduce the number of children with perforations of the eardrum and AOM episodes in the initially unaffected ear compared with placebo. Results from an individual patient data meta-analysis including data from six high-quality trials (1643 children), which were also included as individual trials in our review, showed that antibiotics seem to be most beneficial in children younger than two years of age with infection in both ears and in children with both AOM and a discharging ear.</P>
<P>We found no difference between immediate antibiotics and expectant observational approaches in the number of children with pain three to seven days and 11 to 14 days after assessment. Furthermore, no differences in the number of children with hearing loss at four weeks, perforations of the eardrum and late AOM recurrences were observed between groups.</P>
<P>There was not enough information to know if antibiotics reduced rare complications such as mastoiditis (infection of the bones around the ear). All of the studies included in this review were from high-income countries. Data are lacking from populations in which the AOM incidence and risk of progression to mastoiditis is higher.</P>
<P>Antibiotics caused unwanted effects such as diarrhoea, vomiting and rash and may also increase resistance to antibiotics in the community. It is difficult to balance the small benefits against the small harms of antibiotics in children with AOM. However, for most children with mild disease in high-income countries, an expectant observational approach seems justified.</P>
<P>
<B>Quality of the evidence</B>
</P>
<P>We judged the quality of the evidence to be high for most of the outcomes in the review of antibiotics against placebo (this means that further research is very unlikely to change our confidence in the estimate of effect).</P>
<P>For the review of immediate antibiotics versus expectant observation, we judged the evidence to be of moderate quality for most of the outcomes (this means that further research is likely to have an important impact on how confident we are in the results and may change those results). Quality was affected by concerns about sample size (perforation of the eardrum, rare complications) and the large number of children who are 'lost to follow-up' (pain at days 11 to 14, hearing loss at four weeks and late AOM recurrences).</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2015-06-19 19:01:29 +1000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2015-01-19 12:09:08 +1000" MODIFIED_BY="Liz  Dooley">
<P>Acute otitis media (AOM) is one of the most common diseases in early infancy and childhood. Antibiotic use for AOM varies from 56% in the Netherlands to 95% in the USA, Canada and Australia. This is an update of a Cochrane review first published in <I>The Cochrane Library </I>in Issue 1, 1997 and previously updated in 1999, 2005, 2009 and 2013.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2015-01-19 12:11:08 +1000" MODIFIED_BY="Liz  Dooley">
<P>To assess the effects of antibiotics for children with AOM.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2015-04-26 21:08:55 +1000" MODIFIED_BY="[Empty name]">
<P>We searched CENTRAL (2015, Issue 3), MEDLINE (1966 to April week 3, 2015), OLDMEDLINE (1958 to 1965), EMBASE (January 1990 to April 2015), Current Contents (1966 to April 2015), CINAHL (2008 to April 2015) and LILACS (2008 to April 2015).</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2012-06-07 09:44:21 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials (RCTs) comparing 1) antimicrobial drugs with placebo and 2) immediate antibiotic treatment with expectant observation (including delayed antibiotic prescribing) in children with AOM.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2012-09-13 20:27:40 +1000" MODIFIED_BY="Liz Dooley">
<P>Two review authors independently assessed trial quality and extracted data.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<P>For the review of antibiotics against placebo, 13 RCTs (3401 children and 3938 AOM episodes) from high-income countries were eligible and had generally low risk of bias. The combined results of the trials revealed that by 24 hours from the start of treatment, 60% of the children had recovered whether or not they had placebo or antibiotics. Pain was not reduced by antibiotics at 24 hours (risk ratio (RR) 0.89, 95% confidence interval (CI) 0.78 to 1.01) but almost a third fewer had residual pain at two to three days (RR 0.70, 95% CI 0.57 to 0.86; number needed to treat for an additional beneficial outcome (NNTB) 20). A quarter fewer had pain at four to seven days (RR 0.76, 95% CI 0.63 to 0.91; NNTB 16) and two-thirds fewer had pain at 10 to 12 days (RR 0.33, 95% CI 0.17 to 0.66; NNTB 7) compared with placebo. Antibiotics did reduce the number of children with abnormal tympanometry findings at two to four weeks (RR 0.82, 95% CI 0.74 to 0.90; NNTB 11), at six to eight weeks (RR 0.88, 95% CI 0.78 to 1.00; NNTB 16) and the number of children with tympanic membrane perforations (RR 0.37, 95% CI 0.18 to 0.76; NNTB 33) and halved contralateral otitis episodes (RR 0.49, 95% CI 0.25 to 0.95; NNTB 11) compared with placebo. However, antibiotics neither reduced the number of children with abnormal tympanometry findings at three months (RR 0.97, 95% CI 0.76 to 1.24) nor the number of children with late AOM recurrences (RR 0.93, 95% CI 0.78 to 1.10) when compared with placebo. Severe complications were rare and did not differ between children treated with antibiotics and those treated with placebo. Adverse events (such as vomiting, diarrhoea or rash) occurred more often in children taking antibiotics (RR 1.38, 95% CI 1.19 to 1.59; number needed to treat for an additional harmful outcome (NNTH) 14). Funnel plots do not suggest publication bias. Individual patient data meta-analysis of a subset of included trials found antibiotics to be most beneficial in children aged less than two years with bilateral AOM, or with both AOM and otorrhoea.</P>
<P>For the review of immediate antibiotics against expectant observation, five trials (1149 children) from high-income countries were eligible and had low to moderate risk of bias. Four trials (1007 children) reported outcome data that could be used for this review. From these trials, data from 959 children could be extracted for the meta-analysis of pain at three to seven days. No difference in pain was detectable at three to seven days (RR 0.75, 95% CI 0.50 to 1.12). One trial (247 children) reported data on pain at 11 to 14 days. Immediate antibiotics were not associated with a reduction in the number of children with pain (RR 0.91, 95% CI 0.75 to 1.10) compared with expectant observation. Additionally, no differences in the number of children with abnormal tympanometry findings at four weeks, tympanic membrane perforations and AOM recurrence were observed between groups. No serious complications occurred in either the antibiotic or the expectant observation group. Immediate antibiotics were associated with a substantial increased risk of vomiting, diarrhoea or rash compared with expectant observation (RR 1.71, 95% CI 1.24 to 2.36; NNTH 9).</P>
<P>Results from an individual patient data meta-analysis including data from six high-quality trials (1643 children) that were also included as individual trials in our review showed that antibiotics seem to be most beneficial in children younger than two years of age with bilateral AOM (NNTB 4) and in children with both AOM and otorrhoea (NNTB 3).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2015-06-19 19:01:29 +1000" MODIFIED_BY="[Empty name]">
<P>This review reveals that antibiotics have no early effect on pain, a slight effect on pain in the days following and only a modest effect on the number of children with tympanic perforations, contralateral otitis episodes and abnormal tympanometry findings at two to four weeks and at six to eight weeks compared with placebo in children with AOM. In high-income countries, most cases of AOM spontaneously remit without complications. The benefits of antibiotics must be weighed against the possible harms: for every 14 children treated with antibiotics one child experienced an adverse event (such as vomiting, diarrhoea or rash) that would not have occurred if antibiotics were withheld. Therefore clinical management should emphasise advice about adequate analgesia and the limited role for antibiotics. Antibiotics are most useful in children under two years of age with bilateral AOM, or with both AOM and otorrhoea. For most other children with mild disease in high-income countries, an expectant observational approach seems justified.<BR/>
</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2015-06-20 08:35:19 +1000" MODIFIED_BY="Liz Dooley">
<BACKGROUND MODIFIED="2015-06-19 19:06:23 +1000" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<P>Acute otitis media (AOM) is one of the most frequent diseases in early infancy and childhood. AOM is defined as the presence of middle-ear effusion and a rapid onset of signs or symptoms of middle-ear inflammation, such as ear pain, otorrhoea or fever (<LINK REF="REF-AAP-2013" TYPE="REFERENCE">AAP 2013</LINK>), and has a high morbidity and low mortality (<LINK REF="REF-Stool-1989" TYPE="REFERENCE">Stool 1989</LINK>). Approximately 10% of children have an episode of AOM by three months of age and, by three years of age, approximately 50% to 85% of all children have experienced at least one AOM episode (<LINK REF="REF-Teele-1989" TYPE="REFERENCE">Teele 1989</LINK>). The peak age-specific incidence is between six and 15 months (<LINK REF="REF-Klein-1989" TYPE="REFERENCE">Klein 1989</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2015-06-19 19:05:05 +1000" MODIFIED_BY="[Empty name]">
<P>Despite a large number of published clinical trials, there is no consensus regarding the most appropriate therapy for AOM; for example, the rates of use of antibiotics for AOM vary from 56% in the Netherlands (<LINK REF="REF-Akkerman-2005" TYPE="REFERENCE">Akkerman 2005</LINK>) to 95% in the USA and Canada (<LINK REF="REF-Froom-2001" TYPE="REFERENCE">Froom 2001</LINK>). One meta-analysis emphasises that AOM resolves spontaneously in most children (<LINK REF="REF-Rosenfeld-1994" TYPE="REFERENCE">Rosenfeld 1994</LINK>). However, one semi-randomised trial of 1365 participants conducted in Sweden in 1954 reported a rate of mastoiditis of 17% in the untreated group versus none in the penicillin-treated groups (<LINK REF="STD-Rudberg-1954" TYPE="STUDY">Rudberg 1954</LINK>). Over recent years, prescription strategies in which antibiotic treatment for acute respiratory infections such as AOM is delayed and instituted only if symptoms persist or worsen after several days have been advocated (<LINK REF="REF-AAP-2013" TYPE="REFERENCE">AAP 2013</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<P>AOM has a multifactorial pathogenesis. Mucosal swelling of the nasopharynx and Eustachian tube due to a viral upper respiratory tract infection can lead to Eustachian tube dysfunction with impaired clearance and pressure regulation of the middle ear. Prolonged dysfunction may be followed by aspiration of potential viral and bacterial pathogens from the nasopharynx to the middle ear. These pathogens might in turn provoke a host inflammatory response, which leads to the clinical manifestations of AOM such as ear pain, otorrhoea, fever and irritability. <I>Streptococcus pneumoniae </I>(<I>S. pneumoniae</I>) has been the predominant pathogen related to AOM for many years, next to <I>Moraxella catarrhalis </I>(<I>M. catarrhalis</I>) and non-typeable <I>Haemophilus influenzae </I>(<I>H. influenzae</I>). However, recent studies suggest that widespread implementation of pneumococcal conjugate vaccination has changed the frequency of otopathogens related to AOM with non-typeable <I>H. influenzae </I>and non-vaccine <I>S. pneumoniae </I>serotypes becoming more prevalent (<LINK REF="REF-Casey-2013" TYPE="REFERENCE">Casey 2013</LINK>; <LINK REF="REF-Coker-2010" TYPE="REFERENCE">Coker 2010</LINK>)<I>.</I> Additionally, viral (co-)infection is known to worsen the clinical and bacteriological outcome of AOM (<LINK REF="REF-Arola-1990" TYPE="REFERENCE">Arola 1990</LINK>; <LINK REF="REF-Chonmaitree-1992" TYPE="REFERENCE">Chonmaitree 1992</LINK>). As bacteria are considered to play a predominant role in the causation of AOM-related symptoms, antibiotic treatment may accelerate clinical recovery and may reduce the number of complications related to AOM.</P>
</THEORY>
<IMPORTANCE MODIFIED="2015-06-19 19:06:23 +1000" MODIFIED_BY="[Empty name]">
<P>Although numerous randomised clinical trials (RCTs) on the effectiveness of antibiotic treatment in children with AOM have been performed over the decades, consensus regarding the most appropriate treatment strategy is lacking. As symptoms consistent with AOM resolve spontaneously in the majority of children, an expectant observational approach might be justified. We therefore performed a systematic review to examine the effects of both immediate antibiotic treatment and an expectant observational approach in children with AOM. This is an update of a Cochrane review first published in <I>The Cochrane Library </I>in Issue 1, 1997 (<LINK REF="REF-Glasziou-1997" TYPE="REFERENCE">Glasziou 1997</LINK>) and updated in 1999 (<LINK REF="REF-Glasziou-1999" TYPE="REFERENCE">Glasziou 1999</LINK>), 2005 (<LINK REF="REF-Glasziou-2005" TYPE="REFERENCE">Glasziou 2005</LINK>), 2009 (<LINK REF="REF-Sanders-2009" TYPE="REFERENCE">Sanders 2009</LINK>), and 2013 (<LINK REF="REF-Venekamp-2013" TYPE="REFERENCE">Venekamp 2013</LINK>).</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<P>To assess the effects of antibiotics for children with AOM.</P>
<P>We attempted to determine to what extent antibiotic therapy was more effective than placebo and what, if any, advantages it offered to children in terms of symptom relief (pain), avoidance of complications (such as tympanic membrane perforations and severe complications such as mastoiditis) and longer-term hearing problems from middle-ear effusion (as measured by tympanometry or audiometry). We also assessed the effect of immediate antibiotic versus expectant observation on AOM. Moreover, we aimed to provide information on subgroups of children with AOM that benefit more or less from antibiotics.</P>
</OBJECTIVES>
<METHODS MODIFIED="2015-06-19 19:12:50 +1000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<P>RCTs of antimicrobial drugs versus placebo control. We also included RCTs comparing immediate antibiotic versus expectant observation.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2012-11-22 22:33:18 +1000" MODIFIED_BY="[Empty name]">
<P>Studies including children (aged from one month to 15 years) of either gender without ventilation tubes, suffering from AOM irrespective of the setting from which they were recruited.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2015-06-18 22:23:41 +1000" MODIFIED_BY="[Empty name]">
<P>Antimicrobial drugs versus placebo control.</P>
<P>Immediate antibiotic versus expectant observation (also known as 'wait and see' or 'watchful waiting' or 'observation therapy'). This includes expectant observational approaches in which prescriptions may or may not be provided.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<P>We focused our data extraction on patient-relevant outcomes, that is, those symptoms or problems that are important to the patient's sense of well-being. While other endpoints, such as microbiological cure, may enhance medical understanding of the disease process, decisions about treatment should focus on helping the patient. We analysed the outcomes listed below in this review, but these outcomes were not used as a basis for including or excluding studies.</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2015-01-19 12:40:08 +1000" MODIFIED_BY="Liz  Dooley">
<OL>
<LI>Proportion of children with pain at various time points (24 hours, two to three days, four to seven days, 10 to 14 days).</LI>
<LI>Adverse effects likely to be related to the use of antibiotics such as vomiting, diarrhoea or rash.</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Abnormal tympanometry findings at various time points (two to four weeks, six to eight weeks, and three months) as a surrogate measure for hearing problems caused by middle-ear fluid.</LI>
<LI>Tympanic membrane perforation.</LI>
<LI>Contralateral otitis (in unilateral cases).</LI>
<LI>AOM recurrences.</LI>
<LI>Serious complications related to AOM such as mastoiditis and meningitis.</LI>
<LI>Long-term effects (including the number of parent-reported AOM-symptom episodes, antibiotic prescriptions and health care utilisation as assessed at least one year after randomisation).</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2015-06-19 19:08:14 +1000" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2015-06-19 19:08:14 +1000" MODIFIED_BY="[Empty name]">
<P>For this update we searched the Cochrane Central Register of Controlled Trials (CENTRAL 2015, Issue 3) (accessed 26 April 2015), which contains the Acute Respiratory Infections (ARI) Group's Specialised Register, MEDLINE (October 2012 to April week 3, 2015), EMBASE (November 2012 to April 2015), Current Contents (2012 to April 2015), CINAHL (October 2012 to April 2015) and LILACS (2012 to April 2015). Our previous update using the same search strategies covered the period 2008 to November 2012. See <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> for details of earlier searches.</P>
<P>We used the search strategy described in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK> to search CENTRAL and MEDLINE. We combined the MEDLINE search with the Cochrane Highly Sensitive Search Strategy for identifying randomised trials in MEDLINE: sensitivity- and precision-maximising version (2008 revision); Ovid format (<LINK REF="REF-Lefebvre-2011" TYPE="REFERENCE">Lefebvre 2011</LINK>). We adapted the search strategy to search EMBASE (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>), Current Contents (<LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>), CINAHL (<LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>) and LILACS (<LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>).</P>
<P>There were no language or publication restrictions.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2015-05-21 16:45:55 +1000" MODIFIED_BY="[Empty name]">
<P>We checked ClinicalTrials.gov (<A HREF="http://clinicaltrials.gov/">clinicaltrials.gov/</A>) for ongoing trials (11 May 2015). To increase the yield of relevant studies, we inspected the reference lists of all identified studies and reviews.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2015-06-19 19:12:50 +1000" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2012-09-14 01:21:27 +1000" MODIFIED_BY="Liz Dooley">
<P>One review author (RPV) screened titles and abstracts obtained from the database searches. Two review authors (RPV, MMR) reviewed the full text of the potentially relevant titles and abstracts against the inclusion criteria.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2012-06-13 10:37:11 +1000" MODIFIED_BY="Liz Dooley">
<P>Two review authors (RPV, MMR) extracted data from the included studies. We resolved disagreements by discussion.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<P>Two review authors (RPV, MMR) independently assessed the methodological quality of the included trials. We resolved any disagreements by discussion. We assessed the methodological quality of the included studies as described in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). As a consequence, methodological quality assessment was based on random sequence generation, allocation concealment, blinding, completeness of data and outcome assessment. Results of the 'Risk of bias' assessment are presented in a 'Risk of bias' summary (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>) and a 'Risk of bias' graph (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>).</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2015-06-19 19:09:20 +1000" MODIFIED_BY="[Empty name]">
<P>We expressed dichotomous outcomes as risk ratio (RR) and risk difference (RD) with 95% confidence intervals (CIs). Additionally, we calculated the number needed to treat for an additional beneficial outcome (NNTB) and the number needed to treat for an additional harmful outcome (NNTH) (1/(absolute risk in exposed minus absolute risk in unexposed)).</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2012-06-18 09:36:13 +1000" MODIFIED_BY="Liz Dooley">
<P>We did not identify any studies with non-standard designs, such as cross-over trials and cluster-randomised trials.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2012-09-13 23:03:29 +1000" MODIFIED_BY="Liz Dooley">
<P>We tried to contact the trial authors to provide additional information in case of missing data.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<P>We assessed the level of clinical heterogeneity between the trials by reviewing differences across trials in study population, setting, intervention and outcome measures used. In the absence of substantial clinical heterogeneity, we performed meta-analyses. We used the Chi<SUP>2</SUP> test, the I<SUP>2 </SUP>statistic and visual inspection of the forest plots to assess statistical heterogeneity. When statistical heterogeneity was present (P value &lt; 0.1), we re-analysed the data using the random-effects model. For the outcome of pain, we explored the magnitude of baseline risk and heterogeneity using L'Abbé plots (a graph of the proportion of participants with an outcome by the proportion of participants without an outcome).</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2012-02-28 07:12:21 +1000" MODIFIED_BY="[Empty name]">
<P>We assessed reporting bias using a funnel plot.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<P>We analysed the data according to the intention-to-treat (ITT) principle, whereby all participants are analysed in the groups to which they were randomly allocated. We performed meta-analysis where we judged clinical heterogeneity to be minimal, to ensure that we would derive clinically meaningful results. We calculated treatment differences by the Mantel-Haenszel method using a fixed-effect or random-effects (when statistical heterogeneity was present) model. We presented results separately for the reviews of antibiotics against placebo and immediate antibiotics versus expectant observation.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2015-06-19 19:11:45 +1000" MODIFIED_BY="[Empty name]">
<P>The publication of <LINK REF="REF-Rovers-2006" TYPE="REFERENCE">Rovers 2006</LINK> describes the results of an individual patient data (IPD) meta-analysis that was performed on a subset of trials included in this review (six trials including 1643 children aged six months to 12 years with AOM) to identify subgroups of children with AOM who might benefit more than others from treatment with antibiotics. Extensive details on the methods and results of this IPD meta-analysis can be found in the original article (<LINK REF="REF-Rovers-2006" TYPE="REFERENCE">Rovers 2006</LINK>). The primary outcome was a prolonged course of AOM defined as having either residual pain or fever (&gt; 38 ºC) at three to seven days. Potential subgroups were selected on the basis of a multivariable prediction tool. The independent baseline predictors, that is, age (&lt; two years versus &gt; two years), fever and bilateral AOM (yes versus no), were used to study whether those at risk of a prolonged course also benefited more from treatment with antibiotics. In addition, otorrhoea (yes versus no) at baseline was studied as this is a clinically relevant outcome that occurred too infrequently to be identified as an independent predictor. To assess whether the effect of antibiotics was modified by age, bilateral disease, otorrhoea or a combination of these, a fixed-effect logistic regression analysis. In this model, antibiotics (yes versus no), the potential effect modifier (age, bilateral disease, otorrhoea, or a combination of these), a dummy for the particular study and an interaction term (antibiotics * potential effect modifier) were included as independent variables and a prolonged course at three to seven days was the dependent variable. If a significant interaction effect was found, stratified analyses were performed to study the rate ratios and rate differences within each stratum of the subgroups.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2015-06-19 19:12:50 +1000" MODIFIED_BY="[Empty name]">
<P>We did not perform sensitivity analysis.</P>
<SUBSECTION>
<HEADING LEVEL="3">GRADE and &#8217;Summary of findings'</HEADING>
<P>For each outcome, we rated the overall quality of evidence as high, moderate, low and very low using the GRADE approach. Randomised controlled trials that do not have serious limitations are rated as high quality. However, we downgraded the evidence to moderate, low or very low depending on the presence of each of the following factors:</P>
<UL>
<LI>study limitations (risk of bias);</LI>
<LI>indirectness of evidence (directness of evidence);</LI>
<LI>imprecision (precision of results);</LI>
<LI>inconsistency (consistency of results); and</LI>
<LI>publication bias (existence of publication bias).</LI>
</UL>
<P>We included a 'Summary of findings' table (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>) for the review of antibiotics against placebo, constructed according to the descriptions as described in Chapter 10 of the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We included our primary outcomes and important secondary outcomes in the 'Summary of findings' table:</P>
<UL>
<LI>pain at 24 hours;</LI>
<LI>pain at two to three days;</LI>
<LI>pain at four to seven days;</LI>
<LI>pain at 10 to 12 days;</LI>
<LI>adverse effects likely to be related to the use of antibiotics (vomiting, diarrhoea or rash);</LI>
<LI>abnormal tympanometry findings at two to four weeks;</LI>
<LI>abnormal tympanometry findings at three months.</LI>
</UL>
</SUBSECTION>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2015-06-19 19:21:24 +1000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2015-06-19 19:16:09 +1000" MODIFIED_BY="[Empty name]">
<P>See <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>, <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> and <LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK> tables.</P>
<SEARCH_RESULTS MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<P>This is an update of a Cochrane review first published in <I>The Cochrane Library </I>in Issue 1, 1997 (<LINK REF="REF-Glasziou-1997" TYPE="REFERENCE">Glasziou 1997</LINK>) and updated in 1999 (<LINK REF="REF-Glasziou-1999" TYPE="REFERENCE">Glasziou 1999</LINK>), 2005 (<LINK REF="REF-Glasziou-2005" TYPE="REFERENCE">Glasziou 2005</LINK>), 2009 (<LINK REF="REF-Sanders-2009" TYPE="REFERENCE">Sanders 2009</LINK>), and 2013 (<LINK REF="REF-Venekamp-2013" TYPE="REFERENCE">Venekamp 2013</LINK>). In the 2013 update of our review (<LINK REF="REF-Venekamp-2013" TYPE="REFERENCE">Venekamp 2013</LINK>), we identified 12 RCTs for the review of antibiotics against placebo (<LINK REF="STD-Appelman-1991" TYPE="STUDY">Appelman 1991</LINK>; <LINK REF="STD-Burke-1991" TYPE="STUDY">Burke 1991</LINK>; <LINK REF="STD-Damoiseaux-2000" TYPE="STUDY">Damoiseaux 2000</LINK>; <LINK REF="STD-Halsted-1968" TYPE="STUDY">Halsted 1968</LINK>; <LINK REF="STD-Hoberman-2011" TYPE="STUDY">Hoberman 2011</LINK>; <LINK REF="STD-Howie-1972" TYPE="STUDY">Howie 1972</LINK>; <LINK REF="STD-Kaleida-1991" TYPE="STUDY">Kaleida 1991</LINK>; <LINK REF="STD-Le-Saux-2005" TYPE="STUDY">Le Saux 2005</LINK>; <LINK REF="STD-Mygind-1981" TYPE="STUDY">Mygind 1981</LINK>; <LINK REF="STD-T_x00e4_htinen-2011" TYPE="STUDY">Tähtinen 2011</LINK>; <LINK REF="STD-Thalin-1985" TYPE="STUDY">Thalin 1985</LINK>; <LINK REF="STD-van-Buchem-1981a" TYPE="STUDY">van Buchem 1981a</LINK> and <LINK REF="STD-van-Buchem-1981b" TYPE="STUDY">van Buchem 1981b</LINK>), while we judged five RCTs eligible for the review of immediate antibiotics versus expectant observation (<LINK REF="STD-Laxdal-1970" TYPE="STUDY">Laxdal 1970</LINK>; <LINK REF="STD-Little-2001" TYPE="STUDY">Little 2001</LINK>; <LINK REF="STD-McCormick-2005" TYPE="STUDY">McCormick 2005</LINK>; <LINK REF="STD-Neumark-2007" TYPE="STUDY">Neumark 2007</LINK>; <LINK REF="STD-Spiro-2006" TYPE="STUDY">Spiro 2006</LINK>). We excluded a total of 11 studies for various reasons (<LINK REF="STD-Arguedas-2011" TYPE="STUDY">Arguedas 2011</LINK>; <LINK REF="STD-Casey-2012" TYPE="STUDY">Casey 2012</LINK>; <LINK REF="STD-Chaput-1982" TYPE="STUDY">Chaput 1982</LINK>; <LINK REF="STD-Engelhard-1989" TYPE="STUDY">Engelhard 1989</LINK>; <LINK REF="STD-Liu-2011" TYPE="STUDY">Liu 2011</LINK>; <LINK REF="STD-Ostfeld-1987" TYPE="STUDY">Ostfeld 1987</LINK>; <LINK REF="STD-Rudberg-1954" TYPE="STUDY">Rudberg 1954</LINK>; <LINK REF="STD-Ruohola-2003" TYPE="STUDY">Ruohola 2003</LINK>; <LINK REF="STD-Sarrell-2003" TYPE="STUDY">Sarrell 2003</LINK>; <LINK REF="STD-T_x00e4_htinen-2012" TYPE="STUDY">Tähtinen 2012</LINK>; <LINK REF="STD-van-Buchem-1985" TYPE="STUDY">van Buchem 1985</LINK>).</P>
<P>With the updated search (November week 2, 2012 to April week 3, 2015), we retrieved a total of 1065 records. Removing duplicates left 937. After screening titles and abstracts, we identified four potentially eligible articles. After reviewing the full text, all articles appeared to be relevant for this review. However, three articles were additional analyses of previously included trials (<LINK REF="STD-Damoiseaux-2000" TYPE="STUDY">Damoiseaux 2000</LINK>; <LINK REF="STD-Hoberman-2011" TYPE="STUDY">Hoberman 2011</LINK>; <LINK REF="STD-Little-2001" TYPE="STUDY">Little 2001</LINK>), providing additional data on pain at 10 to 12 days (<LINK REF="STD-Hoberman-2011" TYPE="STUDY">Hoberman 2011</LINK>) and long-term effects (<LINK REF="STD-Damoiseaux-2000" TYPE="STUDY">Damoiseaux 2000</LINK>) for the review of antibiotics against placebo and data on long-term effects (<LINK REF="STD-Little-2001" TYPE="STUDY">Little 2001</LINK>) for the review of immediate antibiotics versus expectant observation. We did not identify any additional trials after reviewing the reference lists of the full-text papers and relevant systematic reviews. This left one new trial eligible for inclusion in the review of antibiotics against placebo (<LINK REF="STD-Tapiainen-2014" TYPE="STUDY">Tapiainen 2014</LINK>). We identified one ongoing trial (<LINK REF="STD-ACTRN12608000424303" TYPE="STUDY">ACTRN12608000424303</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2015-06-19 19:16:09 +1000" MODIFIED_BY="[Empty name]">
<P>Methods, participants, interventions and outcomes of the included studies are described in more detail in the table of <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="3">Antibiotics versus placebo</HEADING>
<P>Thirteen trials including 3401 children (3938 AOM episodes) were eligible for the review of antibiotics against placebo (<LINK REF="STD-Appelman-1991" TYPE="STUDY">Appelman 1991</LINK>; <LINK REF="STD-Burke-1991" TYPE="STUDY">Burke 1991</LINK>; <LINK REF="STD-Damoiseaux-2000" TYPE="STUDY">Damoiseaux 2000</LINK>; <LINK REF="STD-Halsted-1968" TYPE="STUDY">Halsted 1968</LINK>; <LINK REF="STD-Hoberman-2011" TYPE="STUDY">Hoberman 2011</LINK>; <LINK REF="STD-Howie-1972" TYPE="STUDY">Howie 1972</LINK>; <LINK REF="STD-Kaleida-1991" TYPE="STUDY">Kaleida 1991</LINK>; <LINK REF="STD-Le-Saux-2005" TYPE="STUDY">Le Saux 2005</LINK>; <LINK REF="STD-Mygind-1981" TYPE="STUDY">Mygind 1981</LINK>; <LINK REF="STD-T_x00e4_htinen-2011" TYPE="STUDY">Tähtinen 2011</LINK>; <LINK REF="STD-Tapiainen-2014" TYPE="STUDY">Tapiainen 2014</LINK>; <LINK REF="STD-Thalin-1985" TYPE="STUDY">Thalin 1985</LINK>; <LINK REF="STD-van-Buchem-1981a" TYPE="STUDY">van Buchem 1981a</LINK> and <LINK REF="STD-van-Buchem-1981b" TYPE="STUDY">van Buchem 1981b</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Design</HEADING>
<P>Twelve trials were double-blind, placebo-controlled, parallel-group randomised clinical trials (<LINK REF="STD-Appelman-1991" TYPE="STUDY">Appelman 1991</LINK>; <LINK REF="STD-Burke-1991" TYPE="STUDY">Burke 1991</LINK>; <LINK REF="STD-Damoiseaux-2000" TYPE="STUDY">Damoiseaux 2000</LINK>; <LINK REF="STD-Halsted-1968" TYPE="STUDY">Halsted 1968</LINK>; <LINK REF="STD-Hoberman-2011" TYPE="STUDY">Hoberman 2011</LINK>; <LINK REF="STD-Howie-1972" TYPE="STUDY">Howie 1972</LINK>; <LINK REF="STD-Kaleida-1991" TYPE="STUDY">Kaleida 1991</LINK>; <LINK REF="STD-Le-Saux-2005" TYPE="STUDY">Le Saux 2005</LINK>; <LINK REF="STD-Mygind-1981" TYPE="STUDY">Mygind 1981</LINK>; <LINK REF="STD-T_x00e4_htinen-2011" TYPE="STUDY">Tähtinen 2011</LINK>; <LINK REF="STD-Tapiainen-2014" TYPE="STUDY">Tapiainen 2014</LINK>; <LINK REF="STD-Thalin-1985" TYPE="STUDY">Thalin 1985</LINK>), while one trial had a 2 x 2 factorial design (<LINK REF="STD-van-Buchem-1981a" TYPE="STUDY">van Buchem 1981a</LINK> and <LINK REF="STD-van-Buchem-1981b" TYPE="STUDY">van Buchem 1981b</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Participants and settings</HEADING>
<P>The sample size of the 13 individual trials ranged from 84 children (<LINK REF="STD-Tapiainen-2014" TYPE="STUDY">Tapiainen 2014</LINK>) to 536 children (<LINK REF="STD-Kaleida-1991" TYPE="STUDY">Kaleida 1991</LINK>). The children were aged between two months and 15 years and 50% to 60% of included children were male. Three trials were performed in primary care (<LINK REF="STD-Burke-1991" TYPE="STUDY">Burke 1991</LINK>; <LINK REF="STD-Damoiseaux-2000" TYPE="STUDY">Damoiseaux 2000</LINK>; <LINK REF="STD-T_x00e4_htinen-2011" TYPE="STUDY">Tähtinen 2011</LINK>), six in secondary care (<LINK REF="STD-Halsted-1968" TYPE="STUDY">Halsted 1968</LINK>; <LINK REF="STD-Hoberman-2011" TYPE="STUDY">Hoberman 2011</LINK>; <LINK REF="STD-Howie-1972" TYPE="STUDY">Howie 1972</LINK>; <LINK REF="STD-Kaleida-1991" TYPE="STUDY">Kaleida 1991</LINK>; <LINK REF="STD-Le-Saux-2005" TYPE="STUDY">Le Saux 2005</LINK>; <LINK REF="STD-Thalin-1985" TYPE="STUDY">Thalin 1985</LINK>), and four in both primary and secondary care (<LINK REF="STD-Appelman-1991" TYPE="STUDY">Appelman 1991</LINK>; <LINK REF="STD-Mygind-1981" TYPE="STUDY">Mygind 1981</LINK>; <LINK REF="STD-Tapiainen-2014" TYPE="STUDY">Tapiainen 2014</LINK>; <LINK REF="STD-van-Buchem-1981a" TYPE="STUDY">van Buchem 1981a</LINK> and <LINK REF="STD-van-Buchem-1981b" TYPE="STUDY">van Buchem 1981b</LINK>). AOM was diagnosed by the presence of acute symptoms and otoscopic signs in nine trials (<LINK REF="STD-Appelman-1991" TYPE="STUDY">Appelman 1991</LINK>; <LINK REF="STD-Burke-1991" TYPE="STUDY">Burke 1991</LINK>; <LINK REF="STD-Damoiseaux-2000" TYPE="STUDY">Damoiseaux 2000</LINK>; <LINK REF="STD-Halsted-1968" TYPE="STUDY">Halsted 1968</LINK>; <LINK REF="STD-Hoberman-2011" TYPE="STUDY">Hoberman 2011</LINK>; <LINK REF="STD-Howie-1972" TYPE="STUDY">Howie 1972</LINK>; <LINK REF="STD-Kaleida-1991" TYPE="STUDY">Kaleida 1991</LINK>; <LINK REF="STD-Mygind-1981" TYPE="STUDY">Mygind 1981</LINK>; <LINK REF="STD-van-Buchem-1981a" TYPE="STUDY">van Buchem 1981a</LINK> and <LINK REF="STD-van-Buchem-1981b" TYPE="STUDY">van Buchem 1981b</LINK>), and by the presence of middle-ear effusion at pneumatic otoscopy and/or tympanometry in three trials (<LINK REF="STD-Le-Saux-2005" TYPE="STUDY">Le Saux 2005</LINK>; <LINK REF="STD-T_x00e4_htinen-2011" TYPE="STUDY">Tähtinen 2011</LINK>; <LINK REF="STD-Tapiainen-2014" TYPE="STUDY">Tapiainen 2014</LINK>), while the criteria were not clearly described in one trial (<LINK REF="STD-Thalin-1985" TYPE="STUDY">Thalin 1985</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Interventions and comparators</HEADING>
<P>Two trials compared penicillin for seven days with placebo (<LINK REF="STD-Mygind-1981" TYPE="STUDY">Mygind 1981</LINK>; <LINK REF="STD-Thalin-1985" TYPE="STUDY">Thalin 1985</LINK>), four trials compared amoxicillin for seven to 14 days with or without myringotomy with placebo (<LINK REF="STD-Burke-1991" TYPE="STUDY">Burke 1991</LINK>; <LINK REF="STD-Damoiseaux-2000" TYPE="STUDY">Damoiseaux 2000</LINK>; <LINK REF="STD-Kaleida-1991" TYPE="STUDY">Kaleida 1991</LINK>; <LINK REF="STD-Le-Saux-2005" TYPE="STUDY">Le Saux 2005</LINK>), and four trials compared amoxicillin/clavulanate for seven to 10 days with placebo (<LINK REF="STD-Appelman-1991" TYPE="STUDY">Appelman 1991</LINK>; <LINK REF="STD-Hoberman-2011" TYPE="STUDY">Hoberman 2011</LINK>; <LINK REF="STD-T_x00e4_htinen-2011" TYPE="STUDY">Tähtinen 2011</LINK>; <LINK REF="STD-Tapiainen-2014" TYPE="STUDY">Tapiainen 2014</LINK>). In one trial, ampicillin for 10 days was compared with pheneticillin and sulfisoxazole and placebo (<LINK REF="STD-Halsted-1968" TYPE="STUDY">Halsted 1968</LINK>), while another trial compared erythromycin and triple sulphonamide with ampicillin, triple sulphonamide, erythromycin and placebo (<LINK REF="STD-Howie-1972" TYPE="STUDY">Howie 1972</LINK>). One trial, <LINK REF="STD-van-Buchem-1981a" TYPE="STUDY">van Buchem 1981a</LINK> and <LINK REF="STD-van-Buchem-1981b" TYPE="STUDY">van Buchem 1981b</LINK>, had a 2 x 2 factorial design resulting in four treatment groups: (1) sham myringotomy plus antibiotics; (2) sham myringotomy plus placebo; (3) myringotomy plus antibiotics; and (4) myringotomy plus placebo. We used all arms of this trial: <LINK REF="STD-van-Buchem-1981a" TYPE="STUDY">van Buchem 1981a</LINK> includes the sham myringotomy plus antibiotic and the sham myringotomy plus placebo arms, whereas <LINK REF="STD-van-Buchem-1981b" TYPE="STUDY">van Buchem 1981b</LINK> includes the myringotomy plus antibiotic and myringotomy plus placebo arms.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Pain</HEADING>
<P>Five trials (1394 children) reported data on pain at 24 hours (<LINK REF="STD-Burke-1991" TYPE="STUDY">Burke 1991</LINK>; <LINK REF="STD-Le-Saux-2005" TYPE="STUDY">Le Saux 2005</LINK>; <LINK REF="STD-Thalin-1985" TYPE="STUDY">Thalin 1985</LINK>; <LINK REF="STD-T_x00e4_htinen-2011" TYPE="STUDY">Tähtinen 2011</LINK>; <LINK REF="STD-van-Buchem-1981a" TYPE="STUDY">van Buchem 1981a</LINK> and <LINK REF="STD-van-Buchem-1981b" TYPE="STUDY">van Buchem 1981b</LINK>), seven (2320 children) on pain at two to three days (<LINK REF="STD-Appelman-1991" TYPE="STUDY">Appelman 1991</LINK>; <LINK REF="STD-Halsted-1968" TYPE="STUDY">Halsted 1968</LINK>; <LINK REF="STD-Kaleida-1991" TYPE="STUDY">Kaleida 1991</LINK>; <LINK REF="STD-Le-Saux-2005" TYPE="STUDY">Le Saux 2005</LINK>; <LINK REF="STD-Mygind-1981" TYPE="STUDY">Mygind 1981</LINK>; <LINK REF="STD-T_x00e4_htinen-2011" TYPE="STUDY">Tähtinen 2011</LINK>; <LINK REF="STD-Thalin-1985" TYPE="STUDY">Thalin 1985</LINK>), seven (1347 children) on pain at four to seven days (<LINK REF="STD-Burke-1991" TYPE="STUDY">Burke 1991</LINK>; <LINK REF="STD-Damoiseaux-2000" TYPE="STUDY">Damoiseaux 2000</LINK>; <LINK REF="STD-Mygind-1981" TYPE="STUDY">Mygind 1981</LINK>; <LINK REF="STD-T_x00e4_htinen-2011" TYPE="STUDY">Tähtinen 2011</LINK>; <LINK REF="STD-Tapiainen-2014" TYPE="STUDY">Tapiainen 2014</LINK>; <LINK REF="STD-Thalin-1985" TYPE="STUDY">Thalin 1985</LINK>; <LINK REF="STD-van-Buchem-1981a" TYPE="STUDY">van Buchem 1981a</LINK> and <LINK REF="STD-van-Buchem-1981b" TYPE="STUDY">van Buchem 1981b</LINK>), and one (278 children) on pain at 10 to 12 days (<LINK REF="STD-Hoberman-2011" TYPE="STUDY">Hoberman 2011</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse effects likely to be related to the use of antibiotics (vomiting, diarrhoea or rash)</HEADING>
<P>Eight trials (2107 children) reported data on adverse events likely to be related to the use of antibiotics such as vomiting, diarrhoea or rash (<LINK REF="STD-Burke-1991" TYPE="STUDY">Burke 1991</LINK>; <LINK REF="STD-Damoiseaux-2000" TYPE="STUDY">Damoiseaux 2000</LINK>; <LINK REF="STD-Hoberman-2011" TYPE="STUDY">Hoberman 2011</LINK>; <LINK REF="STD-Le-Saux-2005" TYPE="STUDY">Le Saux 2005</LINK>; <LINK REF="STD-Mygind-1981" TYPE="STUDY">Mygind 1981</LINK>; <LINK REF="STD-T_x00e4_htinen-2011" TYPE="STUDY">Tähtinen 2011</LINK>; <LINK REF="STD-Tapiainen-2014" TYPE="STUDY">Tapiainen 2014</LINK>; <LINK REF="STD-Thalin-1985" TYPE="STUDY">Thalin 1985</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Abnormal tympanometry findings as a surrogate measure for hearing problems</HEADING>
<P>Seven trials (2138 children) reported data on abnormal tympanometry findings at two to four weeks (<LINK REF="STD-Appelman-1991" TYPE="STUDY">Appelman 1991</LINK>; <LINK REF="STD-Burke-1991" TYPE="STUDY">Burke 1991</LINK>; <LINK REF="STD-Kaleida-1991" TYPE="STUDY">Kaleida 1991</LINK>; <LINK REF="STD-Le-Saux-2005" TYPE="STUDY">Le Saux 2005</LINK>; <LINK REF="STD-Mygind-1981" TYPE="STUDY">Mygind 1981</LINK>; <LINK REF="STD-Tapiainen-2014" TYPE="STUDY">Tapiainen 2014</LINK>; <LINK REF="STD-Thalin-1985" TYPE="STUDY">Thalin 1985</LINK>), three (953 children) on abnormal tympanometry findings at six to eight weeks (<LINK REF="STD-Damoiseaux-2000" TYPE="STUDY">Damoiseaux 2000</LINK>; <LINK REF="STD-Kaleida-1991" TYPE="STUDY">Kaleida 1991</LINK>; <LINK REF="STD-Tapiainen-2014" TYPE="STUDY">Tapiainen 2014</LINK>), and three (809 children) on abnormal tympanometry findings at three months (<LINK REF="STD-Burke-1991" TYPE="STUDY">Burke 1991</LINK>; <LINK REF="STD-Le-Saux-2005" TYPE="STUDY">Le Saux 2005</LINK>; <LINK REF="STD-Mygind-1981" TYPE="STUDY">Mygind 1981</LINK>), as a surrogate measure for hearing problems caused by middle-ear fluid.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Tympanic membrane perforation</HEADING>
<P>Five trials (1075 children) reported data on tympanic membrane perforation (<LINK REF="STD-Burke-1991" TYPE="STUDY">Burke 1991</LINK>; <LINK REF="STD-Hoberman-2011" TYPE="STUDY">Hoberman 2011</LINK>; <LINK REF="STD-Mygind-1981" TYPE="STUDY">Mygind 1981</LINK>; <LINK REF="STD-T_x00e4_htinen-2011" TYPE="STUDY">Tähtinen 2011</LINK>; <LINK REF="STD-Tapiainen-2014" TYPE="STUDY">Tapiainen 2014</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Progression of symptoms (contralateral otitis or late AOM recurrences)</HEADING>
<P>Four trials (906 children) reported data on contralateral otitis (in unilateral cases) (<LINK REF="STD-Burke-1991" TYPE="STUDY">Burke 1991</LINK>; <LINK REF="STD-Hoberman-2011" TYPE="STUDY">Hoberman 2011</LINK>; <LINK REF="STD-Mygind-1981" TYPE="STUDY">Mygind 1981</LINK>; <LINK REF="STD-Thalin-1985" TYPE="STUDY">Thalin 1985</LINK>), while six trials (2200 children) reported data on late AOM recurrences (<LINK REF="STD-Hoberman-2011" TYPE="STUDY">Hoberman 2011</LINK>; <LINK REF="STD-Kaleida-1991" TYPE="STUDY">Kaleida 1991</LINK>; <LINK REF="STD-Le-Saux-2005" TYPE="STUDY">Le Saux 2005</LINK>; <LINK REF="STD-Mygind-1981" TYPE="STUDY">Mygind 1981</LINK>; <LINK REF="STD-Thalin-1985" TYPE="STUDY">Thalin 1985</LINK>; <LINK REF="STD-van-Buchem-1981a" TYPE="STUDY">van Buchem 1981a</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Serious complications</HEADING>
<P>Ten trials reported on serious complications including mastoiditis or meningitis (<LINK REF="STD-Burke-1991" TYPE="STUDY">Burke 1991</LINK>; <LINK REF="STD-Damoiseaux-2000" TYPE="STUDY">Damoiseaux 2000</LINK>; <LINK REF="STD-Hoberman-2011" TYPE="STUDY">Hoberman 2011</LINK>; <LINK REF="STD-Howie-1972" TYPE="STUDY">Howie 1972</LINK>; <LINK REF="STD-Kaleida-1991" TYPE="STUDY">Kaleida 1991</LINK>; <LINK REF="STD-Le-Saux-2005" TYPE="STUDY">Le Saux 2005</LINK>; <LINK REF="STD-Mygind-1981" TYPE="STUDY">Mygind 1981</LINK>; <LINK REF="STD-T_x00e4_htinen-2011" TYPE="STUDY">Tähtinen 2011</LINK>; <LINK REF="STD-Tapiainen-2014" TYPE="STUDY">Tapiainen 2014</LINK>; <LINK REF="STD-van-Buchem-1981a" TYPE="STUDY">van Buchem 1981a</LINK> and <LINK REF="STD-van-Buchem-1981b" TYPE="STUDY">van Buchem 1981b</LINK>), while information on complications was not explicitly reported in three trials (<LINK REF="STD-Appelman-1991" TYPE="STUDY">Appelman 1991</LINK>; <LINK REF="STD-Halsted-1968" TYPE="STUDY">Halsted 1968</LINK>; <LINK REF="STD-Thalin-1985" TYPE="STUDY">Thalin 1985</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Long-term effects</HEADING>
<P>One trial reported data on secondary care referrals at one year after randomisation as assessed by reviewing the children's notes (<LINK REF="STD-Burke-1991" TYPE="STUDY">Burke 1991</LINK>). Four children in the antibiotic group (4%) and seven in the placebo group (6%) were lost to follow-up.</P>
<P>One trial reported data on the proportion of children with AOM recurrences, secondary care referrals and ENT surgery at approximately 3.5 years after randomisation (<LINK REF="STD-Damoiseaux-2000" TYPE="STUDY">Damoiseaux 2000</LINK>). These long-term outcome data were collected by questionnaires. Questionnaires were returned in 168 of the 240 children (70%) that were originally randomised.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Immediate antibiotics versus expectant observation</HEADING>
<P>Five trials including a total of 1149 children were eligible for the review of immediate antibiotics versus expectant observation (<LINK REF="STD-Laxdal-1970" TYPE="STUDY">Laxdal 1970</LINK>; <LINK REF="STD-Little-2001" TYPE="STUDY">Little 2001</LINK>; <LINK REF="STD-McCormick-2005" TYPE="STUDY">McCormick 2005</LINK>; <LINK REF="STD-Neumark-2007" TYPE="STUDY">Neumark 2007</LINK>; <LINK REF="STD-Spiro-2006" TYPE="STUDY">Spiro 2006</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Design</HEADING>
<P>All trials were open-label, parallel-group randomised clinical trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Participants and settings</HEADING>
<P>The sample size of the five individual trials ranged from 142 children (<LINK REF="STD-Laxdal-1970" TYPE="STUDY">Laxdal 1970</LINK>) to 315 children (<LINK REF="STD-Little-2001" TYPE="STUDY">Little 2001</LINK>). The children were aged 15 years and younger and 50% to 60% of included children were male. Two trials were performed in primary care (<LINK REF="STD-Little-2001" TYPE="STUDY">Little 2001</LINK>; <LINK REF="STD-Neumark-2007" TYPE="STUDY">Neumark 2007</LINK>), and three in secondary care (<LINK REF="STD-Laxdal-1970" TYPE="STUDY">Laxdal 1970</LINK>; <LINK REF="STD-McCormick-2005" TYPE="STUDY">McCormick 2005</LINK>; <LINK REF="STD-Spiro-2006" TYPE="STUDY">Spiro 2006</LINK>). AOM was diagnosed by the presence of acute symptoms and otoscopic signs in three trials (<LINK REF="STD-Laxdal-1970" TYPE="STUDY">Laxdal 1970</LINK>; <LINK REF="STD-Little-2001" TYPE="STUDY">Little 2001</LINK>; <LINK REF="STD-McCormick-2005" TYPE="STUDY">McCormick 2005</LINK>), by pneumatic otoscopy or preferably an aural microscope in one trial (<LINK REF="STD-Neumark-2007" TYPE="STUDY">Neumark 2007</LINK>), while diagnostic criteria were unclear in one trial (AOM diagnosis was made at the discretion of the clinician) (<LINK REF="STD-Spiro-2006" TYPE="STUDY">Spiro 2006</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Intervention and comparators</HEADING>
<P>In two of these trials provision of an immediate antibiotic script was compared with an antibiotic script with instructions not to commence antibiotic treatment unless the child was not better or was worse at 48 hours (<LINK REF="STD-Spiro-2006" TYPE="STUDY">Spiro 2006</LINK>) or 72 hours (<LINK REF="STD-Little-2001" TYPE="STUDY">Little 2001</LINK>). In these trials, 24% (36/150) and 38% (50/132) of children in the delayed arms reported using antibiotics at some stage during the illness.</P>
<P>The other three trials compared immediate antibiotics with a watchful waiting approach (<LINK REF="STD-Laxdal-1970" TYPE="STUDY">Laxdal 1970</LINK>; <LINK REF="STD-McCormick-2005" TYPE="STUDY">McCormick 2005</LINK>; <LINK REF="STD-Neumark-2007" TYPE="STUDY">Neumark 2007</LINK>). In the <LINK REF="STD-Laxdal-1970" TYPE="STUDY">Laxdal 1970</LINK> trial, children in the control group were closely monitored, especially during the first 48 hours and particularly when severe involvement was evident. In the <LINK REF="STD-McCormick-2005" TYPE="STUDY">McCormick 2005</LINK> trial, antibiotics were administered to the watchful waiting group if a child returned to the office with a treatment failure or recurrence (four children in the expectant observation group had received antibiotics by day four). In the <LINK REF="STD-Neumark-2007" TYPE="STUDY">Neumark 2007</LINK> trial, 5% (4/87) of children randomised to the watchful waiting group received antibiotics due to treatment failure.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcomes</HEADING>
<P>One trial did not report any data on our primary or secondary outcomes (<LINK REF="STD-Laxdal-1970" TYPE="STUDY">Laxdal 1970</LINK>), leaving four trials from which relevant data could be extracted (<LINK REF="STD-Little-2001" TYPE="STUDY">Little 2001</LINK>; <LINK REF="STD-McCormick-2005" TYPE="STUDY">McCormick 2005</LINK>; <LINK REF="STD-Neumark-2007" TYPE="STUDY">Neumark 2007</LINK>; <LINK REF="STD-Spiro-2006" TYPE="STUDY">Spiro 2006</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="5">Pain</HEADING>
<P>Data on pain at three to seven days could be derived from four trials (959 children) (<LINK REF="STD-Little-2001" TYPE="STUDY">Little 2001</LINK>; <LINK REF="STD-McCormick-2005" TYPE="STUDY">McCormick 2005</LINK>; <LINK REF="STD-Neumark-2007" TYPE="STUDY">Neumark 2007</LINK>; <LINK REF="STD-Spiro-2006" TYPE="STUDY">Spiro 2006</LINK>). The data on pain from the <LINK REF="STD-Little-2001" TYPE="STUDY">Little 2001</LINK> trial have been derived from data from the IPD meta-analysis (<LINK REF="REF-Rovers-2006" TYPE="REFERENCE">Rovers 2006</LINK>), while the data on pain from the <LINK REF="STD-McCormick-2005" TYPE="STUDY">McCormick 2005</LINK> trial have been provided by the author. One trial (247 children) reported data on pain at 11 to 14 days (<LINK REF="STD-Spiro-2006" TYPE="STUDY">Spiro 2006</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse effects likely to be related to the use of antibiotics (vomiting, diarrhoea or rash)</HEADING>
<P>Two trials (550 children) reported data on adverse events likely to be related to the use of antibiotics such as vomiting, diarrhoea or rash (<LINK REF="STD-Little-2001" TYPE="STUDY">Little 2001</LINK>; <LINK REF="STD-Spiro-2006" TYPE="STUDY">Spiro 2006</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Abnormal tympanometry findings as a surrogate measure for hearing problems</HEADING>
<P>One trial (207 children) reported data on abnormal tympanometry findings at two to four weeks (<LINK REF="STD-McCormick-2005" TYPE="STUDY">McCormick 2005</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Tympanic membrane perforation</HEADING>
<P>One trial (179 children) reported data on tympanic membrane perforation (<LINK REF="STD-Neumark-2007" TYPE="STUDY">Neumark 2007</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Progression of symptoms (contralateral otitis or late AOM recurrences)</HEADING>
<P>None of the trials reported data on contralateral otitis (in unilateral cases), while one trial (209 children) reported data on late AOM recurrences (<LINK REF="STD-McCormick-2005" TYPE="STUDY">McCormick 2005</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Serious complications</HEADING>
<P>Three trials reported on serious complications including mastoiditis or meningitis (<LINK REF="STD-McCormick-2005" TYPE="STUDY">McCormick 2005</LINK>; <LINK REF="STD-Neumark-2007" TYPE="STUDY">Neumark 2007</LINK>; <LINK REF="STD-Spiro-2006" TYPE="STUDY">Spiro 2006</LINK>), while information on complications was not explicitly reported in one trial (<LINK REF="STD-Little-2001" TYPE="STUDY">Little 2001</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Long-term effects</HEADING>
<P>One trial reported data on the further ear pain episodes at three months and one year after randomisation (<LINK REF="STD-Little-2001" TYPE="STUDY">Little 2001</LINK>). These long-term outcome data were collected by questionnaires. Questionnaires were returned in 219 of the 315 children (70%) that were originally randomised at one year.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<P>We excluded 11 studies after reviewing the full text. Three were non-randomised studies (<LINK REF="STD-Ostfeld-1987" TYPE="STUDY">Ostfeld 1987</LINK>; <LINK REF="STD-Rudberg-1954" TYPE="STUDY">Rudberg 1954</LINK>; <LINK REF="STD-van-Buchem-1985" TYPE="STUDY">van Buchem 1985</LINK>), while three other studies had no comparison of antibiotic with placebo or expectant observation (<LINK REF="STD-Casey-2012" TYPE="STUDY">Casey 2012</LINK>; <LINK REF="STD-Engelhard-1989" TYPE="STUDY">Engelhard 1989</LINK>; <LINK REF="STD-Sarrell-2003" TYPE="STUDY">Sarrell 2003</LINK>). Two trials studied the effectiveness of short- versus long-course antibiotics (<LINK REF="STD-Arguedas-2011" TYPE="STUDY">Arguedas 2011</LINK>; <LINK REF="STD-Chaput-1982" TYPE="STUDY">Chaput 1982</LINK>), one trial studied a single-dose antibiotic with slow versus immediate-release formulations (<LINK REF="STD-Liu-2011" TYPE="STUDY">Liu 2011</LINK>), whereas another trial was conducted in children with ventilation tubes (<LINK REF="STD-Ruohola-2003" TYPE="STUDY">Ruohola 2003</LINK>). Moreover, we excluded one trial report as this study reported on the effectiveness of immediate versus delayed antibiotic prescription based on a secondary analysis of a placebo-controlled trial (<LINK REF="STD-T_x00e4_htinen-2012" TYPE="STUDY">Tähtinen 2012</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<P>The methodological quality of the included studies was generally high. For further details on the risk of bias in included studies see the 'Risk of bias' summary (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>) and 'Risk of bias' graph (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>).</P>
<ALLOCATION MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<P>Concealment of allocation was adequately described in 11 of the 13 included trials comparing antibiotics with placebo (<LINK REF="STD-Appelman-1991" TYPE="STUDY">Appelman 1991</LINK>; <LINK REF="STD-Burke-1991" TYPE="STUDY">Burke 1991</LINK>; <LINK REF="STD-Damoiseaux-2000" TYPE="STUDY">Damoiseaux 2000</LINK>; <LINK REF="STD-Hoberman-2011" TYPE="STUDY">Hoberman 2011</LINK>; <LINK REF="STD-Howie-1972" TYPE="STUDY">Howie 1972</LINK>; <LINK REF="STD-Le-Saux-2005" TYPE="STUDY">Le Saux 2005</LINK>; <LINK REF="STD-Mygind-1981" TYPE="STUDY">Mygind 1981</LINK>; <LINK REF="STD-T_x00e4_htinen-2011" TYPE="STUDY">Tähtinen 2011</LINK>; <LINK REF="STD-Tapiainen-2014" TYPE="STUDY">Tapiainen 2014</LINK>; <LINK REF="STD-Thalin-1985" TYPE="STUDY">Thalin 1985</LINK>; <LINK REF="STD-van-Buchem-1981a" TYPE="STUDY">van Buchem 1981a</LINK> and <LINK REF="STD-van-Buchem-1981b" TYPE="STUDY">van Buchem 1981b</LINK>), and two out of five trials comparing immediate antibiotics with expectant observation (<LINK REF="STD-Little-2001" TYPE="STUDY">Little 2001</LINK>; <LINK REF="STD-Spiro-2006" TYPE="STUDY">Spiro 2006</LINK>). Random sequence generation was adequate in seven of the 13 trials (<LINK REF="STD-Appelman-1991" TYPE="STUDY">Appelman 1991</LINK>; <LINK REF="STD-Burke-1991" TYPE="STUDY">Burke 1991</LINK>; <LINK REF="STD-Damoiseaux-2000" TYPE="STUDY">Damoiseaux 2000</LINK>; <LINK REF="STD-Hoberman-2011" TYPE="STUDY">Hoberman 2011</LINK>; <LINK REF="STD-Le-Saux-2005" TYPE="STUDY">Le Saux 2005</LINK>; <LINK REF="STD-T_x00e4_htinen-2011" TYPE="STUDY">Tähtinen 2011</LINK>; <LINK REF="STD-Tapiainen-2014" TYPE="STUDY">Tapiainen 2014</LINK>), and in three of the five included trials (<LINK REF="STD-McCormick-2005" TYPE="STUDY">McCormick 2005</LINK>; <LINK REF="STD-Neumark-2007" TYPE="STUDY">Neumark 2007</LINK>; <LINK REF="STD-Spiro-2006" TYPE="STUDY">Spiro 2006</LINK>), respectively.</P>
</ALLOCATION>
<BLINDING MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<P>All included trials in the review of antibiotics against placebo stated that they were double-blinded. However, we judged blinding to be adequate in eight of the 13 included trials (<LINK REF="STD-Burke-1991" TYPE="STUDY">Burke 1991</LINK>; <LINK REF="STD-Damoiseaux-2000" TYPE="STUDY">Damoiseaux 2000</LINK>; <LINK REF="STD-Hoberman-2011" TYPE="STUDY">Hoberman 2011</LINK>; <LINK REF="STD-Le-Saux-2005" TYPE="STUDY">Le Saux 2005</LINK>; <LINK REF="STD-T_x00e4_htinen-2011" TYPE="STUDY">Tähtinen 2011</LINK>; <LINK REF="STD-Tapiainen-2014" TYPE="STUDY">Tapiainen 2014</LINK>; <LINK REF="STD-Thalin-1985" TYPE="STUDY">Thalin 1985</LINK>; <LINK REF="STD-van-Buchem-1981a" TYPE="STUDY">van Buchem 1981a</LINK> and <LINK REF="STD-van-Buchem-1981b" TYPE="STUDY">van Buchem 1981b</LINK>). All five trials comparing immediate antibiotics with expectant observation were open-label trials (<LINK REF="STD-Laxdal-1970" TYPE="STUDY">Laxdal 1970</LINK>; <LINK REF="STD-Little-2001" TYPE="STUDY">Little 2001</LINK>; <LINK REF="STD-McCormick-2005" TYPE="STUDY">McCormick 2005</LINK>; <LINK REF="STD-Neumark-2007" TYPE="STUDY">Neumark 2007</LINK>; <LINK REF="STD-Spiro-2006" TYPE="STUDY">Spiro 2006</LINK>). As a consequence, reporting of the child's symptoms by parents was not blinded in these trials. However, investigators were blinded in two of the five trials (<LINK REF="STD-McCormick-2005" TYPE="STUDY">McCormick 2005</LINK>; <LINK REF="STD-Spiro-2006" TYPE="STUDY">Spiro 2006</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<P>The loss to follow-up was below 5% in eight of the 13 trials comparing antibiotics with placebo (<LINK REF="STD-Appelman-1991" TYPE="STUDY">Appelman 1991</LINK>; <LINK REF="STD-Burke-1991" TYPE="STUDY">Burke 1991</LINK>; <LINK REF="STD-Hoberman-2011" TYPE="STUDY">Hoberman 2011</LINK>; <LINK REF="STD-Howie-1972" TYPE="STUDY">Howie 1972</LINK>; <LINK REF="STD-Le-Saux-2005" TYPE="STUDY">Le Saux 2005</LINK>; <LINK REF="STD-T_x00e4_htinen-2011" TYPE="STUDY">Tähtinen 2011</LINK>; <LINK REF="STD-Tapiainen-2014" TYPE="STUDY">Tapiainen 2014</LINK>; <LINK REF="STD-Thalin-1985" TYPE="STUDY">Thalin 1985</LINK>). Loss to follow-up was high in three trials with a total loss to follow-up of 15% (<LINK REF="STD-van-Buchem-1981a" TYPE="STUDY">van Buchem 1981a</LINK> and <LINK REF="STD-van-Buchem-1981b" TYPE="STUDY">van Buchem 1981b</LINK>), 7% (<LINK REF="STD-Kaleida-1991" TYPE="STUDY">Kaleida 1991</LINK>), and 12% (<LINK REF="STD-Damoiseaux-2000" TYPE="STUDY">Damoiseaux 2000</LINK>), respectively. However, one of these trials included all randomised patients in the primary analysis at day four (<LINK REF="STD-Damoiseaux-2000" TYPE="STUDY">Damoiseaux 2000</LINK>). In two of the 13 trials the total number of loss to follow-up/exclusions are described but it was unclear from which treatment group children were excluded (<LINK REF="STD-Halsted-1968" TYPE="STUDY">Halsted 1968</LINK>; <LINK REF="STD-Mygind-1981" TYPE="STUDY">Mygind 1981</LINK>). For the review of immediate antibiotics against expectant observation, the loss to follow-up was below 5% in two of the five trials (<LINK REF="STD-McCormick-2005" TYPE="STUDY">McCormick 2005</LINK>; <LINK REF="STD-Neumark-2007" TYPE="STUDY">Neumark 2007</LINK>). The total loss to follow-up in the other trials was 11% (<LINK REF="STD-Laxdal-1970" TYPE="STUDY">Laxdal 1970</LINK>), 10% (<LINK REF="STD-Little-2001" TYPE="STUDY">Little 2001</LINK>), and 6% (<LINK REF="STD-Spiro-2006" TYPE="STUDY">Spiro 2006</LINK>), respectively.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2015-01-20 11:33:50 +1000" MODIFIED_BY="Liz  Dooley">
<P>Eight of the 13 included trials comparing antibiotics with placebo used intention-to-treat (ITT) analyses, while in the other five this was not clear (<LINK REF="STD-Halsted-1968" TYPE="STUDY">Halsted 1968</LINK>; <LINK REF="STD-Howie-1972" TYPE="STUDY">Howie 1972</LINK>; <LINK REF="STD-Mygind-1981" TYPE="STUDY">Mygind 1981</LINK>; <LINK REF="STD-Thalin-1985" TYPE="STUDY">Thalin 1985</LINK>; <LINK REF="STD-van-Buchem-1981a" TYPE="STUDY">van Buchem 1981a</LINK> and <LINK REF="STD-van-Buchem-1981b" TYPE="STUDY">van Buchem 1981b</LINK>). For the review of immediate antibiotics versus expectant observation, three of the five included trials used ITT analyses, while this was not clear in the other two trials (<LINK REF="STD-Laxdal-1970" TYPE="STUDY">Laxdal 1970</LINK>; <LINK REF="STD-Neumark-2007" TYPE="STUDY">Neumark 2007</LINK>).</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<P>No other potential sources of bias could be detected in the included trials, except for the <LINK REF="STD-Laxdal-1970" TYPE="STUDY">Laxdal 1970</LINK> trial, which we judged as having a high risk of detection bias since children in the control group were subjected to very close scrutiny, especially during the first 48 hours and particularly when severe involvement was evident. However, this trial did not report any data on our primary or secondary outcomes.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2015-06-19 19:21:24 +1000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Antibiotics versus placebo</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">1. Proportion of children with pain at various time points</HEADING>
<P>The combined results of the trials revealed that by 24 hours from the start of treatment, 60% of the children had recovered whether or not they had placebo or antibiotics. The proportion of children that recovered spontaneously at two to three days, four to seven days and 10 to 12 days was 84%, 76% and 78%, respectively. Antibiotics achieved a 30% (95% confidence interval (CI) 14% to 43%) relative reduction in the risk of pain at two to three days, 24% (95% CI 9% to 37%) relative reduction in the risk of pain at four to seven days and 67% (95% CI 34% to 83%) relative reduction in the risk of pain at 10 to 12 days (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). This means 5% (95% CI 2% to 7%) fewer children had pain after two to three days (number needed to treat for an additional beneficial outcome (NNTB) 20, 95% CI 14 to 50), 6% (95% CI 2% to 9%) fewer children had pain after four to seven days (NNTB 16, 95% CI 11 to 50) and 14% (95% CI 6% to 22%) fewer children had pain after 10 to 12 days (NNTB 7, 95% CI 4 to 16), respectively. Plots of the event rate (pain) in the treatment and control groups for each study at 24 hours and two to three days are reported in <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> and <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>. The funnel plot for pain at the various time points did not reveal asymmetry (<LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="5">Quality of the evidence</HEADING>
<P>We judged the data on pain at 24 hours, two to three days and four to seven days to be of high quality, while we judged the data on pain at 10 to 12 days to be of moderate quality. We downgraded the evidence for pain at days 10 to 12 from high quality as this outcome was not specified a priori in this trial (secondary analysis).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Adverse effects likely to be related to the use of antibiotics</HEADING>
<P>Antibiotics resulted in a 38% (95% CI 15% to 73%) relative increase in the risk of adverse effects likely to be related to the use of antibiotics (defined as vomiting, diarrhoea or rash) compared with placebo; 27% (283/1044) of children treated with antibiotics versus 20% (208/1063) of children treated with placebo experienced vomiting, diarrhoea or rash (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). The number needed to treat for an additional harmful outcome (NNTH) was 14 (9 to 26).</P>
<SUBSECTION>
<HEADING LEVEL="5">Quality of the evidence</HEADING>
<P>We judged the evidence for adverse effects likely to be related to the use of antibiotics (vomiting, diarrhoea or rash) to be of high quality.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">1. Abnormal tympanometry findings at various time points</HEADING>
<P>Antibiotics achieved an 18% (95% CI 10% to 26%) relative reduction in the risk of abnormal tympanometry findings at two to four weeks, and a 12% (95% CI 0% to 22%) relative reduction in the risk of abnormal tympanometry findings at six to eight weeks (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). This means 9% (95% CI 5% to 13%) fewer children had abnormal tympanometry findings at two to four weeks (NNTB 11, 95% CI 7 to 20) and 6% (95% CI 0% to 12%) fewer children had abnormal tympanometry findings at six to eight weeks (NNTB 16, 95% CI 8 to 277), respectively.</P>
<P>However, antibiotics were not associated with a statistically significant reduction in the risk of abnormal tympanometry findings at three months compared with placebo (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). Furthermore, audiometry was done in only two studies and incompletely reported. The two studies that used audiograms were <LINK REF="STD-van-Buchem-1981a" TYPE="STUDY">van Buchem 1981a</LINK> and <LINK REF="STD-Kaleida-1991" TYPE="STUDY">Kaleida 1991</LINK>: (i) <LINK REF="STD-van-Buchem-1981a" TYPE="STUDY">van Buchem 1981a</LINK> reported that, "After one month, 31% of the patients showed an air/bone gap of more than 20 dB. After two months, this was still the case with 19% of the patients. Here again, there were no significant differences between the groups"; (ii) <LINK REF="STD-Kaleida-1991" TYPE="STUDY">Kaleida 1991</LINK> stated that "Analysis of hearing acuity in children two years of age and older indicated that elevated hearing thresholds ... bore no apparent relationship ... to mode of treatment (amoxicillin versus placebo)".</P>
<SUBSECTION>
<HEADING LEVEL="5">Quality of the evidence</HEADING>
<P>We judged the evidence for abnormal tympanometry findings at the various time points to be of high quality.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Tympanic membrane perforation</HEADING>
<P>Antibiotic treatment was associated with a 63% (95% CI 24% to 82%) relative reduction in the risk of tympanic membrane perforation compared with placebo (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>). However, absolute benefits of antibiotics appeared to be small: 3% (95% CI 1% to 5%) fewer children had a tympanic membrane perforation. Therefore, 33 children (95% CI 20 to 100) needed to be treated to prevent one child experiencing a tympanic membrane perforation.</P>
<SUBSECTION>
<HEADING LEVEL="5">Quality of the evidence</HEADING>
<P>We judged the evidence for tympanic membrane perforation to be of high quality.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Contralateral otitis</HEADING>
<P>Antibiotics were associated with a 51% (5% to 75%) relative reduction in the development of contralateral otitis compared with placebo (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>). This means 9% (95% CI 5% to 13%) fewer children had contralateral otitis (NNTB 11, 95% CI 7 to 20).</P>
<SUBSECTION>
<HEADING LEVEL="5">Quality of the evidence</HEADING>
<P>We judged the evidence for contralateral otitis to be of high quality.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4. AOM recurrences</HEADING>
<P>Antibiotics were not associated with a statistically significant reduction in the occurrence of late AOM recurrences compared with placebo (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>). AOM recurrences were common. <LINK REF="STD-Burke-1991" TYPE="STUDY">Burke 1991</LINK> stated "The mean number of recorded recurrences of otitis media or acute red ear was 0.70 (range 0 to 4) in the antibiotic group and 0.63 (range 0 to 7) in the placebo group and this difference was not significant (difference 0.06, 95% CI -0.22 to 0.339)." Six other trials reported the proportions who relapsed; combined, these give a risk ratio (RR) of 0.93 (95% CI 0.78 to 1.10), which is consistent with Burke's findings.</P>
<SUBSECTION>
<HEADING LEVEL="5">Quality of the evidence</HEADING>
<P>We judged the evidence for late AOM recurrences to be of high quality.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5. Serious complications related to AOM</HEADING>
<P>Few serious complications occurred in either the antibiotic treatment group or the control group. In just over 3000 children studied, only one case of mastoiditis occurred in both the antibiotic group (<LINK REF="STD-Mygind-1981" TYPE="STUDY">Mygind 1981</LINK>) and the placebo group (<LINK REF="STD-Hoberman-2011" TYPE="STUDY">Hoberman 2011</LINK>). Moreover, one child suffered from meningitis (<LINK REF="STD-Damoiseaux-2000" TYPE="STUDY">Damoiseaux 2000</LINK>), pneumococcal bacteraemia and radiologically confirmed pneumonia (<LINK REF="STD-Hoberman-2011" TYPE="STUDY">Hoberman 2011</LINK>) in the placebo group and one child had transient facial paralysis in the antibiotic group (<LINK REF="STD-Kaleida-1991" TYPE="STUDY">Kaleida 1991</LINK>). Hence, the applicability of these findings to groups of children in whom serious complications such as mastoiditis is common is uncertain. One of the excluded studies did report high rates of mastoiditis (<LINK REF="STD-Rudberg-1954" TYPE="STUDY">Rudberg 1954</LINK>). This was an open, semi-randomised study conducted in Sweden in 1954. Participants were randomised by case-sheet number but a proportion (about 30 of 220) requested, and were granted, entry to the penicillin group. The rate of mastoiditis was 17% in the untreated group versus 1.5% in the sulphonamide-treated group and 0% in the penicillin-treated group. The biases of this study (semi-randomisation and unblinded outcome assessment) are unlikely to explain such a large difference.</P>
<SUBSECTION>
<HEADING LEVEL="5">Quality of the evidence</HEADING>
<P>We judged the evidence for serious complications to be of moderate quality. We downgraded the evidence from high quality as we considered the sample size to be insufficient to draw any definite conclusions based on these data and due to the conflicting results found in an open, semi-randomised study that was not included in our review.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6. Long-term effects</HEADING>
<P>Based on reviewing children's notes, antibiotics were not associated with a statistically significant reduction in the number of secondary care referrals at one year after randomisation: 7/110 (6%) in the antibiotic group and 9/111 (8%) in the placebo group (RR 0.78, 95% 0.30 to 2.03).</P>
<P>Based on questionnaires returned by parents approximately 3.5 years after initial randomisation, antibiotics were associated with a 46% (95% CI 8% to 97%) relative increase in the risk of AOM recurrences. This means 20% (95% CI 5% to 35%) fewer children had AOM recurrences (NNTB 5, 95% CI 2 to 20). No between-group differences were observed for secondary care referrals. Furthermore, antibiotics were not associated with a statistically significant reduction in the number of ear, nose and throat surgeries (RR 0.68, 95% CI 0.40 to 1.17).</P>
<SUBSECTION>
<HEADING LEVEL="5">Quality of the evidence</HEADING>
<P>We judged the evidence for long-term effects at one year to be of high quality, while we judged the 3.5 years data to be of moderate quality. We mainly downgraded the evidence from high quality because of the high proportion of children that were not included in the analysis (30%), which introduced a significant risk of (attrition) bias.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Immediate antibiotics versus expectant observation</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">1. Proportion of children with pain at various time points</HEADING>
<P>Immediate antibiotics were not associated with a statistically significant reduction in the risk of pain at three to seven days (RR 0.75, 95% CI 0.50 to 1.12) and 11 to 14 days (RR 0.91, 95% CI 0.75 to 1.10) compared with expectant observation (observation with or without an antibiotic prescription) (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="5">Quality of the evidence</HEADING>
<P>We judged the data on pain at three to seven days to be of high quality, while we judged the data on pain at 11 to 14 days to be of moderate quality. We downgraded the evidence for pain at days 11 to 14 from high quality because of the substantial number of children that were 'lost to follow-up' (13%), which introduced a risk of (attrition) bias.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Adverse effects likely to be related to the use of antibiotics</HEADING>
<P>Immediate antibiotics were associated with a 71% (95% CI 24% to 136%) relative increase in the risk of adverse effects likely to be related to the use of antibiotics (defined as vomiting, diarrhoea or rash) compared with expectant observation; 29% (77/268) of children treated with immediate antibiotics versus 17% (47/282) of children treated with expectant observation experienced vomiting, diarrhoea or rash (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>). The NNTH was 9 (6 to 20).</P>
<SUBSECTION>
<HEADING LEVEL="5">Quality of the evidence</HEADING>
<P>We judged the evidence for adverse effects likely to be related to the use of antibiotics (vomiting, diarrhoea or rash) to be of high quality.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">1. Abnormal tympanometry findings at various time points</HEADING>
<P>In one trial (207 children), the proportion of children with abnormal tympanometry findings at four weeks did not substantially differ between those receiving immediate antibiotics and expectant observation (RR 1.03, 95% CI 0.78 to 1.35) (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="5">Quality of the evidence</HEADING>
<P>We judged the data on abnormal tympanometry findings at four weeks to be of moderate quality. We downgraded the evidence from high quality as the number of children that were 'lost to follow-up' in the immediate antibiotics group was substantially lower than in the expectant observation group (4% versus 11%), thereby introducing a risk of (attrition) bias.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Tympanic membrane perforation</HEADING>
<P>No tympanic membrane perforations were observed in either group in the only trial (179 children) reporting on this outcome (<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="5">Quality of the evidence</HEADING>
<P>We judged the data on tympanic membrane perforation to be of moderate quality. We downgraded the evidence from high quality as we considered the sample size to be insufficient to draw any definite conclusions based on these data</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Contralateral otitis</HEADING>
<P>None of the trials reported data on contralateral otitis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4. AOM recurrences</HEADING>
<P>In one trial (209 children), immediate antibiotics were associated with a non-statistically significant 41% (95% CI -26% to 169%) relative increase in the risk of AOM recurrences (<LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="5">Quality of the evidence</HEADING>
<P>We judged the data on late AOM recurrences to be of moderate quality. We downgraded the evidence from high quality as the number of children that were 'lost to follow-up' in the immediate antibiotics group was substantially lower than in the expectant observation group (3% versus 10%), thereby introducing a risk of (attrition) bias.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5. Serious complications related to AOM</HEADING>
<P>No serious complications occurred in either the immediate antibiotic group or the expectant observation group.</P>
<SUBSECTION>
<HEADING LEVEL="5">Quality of the evidence</HEADING>
<P>We judged the evidence for serious complications to be of moderate quality. We downgraded the evidence from high quality as we considered the sample size to be insufficient to draw any definite conclusions based on these data.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6. Long-term effects</HEADING>
<P>No statistically significant differences were observed between the immediate antibiotics and the delayed antibiotics group in parent-reported ear pain episodes at one year (odds ratio (OR) 1.03, 95% 0.60 to 1.78).</P>
<SUBSECTION>
<HEADING LEVEL="5">Quality of the evidence</HEADING>
<P>We judged the evidence for long-term effects to be of moderate quality. We mainly downgraded the evidence from high quality as this evidence was derived from a secondary analysis and because of the high proportion of children that were not included in the analysis at one year (30%), which introduced a significant risk of (attrition) bias.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Individual patient data (IPD) meta-analysis to identify children most likely to benefit from antibiotic treatment</HEADING>
<P>In 2006, an individual patient data (IPD) meta-analysis was performed, <LINK REF="REF-Rovers-2006" TYPE="REFERENCE">Rovers 2006</LINK>, using data from six high-quality RCTs, including a total of 1643 children, which were also included in this review as individual trials (<LINK REF="STD-Appelman-1991" TYPE="STUDY">Appelman 1991</LINK>; <LINK REF="STD-Burke-1991" TYPE="STUDY">Burke 1991</LINK>; <LINK REF="STD-Damoiseaux-2000" TYPE="STUDY">Damoiseaux 2000</LINK>; <LINK REF="STD-Le-Saux-2005" TYPE="STUDY">Le Saux 2005</LINK>; <LINK REF="STD-Little-2001" TYPE="STUDY">Little 2001</LINK>; <LINK REF="STD-McCormick-2005" TYPE="STUDY">McCormick 2005</LINK>). The main findings of this IPD meta-analysis were that significant effect modifications were noted for age and bilateral AOM and for otorrhoea; in children aged less than two years with bilateral AOM, 55% of the control group and 30% of the antibiotics group still had pain, fever or both at three to seven days (absolute risk reduction of 25%, 95% CI 14% to 36%; NNTB 4). In children aged two years or older with bilateral AOM the absolute risk reduction was 12% (95% CI -1% to 25%; P value for interaction = 0.022). Among children with otorrhoea, 60% of those in the control group had pain, fever or both at three to seven days versus 24% in the antibiotics group (risk reduction of 36%, 95% CI 19% to 53%; NNTB 3). The absolute reduction in risk among those without otorrhoea was 14% (95% CI 5% to 23%; NNTB 8; P value for interaction = 0.039). No differences were identified for age alone.</P>
<SUBSECTION>
<HEADING LEVEL="5">Quality of the evidence</HEADING>
<P>We judged the evidence for subgroup analyses based on the IPD meta-analysis to be of high quality.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2015-06-20 08:35:19 +1000" MODIFIED_BY="Liz Dooley">
<SUMMARY_OF_RESULTS MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<P>This review reveals that antibiotics have no early effect on pain, a slight effect on pain in the days following and only a modest effect on the number of children with tympanic perforations, contralateral otitis episodes and abnormal tympanometry findings at two to four weeks and at six to eight weeks, compared with placebo in children with acute otitis media (AOM). However, in applying these results, there are a number of issues to consider, including the individual potential for serious complications and subgroups of children in whom there may be greater benefits.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2015-06-19 19:26:40 +1000" MODIFIED_BY="[Empty name]">
<P>Does the effect vary in different clinical groups? Our number needed to treat for an additional beneficial outcome (NNTB) of 20 for pain at days two to three days, 16 for pain at four to seven days and seven for pain at 10 to 12 days is for the 'average' case and may vary in subgroups. Several studies reported higher rates of failure of placebo treatment among children less than two years of age and those with bilateral disease (<LINK REF="STD-Appelman-1991" TYPE="STUDY">Appelman 1991</LINK>; <LINK REF="STD-Burke-1991" TYPE="STUDY">Burke 1991</LINK>; <LINK REF="STD-Damoiseaux-2000" TYPE="STUDY">Damoiseaux 2000</LINK>; <LINK REF="STD-Hoberman-2011" TYPE="STUDY">Hoberman 2011</LINK>; <LINK REF="STD-T_x00e4_htinen-2011" TYPE="STUDY">Tähtinen 2011</LINK>), and another trial has suggested that most benefit is seen in children with high fever or vomiting (<LINK REF="STD-Little-2001" TYPE="STUDY">Little 2001</LINK>). Moreover, some studies found that children with bilateral AOM differ with regards to clinical and microbiological (increased presence of (non-typeable) <I>H. influenzae</I>) characteristics compared with children with unilateral AOM (<LINK REF="REF-Barkai-2009" TYPE="REFERENCE">Barkai 2009</LINK>; <LINK REF="REF-McCormick-2007" TYPE="REFERENCE">McCormick 2007</LINK>). However, the individual patient data (IPD) meta-analysis demonstrated that the relative effects of antibiotics were not significantly modified by either age or bilateral disease alone but the absolute differences were larger in the younger patients (less than two years) with bilateral disease and in children with both AOM and otorrhoea (<LINK REF="REF-Rovers-2006" TYPE="REFERENCE">Rovers 2006</LINK>). Further analysis of these data has shown that age younger than two years is an independent predictor of the development of asymptomatic middle-ear effusion (<LINK REF="REF-Koopman-2008" TYPE="REFERENCE">Koopman 2008</LINK>). This analysis also found that antibiotic therapy has a marginal effect on the development of asymptomatic middle-ear effusion in children with AOM.</P>
<P>Does the impact vary by duration and dose of antibiotics? Most trials use seven days of antibiotic treatment. One recent meta-analysis of a short (less than seven days) versus long (more than seven days) course of antibiotics reported that risk of treatment failure at one month was higher with short courses of antibiotics (odds ratio (OR) 1.34, 95% confidence interval (CI) 1.15 to 1.55) (<LINK REF="REF-Kozyrskyj-2010" TYPE="REFERENCE">Kozyrskyj 2010</LINK>). However, the absolute difference in treatment effect was small (3%) and short courses of antibiotics were associated with a statistically significant reduction in gastrointestinal adverse events compared with longer courses. A recommendation regarding the most appropriate dose of antibiotics is not possible due to a lack of sufficient data.</P>
<P>What are the potential consequences of not using antibiotics? Besides the immediate pain associated with AOM, there are some more serious complications. Though only two cases of mastoiditis were reported in the included trials (one child received antibiotics and one child was assigned to placebo), a semi-randomised trial in Sweden in 1954 reported a rate of 17% in the untreated group versus none in the penicillin-treated groups (<LINK REF="STD-Rudberg-1954" TYPE="STUDY">Rudberg 1954</LINK>). In populations or sub-populations where mastoiditis is still judged a frequent problem, such as in some low-income countries, antibiotic treatment would be strongly advised (<LINK REF="REF-Berman-1995" TYPE="REFERENCE">Berman 1995</LINK>).</P>
<P>Of note is an article that revealed that doctors commonly over-diagnose AOM (<LINK REF="REF-Rothman-2003" TYPE="REFERENCE">Rothman 2003</LINK>). What effect might this have on the efficacy of antibiotics (or any treatment)? One effect will be to blunt any treatment effect by dilution (from the cases of non-AOM). The results of two recently performed trials (<LINK REF="STD-Hoberman-2011" TYPE="STUDY">Hoberman 2011</LINK>; <LINK REF="STD-T_x00e4_htinen-2011" TYPE="STUDY">Tähtinen 2011</LINK>), in which AOM has been diagnosed with the use of stringent criteria (including pneumatic otoscopic examination in one trial (<LINK REF="STD-T_x00e4_htinen-2011" TYPE="STUDY">Tähtinen 2011</LINK>), underline this phenomenon. Nevertheless, physicians in daily practice are likely to use the same diagnostic methods (perhaps even less stringent) as used in the majority of the included trials in this review. As a consequence, the effectiveness of antibiotics reported in this review is likely to be a true reflection of the effectiveness in actual clinical practice. However, if new and more accurate diagnostic procedures are introduced in future daily practice, then the current estimate of effectiveness will have to be reconsidered.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2015-06-20 08:35:19 +1000" MODIFIED_BY="Liz Dooley">
<P>The methodological quality of the included studies was generally high. We judged the evidence to be of high quality for most of the outcomes in the review of antibiotics against placebo. We judged the quality of evidence to be moderate for pain at 10 to 12 days, serious complications and long-term effects (3.5 years data). We downgraded the evidence mainly because of the risk of reporting bias (pain at 10 to 12 days), sample size considerations (serious complications) and the risk of attrition bias (long-term effects).</P>
<P>For the review of immediate antibiotics versus expectant observation, we judged the evidence to be of moderate quality for most of the outcomes. We downgraded the evidence mainly because of sample size considerations (tympanic membrane perforation, serious complications) and the risk of attrition bias (pain at days 11 to 14, abnormal tympanometry findings at four weeks, late AOM recurrences, long-term effects). We judged the evidence to be of high quality for pain at days four to seven and adverse effects likely to be related to the use of antibiotics.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2015-06-19 19:29:47 +1000" MODIFIED_BY="[Empty name]">
<P>There was some clinical heterogeneity among the included trials. For example, patients were recruited from different settings (general practice, ear, nose and throat and paediatric clinics). However, the majority of included trials did use a diagnostic method (clinical diagnosis of AOM as inclusion criteria) that resembles daily clinical practice. Besides, duration and dosage of the antibiotic treatment varied to some extent. For the review of antibiotics against placebo, the duration of antibiotic treatment varied from seven to 14 days. However, we do not consider this as a major drawback since most trials used seven days of antibiotic treatment and current evidence indicates only a small absolute treatment difference (3%) in treatment failure at one month in favour of a long (more than seven days) versus a short (less than seven days) course of antibiotics. Moreover, the primary outcome of this review (proportions of children with pain) is reported within the first seven days of antibiotic treatment. In addition, we assessed funnel plots for potential reporting biases for the primary analysis (<LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>). No asymmetry could be detected in the included trials.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2015-06-19 19:30:55 +1000" MODIFIED_BY="[Empty name]">
<P>This review demonstrated that at 24 hours pain had recovered spontaneously in 60% of children and that the majority had recovered in the following two to 12 days regardless of whether they had received placebo or antibiotics. However, the IPD meta-analysis, which included six of the trials included in this review, revealed a slower rate of recovery (<LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>) with only 22% of children experiencing spontaneous recovery at 24 hours (<LINK REF="REF-Rovers-2006" TYPE="REFERENCE">Rovers 2006</LINK>). There are a number of possible explanations for this. First, data from older trials were not included in the IPD meta-analysis and consequently the study population may reflect a higher threshold of doctor visitation; for example, the children may be 'sicker' or presenting to the doctor later in the course of their illness. Variation in the definitions of pain/no pain cut-offs among the trials included in the reviews may also explain some of this variation. From the IPD meta-analysis survival curve (<LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>) it can be seen that antibiotics had greatest effect compared with placebo at day three.</P>
<P>A previous meta-analysis has examined the question of whether antibiotics were indicated for AOM in children and concluded that the answer is a qualified 'yes' (<LINK REF="REF-Rosenfeld-1994" TYPE="REFERENCE">Rosenfeld 1994</LINK>). It estimated a NNTB of seven for "primary control" (complete clinical resolution), compared with our NNTB of 20 for symptom relief. The difference may be the consequence of our focus on patient-oriented outcomes, such as pain, rather than clinical signs, such as eardrum appearance. The previous systematic review suggests that where mastoiditis is not a concern, primary care physicians could weigh the benefits against the risks of adverse effects from antibiotics with their patients. This statement is in agreement with the findings of our review as adverse events such as diarrhoea, vomiting or rash were more common in children receiving antibiotics. In the IPD meta-analysis the most commonly described adverse effect of antibiotic treatment was diarrhoea, ranging from 2% to 14% in controls and from 4% to 21% in those given antibiotics (<LINK REF="REF-Rovers-2006" TYPE="REFERENCE">Rovers 2006</LINK>). Occurrence of rash ranged from 2% to 6% in the control groups and from 1% to 8% in the antibiotic groups. A recent systematic review and meta-analysis on common harms of amoxicillin revealed that harms were poorly reported in most placebo-controlled trials (<LINK REF="REF-Gillies-2014" TYPE="REFERENCE">Gillies 2014</LINK>). In this review, diarrhoea was attributed to amoxicillin only in the form of amoxicillin/clavulanate. Amoxicillin did increase the risk of candidiasis compared with placebo, but no association between amoxicillin and rash or vomiting was observed (<LINK REF="REF-Gillies-2014" TYPE="REFERENCE">Gillies 2014</LINK>). Bacterial resistance to antibiotics is also a consideration, with an association between antibiotic use and resistant bacteria demonstrated for many important pathogens (<LINK REF="REF-Arnold-2005" TYPE="REFERENCE">Arnold 2005</LINK>).</P>
<P>Several trials evaluated a management approach for AOM in which an expectant observational approach is used (<LINK REF="STD-Laxdal-1970" TYPE="STUDY">Laxdal 1970</LINK>; <LINK REF="STD-Little-2001" TYPE="STUDY">Little 2001</LINK>; <LINK REF="STD-McCormick-2005" TYPE="STUDY">McCormick 2005</LINK>; <LINK REF="STD-Neumark-2007" TYPE="STUDY">Neumark 2007</LINK>; <LINK REF="STD-Spiro-2006" TYPE="STUDY">Spiro 2006</LINK>). In one of these trials pain and malaise at day three were greater among those randomised to receive an antibiotic prescription with advice to fill it only if there was no improvement after 72 hours compared with those receiving immediate antibiotics (<LINK REF="STD-Little-2001" TYPE="STUDY">Little 2001</LINK>). In a secondary analysis of the trial no difference was found between delayed and immediate treatment groups in ear function and ear pain at three and 12 months (<LINK REF="REF-Little-2006" TYPE="REFERENCE">Little 2006</LINK>). Another study using a similar prescribing approach and examining clinical outcomes at four to six days found no difference between immediate and delayed antibiotic groups (<LINK REF="STD-Spiro-2006" TYPE="STUDY">Spiro 2006</LINK>). In the third study (<LINK REF="STD-McCormick-2005" TYPE="STUDY">McCormick 2005</LINK>), immediate antibiotic treatment was associated with decreased numbers of treatment failures and improved symptom control at day four and day 12 compared with those allocated to expectant observation with no prescription. <LINK REF="STD-Neumark-2007" TYPE="STUDY">Neumark 2007</LINK>, in a similar comparison, found that immediate antibiotics provided some symptomatic benefit; children who received antibiotics had less pain, used fewer analgesics and consulted less during the first seven days. Meta-analysis of data from these four trials found no difference in pain between immediate antibiotics and expectant observational approaches at three to seven days. Another review (<LINK REF="REF-Spurling-2013" TYPE="REFERENCE">Spurling 2013</LINK>), which evaluated the effect of delayed versus immediate or no antibiotics for respiratory infections and which included two studies on AOM (<LINK REF="STD-Little-2001" TYPE="STUDY">Little 2001</LINK>; <LINK REF="STD-Spiro-2006" TYPE="STUDY">Spiro 2006</LINK>), concluded that immediate antibiotics was the strategy most likely to provide the best clinical outcomes for AOM. One randomised study found that observation therapy with or without a prescription in children with AOM was well accepted by parents (<LINK REF="REF-Chao-2008" TYPE="REFERENCE">Chao 2008</LINK>). Antibiotic use was less in those randomised to observation without prescription and no complications were reported.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<P>Antibiotics produce a (small) reduction in the number of children with pain at two to three days (number needed to treat for an additional beneficial outcome (NNTB) 20), four to seven days (NNTB 16) and 10 to 12 days (NNTB 7) from initial assessment, and reduce the number of children with tympanic membrane perforations (NNTB 33), contralateral otitis episodes (NNTB 11) and abnormal tympanometry findings at two to four weeks (NNTB 11) and six to eight weeks (NNTB 16) compared with placebo. However, in high-income countries, most cases of acute otitis media (AOM) spontaneously remit without complications. The benefits of antibiotics must be weighed against the possible harms: for every 14 children treated with antibiotics one child experienced an adverse event (such as vomiting, diarrhoea or rash) that would not have occurred if antibiotics were withheld. Therefore management should emphasise advice about adequate analgesia and the limited role for antibiotics. Antibiotics are most useful in children under two years of age with bilateral AOM, or with both AOM and otorrhoea. For most other children with mild disease, an expectant observational approach seems justified. Cates has developed an appropriate handout and tested this together with an optional antibiotic prescription (<LINK REF="REF-Cates-1999" TYPE="REFERENCE">Cates 1999</LINK>). The handout is available at <A HREF="http://www.nntonline.net/ebm/main_pages/AOM.asp">www.nntonline.net/ebm/main_pages/AOM.asp</A> (accessed 22 November 2012).</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2015-06-19 00:46:28 +1000" MODIFIED_BY="[Empty name]">
<P>Further research is needed to determine if it is possible to predict which children are more likely to suffer from the complications of AOM and whether an expectant observation approach can be safely applied to children with mild AOM in low-income countries.<BR/>
</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2015-05-21 16:47:09 +1000" MODIFIED_BY="[Empty name]">
<P>We would like to thank Professor Charles Bridges-Webb (deceased) for stimulating initial discussions and for constructive advice on the protocol for this review and Professor Steve Berman for helpful comments on the draft review. We would like to thank Bruce Arroll and Tom Fahey for peer refereeing the 2005 updated review and Dilip Raghavan, Brian Westerberg, Mark Jones and Peter Morris for peer refereeing the 2009 updated review. We also thank Dilip Raghavan, Brian Westerberg, Teresa Neeman and Peter Morris for commenting on the 2012 updated review and Ann Fonfa, Julie Gildie, Conor Teljeur, Bruce Arroll, Brian Westerberg and Peter Morris for peer refereeing the 2015 updated review.</P>
<P>Thank you to David McCormick and his colleagues for allowing us to access raw study data from the trial comparing immediate antibiotics and expectant observation (<LINK REF="STD-McCormick-2005" TYPE="STUDY">McCormick 2005</LINK>).</P>
<P>Thank you to Chris Cates for noticing and advising us of an error in the confidence intervals presented in the review.</P>
<P>We gratefully thank Sarah Thorning for her support with the search strategy and searches.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2015-06-19 19:34:50 +1000" MODIFIED_BY="[Empty name]">
<P>Chris Del Mar (CDM) declares no conflicts of interests in the current work.<BR/>Maroeska M. Rovers (MMR) has participated in workshops and educational activities on otitis media organised by GlaxoSmithKline and received a grant from GlaxoSmithKline for a study on the microbiology of otitis media in 2009.<BR/>Roderick P. Venekamp (RPV) is an Editor of the Cochrane Acute Respiratory Infections Group.<BR/>Sharon L Sanders (SLS) declares no conflicts of interests in the current work.<BR/>Paul P Glasziou (PPG) is co-investigator on NHMRC funded grant Antibiotic Resistance.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<P>Chris Del Mar (CDM) and Paul P Glasziou (PPG) prepared the original version of the review.<BR/>Sharon L. Sanders (SLS) conducted searches, identified studies, extracted data and prepared the manuscript for the updated reviews in 2003, 2007 and 2008.<BR/>Maroeska M. Rovers (MMR) participated in the 2007 update by providing data and information from the individual patient data meta-analysis that has been included in this update.<BR/>Roderick P. Venekamp (RPV) conducted searches, identified studies, extracted data and prepared the manuscript for the updated review in 2012 and 2015.<BR/>PPG, CDM, MMR, SLS and RPV have reviewed and provided comments on the updated version of the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2015-06-19 19:35:25 +1000" MODIFIED_BY="[Empty name]">
<P>In this 2015 updated review, we now provide outcome data on:</P>
<UL>
<LI>pain at 24 hours, two to three days, four to seven days and 10 to 14 days (in earlier versions outcome data on pain were presented at 24 hours, two to three days and four to seven days);</LI>
<LI>abnormal tympanometry findings at two to four weeks, six to eight weeks and three months (in earlier versions outcome data on abnormal tympanometry findings were presented at four to six weeks and three months);</LI>
<LI>long-term effects including number of parent-reported AOM-symptom episodes, antibiotic prescriptions and health care utilisation as assessed at least one year after randomisation (in earlier versions no data on long-term effects were presented).</LI>
</UL>
<P>The outcome 'Adverse effects likely to be related to the use of antibiotics such as vomiting, diarrhoea or rash' has been added to primary outcomes (in earlier versions this outcome was listed as a secondary outcome) according to the recommendations described in Chapter 5.4.2 of the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>("the primary outcomes should include at least one desirable and at least one undesirable outcome") (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Appelman-1991" MODIFIED="2012-06-13 10:28:27 +1000" MODIFIED_BY="Roderick P. Venekamp" NAME="Appelman 1991" YEAR="1991">
<REFERENCE MODIFIED="2012-06-13 10:28:27 +1000" MODIFIED_BY="Roderick P. Venekamp" NOTES="&lt;p&gt;Appelman CL, Claessen JQ, Touw Otten FW, Hordijk GJ, de Melker RA. Co-amoxiclav in recurrent acute otitis media: placebo controlled study. British Medical Journal 1991; 303: 1450-2&lt;/p&gt;" NOTES_MODIFIED="2012-06-13 10:28:27 +1000" NOTES_MODIFIED_BY="Roderick P. Venekamp" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Appelman CL, Claessen JQ, Touw Otten FW, Hordijk GJ, de Melker RA</AU>
<TI>Co-amoxiclav in recurrent acute otitis media: placebo controlled study</TI>
<SO>BMJ</SO>
<YR>1991</YR>
<VL>303</VL>
<PG>1450-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Appelman CL, Claessen JQ, Touw Otten FW, Hordijk GJ, de Melker RA. Severity of inflammation of tympanic membrane as predictor of clinical course of recurrent acute otitis media. British Medical Journal 1993; 306: 895.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Appelman CL, Claessen JQ, Touw Otten FW, Hordijk GJ, de Melker RA</AU>
<TI>Severity of inflammation of tympanic membrane as predictor of clinical course of recurrent acute otitis media</TI>
<SO>BMJ</SO>
<YR>1993</YR>
<VL>306</VL>
<PG>895</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Claessen JQ, Appelman CL, Touw Otten FW, de Melker RA, Hordijk GJ. Persistence of middle ear dysfunction after recurrent acute otitis media. Clinical Otolaryngology 1994; 19: 35-40&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Claessen JQ, Appelman CL, Touw Otten FW, de Melker RA, Hordijk GJ</AU>
<TI>Persistence of middle ear dysfunction after recurrent acute otitis media</TI>
<SO>Clinical Otolaryngology</SO>
<YR>1994</YR>
<VL>19</VL>
<PG>35-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Burke-1991" MODIFIED="2008-11-22 21:48:26 +1000" MODIFIED_BY="[Empty name]" NAME="Burke 1991" YEAR="1991">
<REFERENCE MODIFIED="2008-11-22 21:48:26 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Burke P, Bain J, Robinson D, et al. Acute red ear in children: controlled trial of non-antibiotic treatment in general practice. BMJ 303:558-562, 1991.&lt;/p&gt;" NOTES_MODIFIED="2008-11-22 21:48:26 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Burke P, Bain J, Robinson D, Dunleavey J</AU>
<TI>Acute red ear in children: controlled trial of non-antibiotic treatment in general practice</TI>
<SO>BMJ</SO>
<YR>1991</YR>
<VL>303</VL>
<PG>558-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Damoiseaux-2000" MODIFIED="2015-01-19 11:38:53 +1000" MODIFIED_BY="Liz  Dooley" NAME="Damoiseaux 2000" YEAR="2000">
<REFERENCE MODIFIED="2015-01-19 11:38:46 +1000" MODIFIED_BY="Liz  Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bezáková N, Damoiseaux RA, Hoes AW, Schilder AG, Rovers MM</AU>
<TI>Recurrence up to 3.5 years after antibiotic treatment of acute otitis media in very young Dutch children: survey of trial participants</TI>
<SO>BMJ</SO>
<YR>2009</YR>
<VL>338</VL>
<PG>b2525</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-19 11:38:53 +1000" MODIFIED_BY="Liz  Dooley" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Damoiseaux RAMJ, van Balen FAM, Hoes AW, Verheij TJM, de Melker RA</AU>
<TI>Primary care based randomised, double blind trial of amoxicillin versus placebo for acute otitis media in children aged under 2 years</TI>
<SO>BMJ</SO>
<YR>2000</YR>
<VL>320</VL>
<PG>350-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Halsted-1968" NAME="Halsted 1968" YEAR="1968">
<REFERENCE NOTES="&lt;p&gt;Halsted C, Lepow ML, Balassanian N, Emmerich j, Wolinsky E. Otitis media: clinical observation, microbiology and evaluation of therapy. Amer J Dis Child, 115: 542-551, 1968.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Halsted C, Lepow ML, Balassanian N, Emmerich J, Wolinsky E</AU>
<TI>Otitis media: clinical observation, microbiology and evaluation of therapy</TI>
<SO>American Journal of Diseases of Children</SO>
<YR>1968</YR>
<VL>115</VL>
<NO>5</NO>
<PG>542-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hoberman-2011" MODIFIED="2014-12-01 21:15:30 +1000" MODIFIED_BY="[Empty name]" NAME="Hoberman 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-12-01 21:10:32 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hoberman A, Paradise JL, Rockette HE, Shaikh N, Wald ER, Kearney DH, et al</AU>
<TI>Treatment of acute otitis media in children under 2 years of age</TI>
<SO>New England Journal of Medicine</SO>
<YR>2011</YR>
<VL>364</VL>
<NO>2</NO>
<PG>105-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-12-01 21:15:30 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Paradise JL, Hoberman A, Rockette HE, Shaikh N</AU>
<TI>Treating acute otitis media in young children: what constitutes success?</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2013</YR>
<VL>32</VL>
<NO>7</NO>
<PG>745-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-02-22 02:31:25 +1000" MODIFIED_BY="Roderick P. Venekamp"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Howie-1972" MODIFIED="2012-02-22 02:26:55 +1000" MODIFIED_BY="Roderick P. Venekamp" NAME="Howie 1972" YEAR="1972">
<REFERENCE MODIFIED="2012-02-22 02:26:55 +1000" MODIFIED_BY="Roderick P. Venekamp" NOTES="&lt;p&gt;Howie VM and Ploussard. Efficacy of fixed combination antibiotics versus separate components in otitis media: effectiveness of erythromycin estolate, triple sulfonamide, ampicillin, erythromycin estolate-triple sulfonamide, and placebo in 280 patients with acute otitis media under two and one-half years of age. Clinical Pediatrics 11:205-214, 1972.&lt;/p&gt;" NOTES_MODIFIED="2012-02-22 02:26:55 +1000" NOTES_MODIFIED_BY="Roderick P. Venekamp" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Howie VM, Ploussard JH</AU>
<TI>Efficacy of fixed combination antibiotics versus separate components in otitis media: effectiveness of erythromycin estolate, triple sulfonamide, ampicillin, erythromycin estolate-triple sulfonamide, and placebo in 280 patients with acute otitis media under two and one-half years of age</TI>
<SO>Clinical Pediatrics</SO>
<YR>1972</YR>
<VL>11</VL>
<NO>4</NO>
<PG>205-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kaleida-1991" MODIFIED="2012-11-22 06:52:38 +1000" MODIFIED_BY="Anne Lawson" NAME="Kaleida 1991" YEAR="1991">
<REFERENCE MODIFIED="2012-11-22 06:52:38 +1000" MODIFIED_BY="Anne Lawson" NOTES="&lt;p&gt;Kaleida PH, Casselhrant ML, Rockette HE, et al. Amoxicillin or myringotomy or both for acute otitis media: results of a randomized clinical trial. Pediatrics 87:466-474, 1991.&lt;/p&gt;" NOTES_MODIFIED="2012-11-22 06:52:38 +1000" NOTES_MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kaleida PH, Casselhrant ML, Rockette HE, Paradise JL, Bluestone CD, Blatter MM, et al</AU>
<TI>Amoxicillin or myringotomy or both for acute otitis media: results of a randomized clinical trial</TI>
<SO>Paediatrics</SO>
<YR>1991</YR>
<VL>87</VL>
<NO>4</NO>
<PG>466-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Laxdal-1970" MODIFIED="2012-02-22 17:10:14 +1000" MODIFIED_BY="Roderick P. Venekamp" NAME="Laxdal 1970" YEAR="1970">
<REFERENCE MODIFIED="2012-02-22 17:09:40 +1000" MODIFIED_BY="Roderick P. Venekamp" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Laxdal OE, Merida J, Jones RHT</AU>
<TI>Treatment of acute otitis media: a controlled study of 142 children</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>1970</YR>
<VL>102</VL>
<NO>3</NO>
<PG>263-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Le-Saux-2005" MODIFIED="2012-06-06 14:46:42 +1000" MODIFIED_BY="Liz Dooley" NAME="Le Saux 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-06-06 14:46:42 +1000" MODIFIED_BY="Liz Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Le Saux N, Gaboury I, Baird M, Klassen TP, MacCormick J, Blanchard C, et al</AU>
<TI>A randomized, double-blind, placebo-controlled noninferiority trial of amoxicillin for clinically diagnosed acute otitis media in children 6 months to 5 years of age</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>2005</YR>
<VL>172</VL>
<NO>3</NO>
<PG>335-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Little-2001" MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]" NAME="Little 2001" YEAR="2001">
<REFERENCE MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Little P, Gould C, Williamson I, Moore M, Warner G, Dunleavey J</AU>
<TI>Pragmatic randomised controlled trial of two prescribing strategies for childhood acute otitis media</TI>
<SO>BMJ</SO>
<YR>2001</YR>
<VL>322</VL>
<PG>336-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-12-01 21:16:57 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Little P, Moore M, Warner G, Dunleavy J, Williamson I</AU>
<TI>Longer term outcomes from a randomised trial of prescribing strategies in otitis media</TI>
<SO>British Journal of General Practitioners</SO>
<YR>2006</YR>
<VL>56</VL>
<NO>524</NO>
<PG>176-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McCormick-2005" MODIFIED="2012-11-22 06:52:59 +1000" MODIFIED_BY="[Empty name]" NAME="McCormick 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-11-22 06:52:59 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McCormick DP, Chonmaitree T, Pittman C, Saeed K, Friedman NR, Uchida T, et al</AU>
<TI>Nonsevere acute otitis media: a clinical trial comparing outcomes of watchful waiting versus immediate antibiotic treatment</TI>
<SO>Pediatrics</SO>
<YR>2005</YR>
<VL>115</VL>
<NO>6</NO>
<PG>1455-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mygind-1981" MODIFIED="2012-06-13 10:29:01 +1000" MODIFIED_BY="Roderick P. Venekamp" NAME="Mygind 1981" YEAR="1981">
<REFERENCE MODIFIED="2012-06-13 10:29:01 +1000" MODIFIED_BY="Roderick P. Venekamp" NOTES="&lt;p&gt;Mygind N, Meistrup-Larsen K-I, Thomsen J, et al. Penicillin in acute otitis media: a double-blind placebo-controlled trial. Clin Otolaryngol 6:5-13, 1981.&lt;/p&gt;" NOTES_MODIFIED="2012-06-13 10:29:01 +1000" NOTES_MODIFIED_BY="Roderick P. Venekamp" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mygind N, Meistrup-Larsen K-I, Thomsen J, Thomsen VF, Josefsson K, Sorensen H</AU>
<TI>Penicillin in acute otitis media: a double-blind placebo-controlled trial</TI>
<SO>Clinical Otolaryngology</SO>
<YR>1981</YR>
<VL>6</VL>
<PG>5-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Thomsen J, Meistrup-Larsen KI, Sorensen H, Larsen PK, Mygind N. Ann Rhinol Laryngol Suppl. 1980, 89: 271-4.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thomsen J, Meistrup-Larsen KI, Sorensen H, Larsen PK, Mygind N</AU>
<TI>Penicillin and acute otitis: short and long term results</TI>
<SO>Annals of Otology, Rhinology and Laryngology, Supplement</SO>
<YR>1980</YR>
<VL>89</VL>
<PG>271-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Neumark-2007" MODIFIED="2012-11-22 06:53:21 +1000" MODIFIED_BY="[Empty name]" NAME="Neumark 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-11-22 06:53:21 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neumark T, Molstad S, Rosen C, Persson L, Torngren A, Brudin L, et al</AU>
<TI>Evaluation of phenoxymethylpenicillin treatment of acute otitis media in children aged 2-16</TI>
<SO>Scandinavian Journal of Primary Health Care</SO>
<YR>2007</YR>
<VL>25</VL>
<PG>166-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Spiro-2006" NAME="Spiro 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Spiro DM, Tay K, Arnold DH, Dziura J, Baker M, Shapiro ED</AU>
<TI>Wait-and-see prescription for the treatment of acute otitis media</TI>
<SO>JAMA</SO>
<YR>2006</YR>
<VL>296</VL>
<NO>10</NO>
<PG>1235-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-T_x00e4_htinen-2011" MODIFIED="2012-06-06 14:47:50 +1000" MODIFIED_BY="Roderick P. Venekamp" NAME="Tähtinen 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-06-06 14:47:50 +1000" MODIFIED_BY="Roderick P. Venekamp" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tähtinen PA, Laine MK, Huovinen P, Jalava J, Ruuskanen O, Ruohola A</AU>
<TI>A placebo-controlled trial of antimicrobial treatment for acute otitis media</TI>
<SO>New England Journal of Medicine</SO>
<YR>2011</YR>
<VL>364</VL>
<NO>2</NO>
<PG>116-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tapiainen-2014" MODIFIED="2014-11-27 22:56:21 +1000" MODIFIED_BY="[Empty name]" NAME="Tapiainen 2014" YEAR="2014">
<REFERENCE MODIFIED="2014-11-27 22:56:19 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tapiainen T, Kujala T, Renko M, Koivunen P, Kontiokari T, Kristo A, et al</AU>
<TI>Effect of antimicrobial treatment of acute otitis media on the daily disappearance of middle ear effusion: a placebo-controlled trial</TI>
<SO>JAMA Pediatrics</SO>
<YR>2014</YR>
<VL>168</VL>
<NO>7</NO>
<PG>635-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thalin-1985" MODIFIED="2015-01-19 11:37:23 +1000" MODIFIED_BY="Liz  Dooley" NAME="Thalin 1985" YEAR="1985">
<REFERENCE MODIFIED="2015-01-19 11:37:23 +1000" MODIFIED_BY="Liz  Dooley" NOTES="&lt;p&gt;Thalin A, Densert 0, Larsson A, Lyden E, and Ripa T. Is penicillin necessary in the treatment of acute otitis media? Proceedings of the International Conference on Acute and Secretory Otitis Media, Jerusalem. pp 441- 446. Kugler Publications, Amsterdam, 1985.&lt;/p&gt;" NOTES_MODIFIED="2015-01-19 11:37:23 +1000" NOTES_MODIFIED_BY="Liz  Dooley" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Thalin A, Densert O, Larsson A, Lyden E, Ripa T</AU>
<TI>Is penicillin necessary in the treatment of acute otitis media?</TI>
<SO>Proceedings of the International Conference on Acute and Secretory Otitis Media 1985, Jerusalem</SO>
<YR>1985</YR>
<PG>441-6</PG>
<PB>Kugler Publications</PB>
<CY>Amsterdam</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Buchem-1981a" MODIFIED="2014-12-01 21:14:43 +1000" MODIFIED_BY="[Empty name]" NAME="van Buchem 1981a" YEAR="1981">
<REFERENCE NOTES="&lt;p&gt;van Buchem FL, Dunk JHM, van't Hof MA. Therapy of acute otitis media: myringotomy, antibiotics or neither? A double-blind study in children. Lancet 2: 883-7, 1981.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Buchem FL, Dunk JHM, van't Hof MA</AU>
<TI>Therapy of acute otitis media: myringotomy, antibiotics or neither? A double-blind study in children</TI>
<SO>Lancet</SO>
<YR>1981</YR>
<VL>2</VL>
<PG>883-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Buchem-1981b" MODIFIED="2014-12-01 21:14:36 +1000" MODIFIED_BY="[Empty name]" NAME="van Buchem 1981b" YEAR="1981">
<REFERENCE NOTES="&lt;p&gt;van Buchem FL, Dunk JHM, van't Hof MA. Therapy of acute otitis media: myringotomy, antibiotics or neither? A double-blind study in children. Lancet 2: 883-7, 1981.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Buchem FL, Dunk JHM, van't Hof MA</AU>
<TI>Therapy of acute otitis media: myringotomy, antibiotics or neither? A double-blind study in children</TI>
<SO>Lancet</SO>
<YR>1981</YR>
<VL>2</VL>
<PG>883-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2015-06-19 18:25:20 +1000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Arguedas-2011" MODIFIED="2012-11-22 06:56:53 +1000" MODIFIED_BY="[Empty name]" NAME="Arguedas 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-11-22 06:56:53 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arguedas A, Soley C, Kamicker BJ, Jorgensen DM</AU>
<TI>Single-dose extended-release azithromycin versus a 10-day regimen of amoxicillin/clavulanate for the treatment of children with acute otitis media</TI>
<SO>International Journal of Infectious Diseases</SO>
<YR>2011</YR>
<VL>15</VL>
<NO>4</NO>
<PG>e240-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Casey-2012" MODIFIED="2012-11-13 19:26:26 +1000" MODIFIED_BY="Roderick P. Venekamp" NAME="Casey 2012" YEAR="2012">
<REFERENCE MODIFIED="2012-11-13 19:26:26 +1000" MODIFIED_BY="Roderick P. Venekamp" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Casey JR, Block SL, Hedrick J, Almudevar A, Pichichero ME</AU>
<TI>Comparison of amoxicillin/clavulanic acid high dose with cefdinir in the treatment of acute otitis media</TI>
<SO>Drugs</SO>
<YR>2012</YR>
<VL>72</VL>
<PG>1991-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chaput-1982" MODIFIED="2015-06-19 18:24:43 +1000" MODIFIED_BY="[Empty name]" NAME="Chaput 1982" YEAR="1982">
<REFERENCE MODIFIED="2015-06-19 18:24:43 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Chaput de Saintonage DM, Levine DF, Temple Savage I, Burgess GW, Sharp J, Mayhew SR, Saddler MG, Moody R, Griffiths F, Meadows G. Trial of three-day and ten-day courses of amoxycillin in otitis media. British Medical J 284:1078-1081, 1994.&lt;/p&gt;" NOTES_MODIFIED="2015-06-19 18:24:43 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chaput de Saintonge DM, Levine DF, Temple Savage IT, Burgess GW, Sharp J, Mayhew SR, et al</AU>
<TI>Trial of three-day and ten-day courses of amoxycillin in otitis media</TI>
<SO>British Medical Journal Clinical Research Edition</SO>
<YR>1982</YR>
<VL>284</VL>
<NO>6322</NO>
<PG>1078-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Engelhard-1989" MODIFIED="2012-11-22 21:55:15 +1000" MODIFIED_BY="[Empty name]" NAME="Engelhard 1989" YEAR="1989">
<REFERENCE MODIFIED="2012-11-22 21:54:38 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Engelhard D, Strauss N, Jorczak-Sarni L, Cohen D, Sacks TG, Shapiro M . Randomised study of myringotomy, amoxyciillin/clavulanate, or both for acute otitis media in infants. Lancet 141-143, 1994.&lt;/p&gt;" NOTES_MODIFIED="2012-11-22 21:54:38 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Engelhard D, Strauss N, Jorczak-Sarni L, Cohen D, Sacjs TG, Shapiro M</AU>
<TI>Randomised study of myringotomy, amoxycillin/clavulanate, or both for acute otitis media in infants</TI>
<SO>Lancet</SO>
<YR>1989</YR>
<VL>2</VL>
<NO>8655</NO>
<PG>141-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2011" MODIFIED="2012-06-06 14:50:10 +1000" MODIFIED_BY="[Empty name]" NAME="Liu 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-06-06 14:50:10 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu P, Fang AF, LaBadie RR, Crownover PH, Arguedas AG</AU>
<TI>Comparison of azithromycin pharmacokinetics following single oral doses of extended-release and immediate-release formulations in children with acute otitis media</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>2011</YR>
<VL>55</VL>
<NO>11</NO>
<PG>5022-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ostfeld-1987" NAME="Ostfeld 1987" YEAR="1987">
<REFERENCE NOTES="&lt;p&gt;Ostfeld E, Segal J, Kaufstein M, Gelernter I. Management of acute otitis media without primary administration of systemic antimicrobial agents. Recent Advances in Otitis Media, Proc Fourth International Symposium, Burlington Ontario 1987.&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Ostfeld E, Segal J, Kaufstein M, Gelernter I</AU>
<TI>Management of acute otitis media without primary administration of systemic antimicrobial agents</TI>
<SO>Recent advances in otitis media. Proceedings of the Fourth International Symposium</SO>
<YR>1987</YR>
<PG>235-9</PG>
<ED>Lim DJ, Bluestone CD, Klein JO, Nelson JD</ED>
<PB>BC Decker</PB>
<CY>Toronto</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rudberg-1954" MODIFIED="2015-06-19 18:25:20 +1000" MODIFIED_BY="[Empty name]" NAME="Rudberg 1954" YEAR="1954">
<REFERENCE MODIFIED="2015-06-19 18:25:20 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Rudberg, RD. Sulfonamide and penicillin in acute otitis media. Acta Oto-Laryngologica, Suppl 113, 1954.&lt;/p&gt;" NOTES_MODIFIED="2015-06-19 18:25:20 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rudberg RD</AU>
<TI>Acute otitis media: comparative therapeutic results of sulphonamide and penicillin administered in various forms</TI>
<SO>Acta Oto-Laryngologica</SO>
<YR>1954</YR>
<VL>113</VL>
<NO>Suppl</NO>
<PG>1-79</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ruohola-2003" MODIFIED="2012-11-22 06:58:45 +1000" MODIFIED_BY="Anne Lawson" NAME="Ruohola 2003" YEAR="2003">
<REFERENCE MODIFIED="2012-11-22 06:58:45 +1000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ruohola A, Heikkinen T, Meurman O, Puhakka T, Lindblad N, Ruuskanen O</AU>
<TI>Antibiotic treatment of acute otorrhea through tympanostomy tube: randomized double-blind placebo-controlled study with daily follow-up</TI>
<SO>Pediatrics</SO>
<YR>2003</YR>
<VL>111</VL>
<NO>5</NO>
<PG>1061-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sarrell-2003" NAME="Sarrell 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sarrell EM, Cohen HA, Kahan E</AU>
<TI>Naturopathic treatment for ear pain in children</TI>
<SO>Pediatrics</SO>
<YR>2003</YR>
<VL>111</VL>
<NO>5</NO>
<PG>574-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-T_x00e4_htinen-2012" MODIFIED="2014-12-01 20:52:43 +1000" MODIFIED_BY="[Empty name]" NAME="Tähtinen 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-12-01 20:52:43 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tähtinen PA, Laine MK, Ruuskanen O, Ruohola A</AU>
<TI>Delayed versus immediate antimicrobial treatment for acute otitis media</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2012</YR>
<VL>31</VL>
<NO>12</NO>
<PG>1227-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Buchem-1985" MODIFIED="2015-01-19 11:36:31 +1000" MODIFIED_BY="Liz  Dooley" NAME="van Buchem 1985" YEAR="1985">
<REFERENCE MODIFIED="2015-01-19 11:36:31 +1000" MODIFIED_BY="Liz  Dooley" NOTES="&lt;p&gt;van Buchem F, Peeters M, Van' t Hof M. Acute otitis media: a new treatment strategy BMJ 290:1033-7. 1985.&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2015-01-19 11:36:31 +1000" NOTES_MODIFIED_BY="Liz  Dooley" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Buchem F, Peeters M, Van' t Hof M</AU>
<TI>Acute otitis media: a new treatment strategy</TI>
<SO>BMJ</SO>
<YR>1985</YR>
<VL>290</VL>
<PG>1033-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2015-06-19 18:25:46 +1000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-ACTRN12608000424303" MODIFIED="2015-06-19 18:25:46 +1000" MODIFIED_BY="[Empty name]" NAME="ACTRN12608000424303" YEAR="4303">
<REFERENCE MODIFIED="2015-06-19 18:25:46 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>ACTRN12608000424303</AU>
<TI>Antibiotics for asymptomatic acute otitis media</TI>
<SO>https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12608000424303 (accessed 26 November 2014)</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-AAP-2013" MODIFIED="2014-11-27 22:58:27 +1000" MODIFIED_BY="[Empty name]" NAME="AAP 2013" TYPE="JOURNAL_ARTICLE">
<AU>American Academy of Pediatrics and American Academy of Family Physicians</AU>
<TI>Clinical practice guidelines: diagnosis and management of acute otitis media</TI>
<SO>Pediatrics</SO>
<YR>2013</YR>
<VL>131</VL>
<NO>3</NO>
<PG>e964-99</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Akkerman-2005" NAME="Akkerman 2005" TYPE="JOURNAL_ARTICLE">
<AU>Akkerman AE, Kuyvenhoven MM, van der Wouden JC, Verhij TJM</AU>
<TI>Analysis of under-and overprescribing of antibiotics in acute otitis media in general practice</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>2005</YR>
<VL>56</VL>
<PG>569-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Arnold-2005" MODIFIED="2012-06-01 00:45:24 +1000" MODIFIED_BY="[Empty name]" NAME="Arnold 2005" TYPE="COCHRANE_REVIEW">
<AU>Arnold SR, Straus SE</AU>
<TI>Interventions to improve antibiotic prescribing in ambulatory care</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2012-06-01 00:45:24 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-06-01 00:45:24 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003539"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Arola-1990" MODIFIED="2012-06-13 06:26:55 +1000" MODIFIED_BY="Roderick P. Venekamp" NAME="Arola 1990" TYPE="JOURNAL_ARTICLE">
<AU>Arola M, Ruuskanen O, Ziegler T, Mertsola J, Näntö-Salonen K, Putto-Laurila A, et al</AU>
<TI>Clinical role of respiratory virus infection in acute otitis media</TI>
<SO>Pediatrics</SO>
<YR>1990</YR>
<VL>86</VL>
<PG>848-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barkai-2009" MODIFIED="2012-09-21 22:48:41 +1000" MODIFIED_BY="[Empty name]" NAME="Barkai 2009" TYPE="JOURNAL_ARTICLE">
<AU>Barkai G, Leibovitz E, Givon-Lavi N, Dagan R</AU>
<TI>Potential contribution by nontypable Haemophilus influenzae in protracted and recurrent acute otitis media</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2009</YR>
<VL>28</VL>
<PG>466-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Berman-1995" NAME="Berman 1995" TYPE="JOURNAL_ARTICLE">
<AU>Berman S</AU>
<TI>Otitis media in developing countries</TI>
<SO>Pediatrics</SO>
<YR>1995</YR>
<VL>96</VL>
<PG>126-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Casey-2013" MODIFIED="2014-11-27 23:06:46 +1000" MODIFIED_BY="[Empty name]" NAME="Casey 2013" TYPE="JOURNAL_ARTICLE">
<AU>Casey JR, Kaur R, Friedel VC, Pichichero ME</AU>
<TI>Acute otitis media otopathogens during 2008 to 2010 in Rochester, New York</TI>
<SO>Pediatic Infectious Disease Journal</SO>
<YR>2013</YR>
<VL>32</VL>
<NO>8</NO>
<PG>805-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cates-1999" MODIFIED="2015-01-19 11:31:43 +1000" MODIFIED_BY="Liz  Dooley" NAME="Cates 1999" TYPE="JOURNAL_ARTICLE">
<AU>Cates C</AU>
<TI>An evidence based approach to reducing antibiotic use in children with acute otitis media: controlled before and after the study</TI>
<SO>BMJ</SO>
<YR>1999</YR>
<VL>318</VL>
<PG>715-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="The handout is available at http://www.cates.cwc.net/"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Chao-2008" MODIFIED="2008-11-19 22:03:06 +1000" MODIFIED_BY="[Empty name]" NAME="Chao 2008" TYPE="JOURNAL_ARTICLE">
<AU>Chao JH, Kunkov S, Reyes LB, Lichten S, Crain EF</AU>
<TI>Comparison of two approaches to observation therapy for acute otitis media in the emergency department</TI>
<SO>Pediatrics</SO>
<YR>2008</YR>
<VL>121</VL>
<PG>31352-e6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chonmaitree-1992" MODIFIED="2012-06-18 09:50:52 +1000" MODIFIED_BY="Roderick P. Venekamp" NAME="Chonmaitree 1992" TYPE="JOURNAL_ARTICLE">
<AU>Chonmaitree T, Owen MJ, Patel JA, Hedgpeth D, Horlick D, Howie VM</AU>
<TI>Effect of viral respiratory tract infection on outcome of acute otitis media</TI>
<SO>Journal of Pediatrics</SO>
<YR>1992</YR>
<VL>120</VL>
<PG>856-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Coker-2010" MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]" NAME="Coker 2010" TYPE="JOURNAL_ARTICLE">
<AU>Coker TR, Chan LS, Newberry SJ, Limbos MA, Suttorp MJ, Shekelle PG, et al</AU>
<TI>Diagnosis, microbial epidemiology, and antibiotic treatment of acute otitis media in children: a systematic review</TI>
<SO>JAMA</SO>
<YR>2010</YR>
<VL>304</VL>
<NO>19</NO>
<PG>2161-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dickersin-1994" MODIFIED="2015-01-19 11:31:07 +1000" MODIFIED_BY="Liz  Dooley" NAME="Dickersin 1994" TYPE="JOURNAL_ARTICLE">
<AU>Dickersin K, Scherer R, Lefebvre C</AU>
<TI>Identifying relevant studies for systematic reviews</TI>
<SO>BMJ</SO>
<YR>1994</YR>
<VL>309</VL>
<NO>6964</NO>
<PG>1286-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Froom-2001" MODIFIED="2012-11-22 07:03:53 +1000" MODIFIED_BY="[Empty name]" NAME="Froom 2001" TYPE="JOURNAL_ARTICLE">
<AU>Froom J, Culpepper L, Green LA, de Melker RA, Grob P, Heeren T, et al</AU>
<TI>A cross-national study of acute otitis media: risk factors, severity, and treatment at initial visit. Report from the International Primary Care Network (IPCN) and the Ambulatory Sentinel Practice Network (ASPN)</TI>
<SO>Journal of the American Board of Family Practice</SO>
<YR>2001</YR>
<VL>14</VL>
<PG>406-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gillies-2014" MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]" NAME="Gillies 2014" TYPE="OTHER">
<AU>Gillies M, Ranakusuma A, Hoffmann T, Thorning S, McGuire T, Glasziou P, et al</AU>
<TI>Common harms from amoxicillin: a systematic review and meta-analysis of randomized placebo-controlled trials for any indication</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>2014 Nov 17 [Epub ahead of print]</YR>
<PG>.</PG>
<IDENTIFIERS MODIFIED="2015-06-19 18:29:08 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-06-19 18:29:08 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1503/cmaj.140848"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2015-01-19 11:29:49 +1000" MODIFIED_BY="Liz  Dooley" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Klein-1989" MODIFIED="2014-11-27 23:05:26 +1000" MODIFIED_BY="[Empty name]" NAME="Klein 1989" TYPE="JOURNAL_ARTICLE">
<AU>Klein JO</AU>
<TI>Epidemiology of otitis media</TI>
<SO>Pediatic Infectious Disease Journal</SO>
<YR>1989</YR>
<VL>8</VL>
<NO>Suppl 1</NO>
<PG>89</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Koopman-2008" MODIFIED="2012-06-06 14:40:27 +1000" MODIFIED_BY="[Empty name]" NAME="Koopman 2008" TYPE="JOURNAL_ARTICLE">
<AU>Koopman L, Hoes AW, Glasziou PP, Appelman CL, Burke P, McCormick DP, et al</AU>
<TI>Antibiotic therapy to prevent the development of asymptomatic middle ear effusion in children with acute otitis media</TI>
<SO>Archives of Otolaryngology - Head and Neck Surgery</SO>
<YR>2008</YR>
<VL>134</VL>
<NO>2</NO>
<PG>128-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kozyrskyj-2010" MODIFIED="2014-11-27 23:06:14 +1000" MODIFIED_BY="[Empty name]" NAME="Kozyrskyj 2010" TYPE="COCHRANE_REVIEW">
<AU>Kozyrskyj A, Klassen TP, Moffatt M, Harvey K</AU>
<TI>Short-course antibiotics for acute otitis media</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>9</NO>
<IDENTIFIERS MODIFIED="2012-06-01 00:57:14 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-06-01 00:57:14 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001095"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lefebvre-2011" MODIFIED="2012-11-22 07:08:10 +1000" MODIFIED_BY="[Empty name]" NAME="Lefebvre 2011" TYPE="OTHER">
<AU>Lefebvre C, Manheimer E, Glanville J</AU>
<TI>Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Little-2006" NAME="Little 2006" TYPE="JOURNAL_ARTICLE">
<AU>Little P, Moore M, Warner G, Dunleavy J, Williamson I</AU>
<TI>Longer term outcomes from a randomised trial of prescribing strategies in otitis media</TI>
<SO>British Journal of General Practice</SO>
<YR>2006</YR>
<VL>56</VL>
<PG>176-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McCormick-2007" MODIFIED="2012-09-21 22:51:13 +1000" MODIFIED_BY="[Empty name]" NAME="McCormick 2007" TYPE="JOURNAL_ARTICLE">
<AU>McCormick DP, Chandler SM, Chonmaitree T</AU>
<TI>Laterality of acute otitis media: different clinical and microbiologic characteristics</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2007</YR>
<VL>26</VL>
<PG>583-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rosenfeld-1994" MODIFIED="2015-01-19 11:27:41 +1000" MODIFIED_BY="Liz  Dooley" NAME="Rosenfeld 1994" TYPE="JOURNAL_ARTICLE">
<AU>Rosenfeld RM, Vertrees JE, Carr J, Cipolle RJ, Uden DL, Giebink GS, et al</AU>
<TI>Clinical efficacy of antimicrobial drugs for acute otitis media: meta-analysis of 5400 children from thirty-three randomized trials</TI>
<SO>Journal of Pediatrics</SO>
<YR>1994</YR>
<VL>124</VL>
<PG>355-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rothman-2003" MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]" NAME="Rothman 2003" TYPE="JOURNAL_ARTICLE">
<AU>Rothman R, Owens T, Simel D</AU>
<TI>Does this child have acute otitis media?</TI>
<SO>JAMA</SO>
<YR>2003</YR>
<VL>290</VL>
<NO>12</NO>
<PG>1633-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rovers-2006" MODIFIED="2012-06-06 14:41:48 +1000" MODIFIED_BY="Liz Dooley" NAME="Rovers 2006" TYPE="JOURNAL_ARTICLE">
<AU>Rovers MM, Glasziou P, Appelman CL, Burke P, McCormick DP, Damoiseaux RA, et al</AU>
<TI>Antibiotics for acute otitis media: a meta-analysis with individual patient data</TI>
<SO>Lancet</SO>
<YR>2006</YR>
<VL>368</VL>
<PG>1429-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Spurling-2013" MODIFIED="2015-01-22 16:41:08 +1000" MODIFIED_BY="[Empty name]" NAME="Spurling 2013" TYPE="COCHRANE_REVIEW">
<AU>Spurling GKP, Del Mar CB, Dooley L, Foxlee R, Farley R</AU>
<TI>Delayed antibiotics for respiratory infections</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2015-01-22 16:41:08 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-01-22 16:41:08 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004417.pub4"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Stool-1989" MODIFIED="2014-11-27 23:05:51 +1000" MODIFIED_BY="[Empty name]" NAME="Stool 1989" TYPE="JOURNAL_ARTICLE">
<AU>Stool SE, Field MJ</AU>
<TI>The impact of otitis media</TI>
<SO>Pediatic Infectious Disease Journal</SO>
<YR>1989</YR>
<VL>8</VL>
<NO>Suppl 1</NO>
<PG>11-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Teele-1989" MODIFIED="2012-06-18 09:53:44 +1000" MODIFIED_BY="Roderick P. Venekamp" NAME="Teele 1989" TYPE="JOURNAL_ARTICLE">
<AU>Teele DW, Klein JO, Rosner B</AU>
<TI>Epidemiology of otitis media during first seven years of life in children in greater Boston: a prospective cohort study</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1989</YR>
<VL>160</VL>
<PG>83-94</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2015-01-19 11:24:57 +1000" MODIFIED_BY="Liz  Dooley">
<REFERENCE ID="REF-Glasziou-1995" MODIFIED="2015-01-19 11:24:52 +1000" MODIFIED_BY="Liz  Dooley" NAME="Glasziou 1995" TYPE="COCHRANE_PROTOCOL">
<AU>Glasziou PP, Hayem M, Del Mar CB</AU>
<TI>A meta-analysis of treatments for acute otitis media: antibiotic vs placebo, short vs long antibiotic course, and myringotomy</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1995</YR>
<NO>1</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD000219"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Glasziou-1997" MODIFIED="2015-01-19 11:24:57 +1000" MODIFIED_BY="Liz  Dooley" NAME="Glasziou 1997" TYPE="COCHRANE_REVIEW">
<AU>Glasziou PP, Hayem M, Del Mar CB</AU>
<TI>Treatments for acute otitis media in children: antibiotic versus placebo</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1997</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2012-06-01 00:46:13 +1000" MODIFIED_BY="Liz Dooley">
<IDENTIFIER MODIFIED="2012-06-01 00:46:13 +1000" MODIFIED_BY="Liz Dooley" TYPE="DOI" VALUE="10.1002/14651858.CD000219"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Glasziou-1999" MODIFIED="2012-06-01 00:48:48 +1000" MODIFIED_BY="[Empty name]" NAME="Glasziou 1999" TYPE="COCHRANE_REVIEW">
<AU>Glasziou PP, Hayem M, Del Mar CB</AU>
<TI>Antibiotics versus placebo for acute otitis media in children</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1999</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2012-06-01 00:48:48 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-06-01 00:48:48 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000219.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Glasziou-2005" MODIFIED="2012-06-01 01:00:26 +1000" MODIFIED_BY="Liz Dooley" NAME="Glasziou 2005" TYPE="COCHRANE_REVIEW">
<AU>Glasziou PP, Del Mar CB, Sanders SL, Hayem M</AU>
<TI>Antibiotics for acute otitis media in children</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2012-06-01 01:00:26 +1000" MODIFIED_BY="Liz Dooley">
<IDENTIFIER MODIFIED="2012-06-01 01:00:26 +1000" MODIFIED_BY="Liz Dooley" TYPE="DOI" VALUE="10.1002/14651858.CD000219.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sanders-2009" MODIFIED="2012-06-13 17:02:42 +1000" MODIFIED_BY="[Empty name]" NAME="Sanders 2009" TYPE="COCHRANE_REVIEW">
<AU>Sanders SL, Glasziou PP, Del Mar CB, Rovers MM</AU>
<TI>Antibiotics for acute otitis media in children</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2012-06-01 01:00:32 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-06-01 01:00:32 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000219.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Venekamp-2013" MODIFIED="2014-11-27 00:20:57 +1000" MODIFIED_BY="[Empty name]" NAME="Venekamp 2013" TYPE="COCHRANE_REVIEW">
<AU>Venekamp RP, Sanders S, Glasziou PP, Del Mar CB, Rovers MM</AU>
<TI>Antibiotics for acute otitis media in children</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2014-11-27 00:20:57 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-11-27 00:20:57 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000219.pub3"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2015-06-20 08:38:53 +1000" MODIFIED_BY="Liz Dooley">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2015-06-20 08:38:53 +1000" MODIFIED_BY="Liz Dooley" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Appelman-1991">
<CHAR_METHODS MODIFIED="2012-11-23 00:21:08 +1000" MODIFIED_BY="Roderick P. Venekamp">
<P>
<B>Randomised -</B> yes, computer-generated random numbers</P>
<P>
<B>Concealment of allocation -</B> adequate<BR/>
<B>Double-blind -</B> yes, blinding procedure not described</P>
<P>
<B>Intention-to-treat (ITT) -</B> unclear</P>
<P>
<B>Loss to follow-up - </B>described</P>
<P>
<B>Design -</B> parallel</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-20 12:55:44 +1000" MODIFIED_BY="Liz  Dooley">
<P>
<B>N -</B> 126 children (N = 121 children included in analysis)</P>
<P>
<B>Age -</B> between 6 months and 12 years<BR/>
<B>Setting - </B>general practice and secondary care in the Netherlands; confirmation of diagnosis and randomisation were done by otorhinolaryngologists</P>
<P>
<B>Inclusion criteria -</B> recurrence of acute otitis media (AOM) characterised by a (sub)acute onset, otalgia and otoscopic signs of middle-ear infection within 4 weeks to 12 months of the previous attack</P>
<P>
<B>Exclusion criteria - </B>antibiotic treatment &lt; 4 weeks prior to randomisation, previous participation in this study, contraindication for penicillin, serious concurrent disease that necessitated antibiotic treatment</P>
<P>
<B>Baseline characteristics -</B> balanced</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-07 08:40:21 +1000" MODIFIED_BY="Roderick P. Venekamp">
<P>
<B>Tx -</B> amoxicillin/clavulanate (weight tailored dose) for 7 days; N = 70 (N = 67 included in analysis)<BR/>
<B>C -</B> matching placebo for 7 days; N = 56 (N = 54 included in analysis)<BR/>
<B>Use of additional medication - </B>each child was given analgesics (paracetamol) as long as earache was present and decongestive nose drops for 1 week</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-22 07:26:31 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcome - </B>treatment failure (i.e. presence of otalgia or fever &gt; 38 °C or both at 3 days)</P>
<P>Assessment by (blinded) general practitioner at 3 days on the presence or absence of fever (&gt; 38 °C) and otalgia and 14 days on the presence or otorrhoea</P>
<P>Assessment by otorhinolaryngologist at 1 month of otoscopy, tympanometry and in children &gt; 3 years of age an audiogram</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Burke-1991">
<CHAR_METHODS MODIFIED="2012-11-22 07:27:24 +1000" MODIFIED_BY="Roderick P. Venekamp">
<P>
<B>Randomised -</B> yes, computer-generated random numbers</P>
<P>
<B>Concealment of allocation -</B> adequate<BR/>
<B>Double-blind -</B> yes</P>
<P>
<B>Intention-to-treat (ITT) -</B> yes</P>
<P>
<B>Loss to follow-up - </B>not described</P>
<P>
<B>Design -</B> parallel</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>N -</B> 232 children</P>
<P>
<B>Age -</B> between 3 and 10 years<BR/>
<B>Setting - </B>general practice; 48 general practitioners in 17 general practices in Southampton, Bristol and Portsmouth (UK)</P>
<P>
<B>Inclusion criteria -</B> acute earache and at least 1 abnormal eardrum</P>
<P>
<B>Exclusion criteria - </B>antibiotic treatment or acute otitis media (AOM) &lt; 2 weeks prior to randomisation, strong indication for antibiotic treatment according to general practitioner, contraindication for amoxicillin, serious chronic conditions</P>
<P>
<B>Baseline characteristics -</B> slight imbalance in gender (boys treated with antibiotics versus boys treated with placebo = 52% versus 42%) and figure 1 appears to demonstrate that fewer children were crying at baseline (0 hours) in the amoxicillin arm compared with the placebo arm, suggesting a failure of randomisation</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-23 00:37:54 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Tx -</B> amoxicillin 250 mg 3 times daily for 7 days; N = 114 (N = 114 included in analysis for short-term outcome)<BR/>
<B>C -</B> matching placebo 3 times daily for 7 days; N = 118 (N = 118 included in analysis for short-term outcome)<BR/>
<B>Use of additional medication - </B>analgesics (paracetamol 120 mg/5 mL) for pain as needed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-23 00:51:56 +1000" MODIFIED_BY="Roderick P. Venekamp">
<P>
<B>Main outcomes</B> were divided into short-term, middle-term and long-term:</P>
<P>
<B>Short-term -</B> (a) duration of symptoms; (b) use of analgesics (assessed by weighing bottles); (c) clinical signs at 1 week; (d) incidence of complications; (e) treatment failure (i.e. second-line antibiotics were required)</P>
<P>
<B>Middle-term -</B> (a) tympanometry findings at 1 and 3 months</P>
<P>
<B>Long-term -</B> (b) number of AOM episodes in 12 months; (b) number of specialist referrals</P>
<P>Home visits by researcher at day 1, days 4 to 6 and general practitioner visit at day 7</P>
<P>Symptom diary kept by parents for 21 days</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<P>It is not clear whether the "discharging ears" in Table 1 should be included as perforations, we now included the number of perforations as summarised in Table 2 in our analysis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Damoiseaux-2000">
<CHAR_METHODS MODIFIED="2015-06-19 00:56:16 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Randomised -</B> yes, computerised 2 block randomisation</P>
<P>
<B>Concealment of allocation -</B> adequate<BR/>
<B>Double-blind -</B> yes</P>
<P>
<B>Intention-to-treat (ITT) -</B> yes</P>
<P>
<B>Loss to follow-up - </B>described</P>
<P>
<B>Design -</B> parallel</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>N -</B> 240 children (N = 212 children included in analysis)</P>
<P>
<B>Age -</B> between 6 months and 2 years<BR/>
<B>Setting - </B>general practice; 53 general practitioners (GPs) in the Netherlands</P>
<P>
<B>Inclusion criteria -</B> acute otitis media (AOM) defined as infection of the middle ear of acute onset and a characteristic eardrum picture (injection along the handle of the malleus and the annulus of the tympanic membrane or a diffusely red or bulging eardrum) or acute otorrhoea. In addition 1 or more symptoms of acute infection (fever, recent earache, general malaise, recent irritability)</P>
<P>
<B>Exclusion criteria - </B>antibiotic treatment &lt; 4 weeks prior to randomisation, contraindication for amoxicillin, comprised immunity, craniofacial abnormalities, Down's syndrome or being entered in this study before</P>
<P>
<B>Baseline characteristics -</B> slight imbalance in the prevalence of recurrent AOM, regular attendance at a daycare centre and parental smoking; logistic regression was used to adjust for these imbalances</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-23 00:38:03 +1000" MODIFIED_BY="Roderick P. Venekamp">
<P>
<B>Tx -</B> amoxicillin suspension 40 mg/kg/day 3 times daily for 10 days; N = 117 (N = 107 included in analysis for short-term outcome)<BR/>
<B>C -</B> matching placebo suspension for 10 days; N = 123 (N = 105 included in analysis for short-term outcome)<BR/>
<B>Use of additional medication - </B>all children received decongestive nose drops for 7 days; analgesics (paracetamol, children &lt; 1 year: 120 mg suppository, &gt; 1 year: 240 mg suppository) was allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcome -</B> persistent symptoms at day 4: assessed by the doctor and defined as persistent earache, fever &gt; 38 °C, crying or being irritable. Additionally, prescription of another antibiotic because of clinical deterioration before the first follow-up visit was to be considered a persistent symptom</P>
<P>
<B>Secondary outcomes -</B> (a) clinical treatment failure at day 11 (i.e. persistent fever, earache, crying, being irritable or no improvement of tympanic membrane (including perforation); (b) duration of fever, pain or crying; (c) mean number of doses analgesics given; (d) adverse effects mentioned in diaries; (e) percentage of children with middle-ear effusion at 6 weeks (i.e. combined otoscopy and tympanometry)</P>
<P>Follow-up visits at the GP's clinic were scheduled at day 4 and 11; home visit at 6 weeks by the researcher collecting data of symptoms, referrals and both otoscopy and tympanometry was performed</P>
<P>Parents were instructed to keep a symptom diary for 10 days</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Halsted-1968">
<CHAR_METHODS MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Randomised -</B> yes, pre-determined code, which was unknown to physician; method of random sequence generation unclear</P>
<P>
<B>Concealment of allocation -</B> adequate<BR/>
<B>Double-blind -</B> yes</P>
<P>
<B>Intention-to-treat (ITT) -</B> unclear</P>
<P>
<B>Loss to follow-up - </B>described, unclear from which treatment group patients were excluded</P>
<P>
<B>Design -</B> parallel</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>N -</B> 106 children (N = 89 children included in analysis; N = 12 children were excluded because they did not adhere to the double-blind protocol; N = 5 children lost to follow-up or excluded because of persistent fever, development of complication requiring antibiotic treatment or if group A streptococci was cultured from the middle ear)</P>
<P>
<B>Age -</B> between 2 months and 5.5 years<BR/>
<B>Setting - </B>secondary care: paediatric department of Cleveland (USA)</P>
<P>
<B>Inclusion criteria -</B> AOM based on otoscopic findings; most of the cases had bulging membrane with loss of normal light reflex and landmarks, in a few the eardrum was only diffusely red</P>
<P>
<B>Exclusion criteria - </B>antibiotic treatment &lt; 10 days prior to randomisation, associated bacterial infection requiring antibiotic treatment, rupture of tympanic membrane, contraindication for study drugs</P>
<P>
<B>Baseline characteristics -</B> not described</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-22 07:36:39 +1000" MODIFIED_BY="Liz Dooley">
<P>
<B>Tx 1 -</B> ampicillin 100 mg/kg/day 4 daily for 10 days; N = ? (N = 30 included in analysis)</P>
<P>
<B>Tx 2 -</B> pheneticillin 30 mg/kg/day 4 daily and sulfisoxazole 150 mg/kg/day 4 daily for 10 days; N = ? (N = 32 included in analysis)<BR/>
<B>C -</B> placebo for 10 days; N = ? (N = 27 included in analysis)<BR/>
<B>Use of additional medication - </B>phenylephrine nose drops and aspirin for children over 6 months was prescribed as necessary; no other medications were employed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-22 07:36:49 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcome -</B> early improvement defined as defervescence and decrease of symptoms at 24 to 72 hours</P>
<P>
<B>Secondary outcomes -</B> (a) late improvement defined as resolution of symptoms and normal tympanic membrane at 14 to 18 days, (b) bacteriological cultures</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hoberman-2011">
<CHAR_METHODS MODIFIED="2012-11-22 21:49:06 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Randomised -</B> yes, stratified block randomisation with computer-generated randomisation lists</P>
<P>
<B>Concealment of allocation -</B> adequate<BR/>
<B>Double-blind -</B> yes</P>
<P>
<B>Intention-to-treat (ITT) -</B> yes</P>
<P>
<B>Loss to follow-up - </B>described</P>
<P>
<B>Design -</B> parallel</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-23 05:45:49 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>N -</B> 291 (N = 291 included in analysis)</P>
<P>
<B>Age -</B> between 6 months and 2 years<BR/>
<B>Setting - </B>secondary care; children's hospital of Pittsburgh and a private paediatric clinic in Kittanning (USA)</P>
<P>
<B>Inclusion criteria -</B> children needed to have received at least 2 doses of pneumococcal conjugate vaccine and to have acute otitis media (AOM) as defined on the basis of 3 criteria: (a) the onset (i.e. within the preceding 48 hours) of symptoms that parents rated with a score of at least 3 on the acute otitis media - severity of symptoms (AOM-SOS) scale (on which scores range from 0 to 14, with higher scores indicating greater severity of symptoms), (b) the presence of middle-ear effusion and (c) moderate or marked bulging of the tympanic membrane or slight bulging accompanied by either otalgia or marked erythema of the membrane</P>
<P>All the study clinicians were otoscopists who had successfully completed an otoscopic validation programme</P>
<P>
<B>Exclusion criteria - </B>antibiotic treatment &lt; 96 hours prior to randomisation, concomitant acute illness (e.g. pneumonia) or a chronic illness (e.g. cystic fibrosis), contraindication to amoxicillin, presence of otalgia for more than 48 hours, perforation of the tympanic membrane</P>
<P>
<B>Baseline characteristics -</B> balanced</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-22 07:40:38 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Tx -</B> amoxicillin-clavulanate 90-6.4 mg/kg daily in 2 doses for 10 days; N = 144 (N = 139 were assessed at day 4 to 5)<BR/>
<B>C -</B> matching placebo in 2 doses for 10 days; N = 147 (N = 142 were assessed at day 4 to 5)<BR/>
<B>Use of additional medication - </B>acetaminophen (paracetamol) as needed for symptom relief</P>
<P>At each visit children were categorised as having met the criteria for either clinical success or clinical failure</P>
<P>Children who met the criteria for clinical failure were treated with a standardised 10-day regimen of orally administered amoxicillin (90 mg/kg daily) and cefixime (8 mg/kg daily)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcomes -</B> (a) time to resolution of symptoms (i.e. time to the first recording of an AOM-SOS score of 0 or 1 and the time to the second of 2 successive recordings of that score; (b) symptom burden over time (i.e. mean AOM-SOS score over time each day for the first 7 days of follow-up and groups' weighted mean scores for that period)</P>
<P>
<B>Secondary outcomes -</B> (a) clinical failure at day 4 to 5; (b) clinical failure at day 10 to 12; (c) use of acetaminophen (paracetamol); (d) occurrence of adverse events; (e) nasopharyngeal colonisation rates; (f) use of healthcare resources; (g) relapses</P>
<P>Clinical failure was defined at or before the day 4 to 5 visit as either a lack of substantial improvement in symptoms, a worsening of signs on otoscopic examination, or both and at the day 10 to 12 visit as the failure to achieve complete or nearly complete resolutions of symptoms and otoscopic signs, without regard to the persistence of resolution of middle-ear effusion. Once a child had met the criteria for clinical failure, he or she remained in that category for the analysis</P>
<P>Daily symptoms were assessed with the use of a structured interview of 1 of the child's parents until the first follow-up visit; visits were scheduled at day 4 or 5, day 10 to 12 (end of treatment) and at day 21 to 25</P>
<P>Patients were asked to complete a diary twice a day for 3 days and once a day thereafter</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-04-25 02:09:20 +1000" MODIFIED_BY="Roderick P. Venekamp">
<P>This study did not report pain data that could be used for the review comparing antibiotics with placebo</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Howie-1972">
<CHAR_METHODS MODIFIED="2012-11-22 21:49:11 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Randomised -</B> yes, method of randomisation not described</P>
<P>
<B>Concealment of allocation -</B> adequate<BR/>
<B>Double-blind -</B> yes</P>
<P>
<B>Intention-to-treat (ITT) -</B> unclear</P>
<P>
<B>Loss to follow-up - </B>not described</P>
<P>
<B>Design -</B> parallel</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-22 21:39:03 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>N -</B> 280 children</P>
<P>
<B>Age -</B> 2.5 years or younger<BR/>
<B>Setting - </B>secondary care: general paediatric practice in Huntsville (USA)</P>
<P>
<B>Inclusion criteria -</B> acute otitis media (AOM) as clinically diagnosed by the participating paediatricians</P>
<P>
<B>Exclusion criteria - </B>if researchers felt that parents would not accept diagnostic aspiration, when condition of the patient required immediate antibiotic treatment</P>
<P>
<B>Baseline characteristics -</B> not described</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Tx 1 -</B> erythromycin estolate 125 mg/5 mL - triple sulphonamide suspension 0.5 g/5 mL; N = 80</P>
<P>
<B>Tx 2 -</B> ampicillin 250 mg/5 mL; N = 36</P>
<P>
<B>Tx 3 -</B> triple sulphonamide suspension 0.5 g/5 mL; N = 23</P>
<P>
<B>Tx 4 -</B> erythromycin estolate 125 mg/5 mL; N = 25<BR/>
<B>C 1 -</B> placebo - equal parts acetaminophen (paracetamol) and chlorpheniramine maleate syrup; N = 33</P>
<P>
<B>C 2 -</B> placebo - 4 parts Kaopectate and 1 part acetaminophen (paracetamol, Tylenol) plus food colouring; N = 83<BR/>
<B>Use of additional medication - </B>all children received decongestive nose drops for 7 days; analgesics (paracetamol, children &lt; 1 year: 120 mg suppository, &gt; 1 year: 240 mg suppository) was allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-22 07:44:47 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcomes - </B>(a) presence or absence of exudate while on medication; (b) bacteriological findings of the exudate when present; no patient-relevant outcomes were described</P>
<P>At baseline and before treatment was started, the middle-ear exudate was aspirated. The decision whether to collect exudate on the first repeat visit was made with no knowledge of the drug regimen to which the patient had been assigned</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kaleida-1991">
<CHAR_METHODS MODIFIED="2012-11-22 21:49:15 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Randomised -</B> yes, stratified randomisation, method of randomisation not described</P>
<P>
<B>Concealment of allocation -</B> unclear, method not described<BR/>
<B>Double-blind -</B> yes, blinding procedure not described</P>
<P>
<B>Intention-to-treat (ITT) -</B> yes</P>
<P>
<B>Loss to follow-up - </B>not described</P>
<P>
<B>Design -</B> parallel</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>N -</B> 536 children (representing 1049 non-severe acute otitis media (AOM) episodes; 980 non-severe AOM episodes included for primary analysis)<BR/>
<B>Age -</B> between 7 months and 12 years</P>
<P>
<B>Setting -</B> secondary care: children's hospital and a private paediatric practice in Pittsburgh (USA)</P>
<P>
<B>Inclusion criteria -</B> AOM based on presence of middle-ear effusion, as determined otoscopically, in association with specified symptoms of acute middle-ear infection (fever, otalgia or irritability), or signs of acute infection (erythema or white opacification, or both, accompanied by fullness or bulging and impaired mobility), or both</P>
<P>
<B>Exclusion criteria -</B> children who recently received antibiotics, who had potential complicating or confounding conditions (e.g. eardrum perforation, asthma or chronic sinusitis)</P>
<P>
<B>Baseline characteristics -</B> balanced<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-23 00:38:31 +1000" MODIFIED_BY="[Empty name]">
<P>Children were enrolled for a 1-year period. At entry each child was assigned randomly to a treatment regimen that specified consistent treatments for episodes of non-severe and severe AOM based on severity of otalgia and the presence of fever (&gt; 39 °C orally or &gt; 39.5 °C rectally within the 24-hour period before presentation)</P>
<P>
<B>Non-severe AOM episodes</B> were treated with:</P>
<P>Tx - amoxicillin 40 mg/kg/day 3 times daily for 14 days; N = 522 (N = 488 included in primary analysis)</P>
<P>C - placebo for 14 days; N = 527 (N = 492 included in primary analysis)</P>
<P>
<B>Severe AOM episodes</B> in children aged &lt; 2 years were treated with:</P>
<P>Tx 1 - amoxicillin 40 mg/kg/day 3 times daily for 14 days</P>
<P>Tx 2 - amoxicillin 40 mg/kg/day 3 times daily for 14 days and myringotomy</P>
<P>
<B>Severe AOM episodes</B> in children aged &#8805; 2 years were treated with:<BR/>Tx 1 - amoxicillin 40 mg/kg/day 3 times daily for 14 days</P>
<P>Tx 2 - amoxicillin 40 mg/kg/day 3 times daily for 14 days and myringotomy</P>
<P>Tx 3 - placebo and myringotomy<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcome - </B>initial treatment failure: in non-severe episodes this was the case when either otalgia, fever or both was present more than 24 hours after treatment was initiated and when 48 hours or more after initial treatment was initiated the child's temperature reached 38 °C orally or 38.5 °C rectally or an otalgia score of &#8805; 6 was present</P>
<P>
<B>Secondary outcomes -</B> (a) recurrent AOM defined as the development of AOM 15 days or more after the initiation of treatment for a preceding episode, (b) new episodes of otitis media with effusion defined by otoscopy and tympanometry findings</P>
<P>After initial visits, children were followed up by telephone to identify those with persistent symptoms and children younger than 2 years of age were re-examined within 48 to 72 hours</P>
<P>Follow-up visits were scheduled routinely after 2 and 6 weeks after initial treatment and monthly thereafter</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-07 08:52:23 +1000" MODIFIED_BY="[Empty name]">
<P>We included only the non-severe AOM episodes in this review (N = 1049 of which 980 were included for primary analysis); children experiencing non-severe AOM episodes were randomly allocated to either antibiotics or placebo</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Laxdal-1970">
<CHAR_METHODS MODIFIED="2012-11-27 08:12:38 +1000" MODIFIED_BY="Roderick P. Venekamp">
<P>
<B>Randomised -</B> yes, method of randomisation not described</P>
<P>
<B>Concealment of allocation -</B> unclear; method not described<BR/>
<B>Double-blind -</B> no; open-label study, investigators not blinded</P>
<P>
<B>Intention-to-treat (ITT) -</B> unclear</P>
<P>
<B>Loss to follow-up - </B>not described</P>
<P>
<B>Design -</B> parallel</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>N -</B> 142 children</P>
<P>
<B>Age -</B> between 0 to 15 years<BR/>
<B>Setting - </B>secondary care (private paediatric clinic) in Saskatoon (Canada)</P>
<P>
<B>Inclusion criteria -</B> at least 1 eardrum had to show redness and loss of landmarks</P>
<P>
<B>Exclusion criteria - </B>predominant respiratory symptoms, if allergy appeared to be a significant factor or if rupture of the eardrum had occurred</P>
<P>
<B>Baseline characteristics -</B> not described</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-22 21:39:55 +1000" MODIFIED_BY="Roderick P. Venekamp">
<P>
<B>Tx 1 -</B> penicillin G 250 mg/m<SUP>2</SUP>/day 4 times daily (approximately 33 mg/kg/day) for at least 7 days; N = 45</P>
<P>
<B>Tx 2 -</B> ampicillin 250 mg/m<SUP>2</SUP>/day 4 times daily (approximately 33 mg/kg/day) for at least 7 days; N = 49<BR/>
<B>C -</B> symptomatic therapy (Auralgan ear drops, acetylsalicylic acid, decongestive nose drops); N = 48<BR/>
<B>Use of additional medication - </B>children in treatment groups also received symptomatic therapy as required</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-12-04 07:48:45 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcomes - </B>(a) treatment failure (i.e. either deterioration or no improvement observed at day 7) (b) relapses</P>
<P>Results were evaluated at 7 days, except in cases where the ear inflammation was severe and the child appeared sufficiently ill (toxic) to warrant further examination 24 to 48 hours after treatment initiation</P>
<P>Children in the control group were subjected to very close scrutiny, especially during the first 48 hours and particularly when severe involvement was evident (high risk of detection bias)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-11-22 07:51:17 +1000" MODIFIED_BY="Roderick P. Venekamp">
<P>Open-label trial comparing immediate antibiotics (penicillin G and ampicillin) versus expectant observation</P>
<P>It was unclear whether otalgia played an important role in the definition of treatment failure</P>
<P>Data on relapses: N = 126 included in analysis, no crude numbers for separate treatment groups provided</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Le-Saux-2005">
<CHAR_METHODS MODIFIED="2012-11-22 21:49:22 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Randomised -</B> yes, computer-generated randomisation sequence</P>
<P>
<B>Concealment of allocation -</B> adequate<BR/>
<B>Double-blind -</B> yes</P>
<P>
<B>Intention-to-treat (ITT) -</B> yes</P>
<P>
<B>Loss to follow-up - </B>described</P>
<P>
<B>Design -</B> parallel</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>N -</B> 531 children (N = 512 children included in analysis; N = 19 were excluded post hoc due to inappropriate randomisation (N = 4) or alternative clinical diagnosis (N = 15))</P>
<P>
<B>Age -</B> between 6 months and 5 years<BR/>
<B>Setting - </B>secondary care: emergency department in Ottawa (Canada)</P>
<P>
<B>Inclusion criteria -</B> new onset (&lt; 4 days) of symptoms referable to the upper respiratory tract and either ear pain or fever (&gt; 38 °C). In addition, all patients had to have evidence of middle-ear effusion, defined by &#8805; 2 of the following signs: opacity, impaired mobility on the basis of pneumatic otoscopy and redness or bulging (or both) of the tympanic membrane</P>
<P>
<B>Exclusion criteria - </B>antibiotic treatment &lt; 2 weeks prior to randomisation, contraindication to amoxicillin or penicillin or sensitivity to ibuprofen or aspirin, presence of otorrhoea, co-morbid disease such as sinusitis or pneumonia, prior middle-ear surgery, placement of a ventilation tube, history of recurrent acute otitis media (more than 4 episodes in 12 months), compromised immunity, craniofacial abnormalities, or any chronic or genetic disorder</P>
<P>
<B>Baseline characteristics -</B> balanced</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-22 21:40:33 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Tx -</B> amoxicillin suspension (60 mg/kg) 3 times daily for 10 days; N = 258 (N = 253 included in analysis for day 3)<BR/>
<B>C -</B> matching placebo for 10 days; N = 254 (N = 246 included in analysis for day 3)<BR/>
<B>Use of additional medication - </B>parents were given a 5-day supply of antipyretic and analgesic medication in the form of ibuprofen suspension as required for pain or fever and a 48-hour supply of codeine elixir to be given as required for pain and fever</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-19 12:26:02 +1000" MODIFIED_BY="Liz  Dooley">
<P>
<B>Primary outcome - </B>clinical resolution of symptoms, defined as absence of receipt of an antimicrobial (other than amoxicillin in the treatment group) at any time during the 14-day period. The initiation of antimicrobial therapy was based on persistence or worsening of symptoms, fever or irritability associated with otoscopic signs of unresolving AOM, or development of symptoms indicative for mastoiditis or invasive disease</P>
<P>
<B>Secondary outcomes -</B> (a) presence of symptoms (i.e. fever, pain, irritability, vomiting, activity level) on days 1, 2 and 3; (b) number of analgesic doses, codeine doses on days 1, 2 and 3; (c) occurrence of any rash or diarrhoea in the 14 days after randomisation; (d) presence of middle-ear effusion assessed by tympanometry at 1 and 3 months after diagnosis</P>
<P>The parents were contacted on days 1, 2 and 3 after randomisation and once between day 10 and day 14 for administration of a standard questionnaire. If the parents or research assistant felt that the symptoms were not improving or were worsening, a medical reassessment was advised and the child was seen by a physician in the emergency department or clinic or by the paediatrician</P>
<P>The child was clinically assessed at 1 month and 3 months after randomisation to determine the number of subsequent episodes of acute otitis media (AOM) and to undergo tympanometry</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Little-2001">
<CHAR_METHODS MODIFIED="2012-11-27 08:14:59 +1000" MODIFIED_BY="Roderick P. Venekamp">
<P>
<B>Randomised -</B> yes, method of randomisation not described</P>
<P>
<B>Concealment of allocation -</B> adequate<BR/>
<B>Double-blind -</B> no; open-label study, investigators not blinded</P>
<P>
<B>Intention-to-treat (ITT) -</B> yes</P>
<P>
<B>Loss to follow-up - </B>described</P>
<P>
<B>Design -</B> parallel</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>N - </B>315 children (N = 285 children included in analysis)</P>
<P>
<B>Age - </B>between 6 months and 10 years</P>
<P>
<B>Setting - </B>general practice; 42 general practitioners in 3 health authorities in south-west England</P>
<P>
<B>Inclusion criteria - </B>acute otalgia and otoscopic evidence of acute inflammation of the eardrum (dullness or cloudiness with erythema, bulging or perforation). When children were too young for otalgia to be specifically documented from their history (under 3 years old) then otoscopic evidence alone was a sufficient entry criterion</P>
<P>
<B>Exclusion criteria - </B>otoscopic appearances consistent with crying or a fever alone (pink drum alone), appearances and history more suggestive of otitis media with effusion and chronic suppurative otitis media, serious chronic disease (such as cystic fibrosis, valvular heart disease), use of antibiotics &lt; 2 weeks prior to randomisation, previous complications (septic complications, hearing impairment) and if the child was unwell to be left to wait and see (e.g. high fever, floppy, drowsy, not responding to antipyretics)</P>
<P>
<B>Baseline characteristics - </B>balanced<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Tx -</B> immediate treatment with antibiotics: amoxicillin syrup 125 mg/5 mL 3 times daily for 7 days (children who were allergic to amoxicillin received erythromycin 125 mg/5 mL 4 times daily; N = 151 (N = 135 included in analysis)<BR/>
<B>C -</B> similar antibiotics were prescribed but parents were asked to wait for 72 hours before considering using the prescription. Parents were instructed that if their child still had substantial otalgia or fever after 72 hours, had discharge for &gt; 10 days or was not starting to get better then they should collect the antibiotic prescription that was left at the practice; N = 164 (N = 150 included in analysis)<BR/>
<B>Use of additional medication - </B>for both groups doctors emphasised the importance of paracetamol in full doses for relief of pain and fever</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-23 05:59:05 +1000" MODIFIED_BY="Roderick P. Venekamp">
<P>
<B>Primary outcomes -</B> (a) duration of symptoms (i.e. earache, ear discharge, night disturbance, crying); (b) daily pain score; (c) episodes of distress; (d) spoons of paracetamol used; (e) use of antibiotics</P>
<P>Doctors were asked to provide information on days of illness, physical signs and antibiotic prescribing; parents were asked to complete a daily symptom diary</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-11-22 08:16:46 +1000" MODIFIED_BY="[Empty name]">
<P>Open-label trial comparing immediate versus delayed antibiotic prescription (prescription provided but advised to fill only if symptoms did not improve or worsened)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McCormick-2005">
<CHAR_METHODS MODIFIED="2012-11-27 08:13:00 +1000" MODIFIED_BY="Roderick P. Venekamp">
<P>
<B>Randomised -</B> yes, computer-generated randomisation sequence</P>
<P>
<B>Concealment of allocation -</B> unclear; method not described<BR/>
<B>Double-blind -</B> no, open-label trial, investigators blinded, parents not blinded</P>
<P>
<B>Intention-to-treat (ITT) -</B> yes</P>
<P>
<B>Loss to follow-up - </B>described</P>
<P>
<B>Design -</B> parallel</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-22 21:41:39 +1000" MODIFIED_BY="Roderick P. Venekamp">
<P>
<B>N - </B>223 children (N = 218 children included in analysis at day 12)</P>
<P>
<B>Age - </B>between 6 months and 12 years</P>
<P>
<B>Setting - </B>secondary care: paediatric clinic of University of Texas Medical Branch (USA)</P>
<P>
<B>Inclusion criteria - </B>children were required to have (a) symptoms of ear infection; (b) otoscopic evidence of acute otitis media (AOM), including middle-ear effusion; (c) non-severe AOM</P>
<P>
<B>Exclusion criteria - </B>co-morbidity requiring antibiotic treatment, anatomic defect of ear or nasopharynx, allergy to study medication, immunologic deficiency, major medical condition and/or indwelling ventilation tube or draining otitis in the affected ear(s)</P>
<P>
<B>Baseline characteristics - </B>balanced</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-22 08:23:07 +1000" MODIFIED_BY="Roderick P. Venekamp">
<P>
<B>Tx -</B> immediate treatment with antibiotics: oral amoxicillin 90 mg/kg/day twice daily for 10 days; N = 112 (N = 110 included in analysis at day 12)<BR/>
<B>C -</B> expectant observation: no immediate antibiotics; N = 111 (N = 108 included in analysis at day 12)</P>
<P>Children in the control group with AOM failure or recurrence received oral amoxicillin 90 mg/kg/day; children in Tx group with AOM failure or recurrence received amoxicillin-clavulanate (90 mg/kg/day of amoxicillin component)<BR/>
<B>Use of additional medication - </B>all parents received saline nose drops and/or cerumen-removal drops (if needed), ibuprofen and over-the-counter decongestant/antihistamine to be given as needed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcomes -</B> (a) parent satisfaction with AOM care; (b) resolution of AOM symptoms after treatment, including number of doses of symptom medication given; (c) AOM failure (days 0 to 12) or recurrence (days 13 to 30) defined as attending to the paediatrician clinic with acute ear symptoms, an abnormal tympanic membrane, or an AOM severity score higher than that at enrolment; (d) nasopharyngeal carriage of <I>Streptococcus pneumoniae</I> strains resistant to antibiotics</P>
<P>
<B>Secondary outcomes -</B> (a) minor adverse events caused by medication (e.g. allergy, diarrhoea and candidal infection); (b) serious AOM-related adverse events (e.g. invasive pneumococcal disease, mastoiditis, bacteraemia, meningitis, perforation of the tympanic membrane, hospitalisation and emergency ear surgery; (c) parent-child quality of life measures related to AOM</P>
<P>Parents were instructed to complete a symptom diary from day 1 to 10 and a satisfaction questionnaire on day 12 and day 30; routine follow-up appointments for data collection were scheduled for day 12 and day 30. Patient-initiated visits were scheduled on request by the parents for children who seemed to not be responding to treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-11-22 08:24:33 +1000" MODIFIED_BY="[Empty name]">
<P>Investigator-blinded trial comparing immediate antibiotic prescribing versus expectant observation (no prescription provided)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mygind-1981">
<CHAR_METHODS MODIFIED="2012-11-22 21:49:33 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Randomised -</B> yes, method of randomisation not described</P>
<P>
<B>Concealment of allocation -</B> adequate<BR/>
<B>Double-blind -</B> yes</P>
<P>
<B>Intention-to-treat (ITT) -</B> unclear</P>
<P>
<B>Loss to follow-up - </B>reasons described, unclear from which treatment group patients were excluded</P>
<P>
<B>Design -</B> parallel</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-23 05:59:08 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>N -</B> 158 children (N = 149 included in analysis)</P>
<P>
<B>Age -</B> between 1 and 10 years<BR/>
<B>Setting - </B>general practice and secondary care: confirmation of diagnosis and trial recruitment were done by otorhinolaryngologists in Copenhagen (Denmark)</P>
<P>
<B>Inclusion criteria -</B> earache for 1 to 24 hours. The diagnosis was made if the child cried because of pain and if the tympanic membrane appeared to be red and inflamed</P>
<P>
<B>Exclusion criteria - </B>antibiotic treatment &lt; 4 weeks prior to randomisation, other treatment apart from acetylsalicylic acid already commenced, secretion in the external ear, suspected chronic otitis media, treatment for secretory otitis media within last 12 months, concurrent disease (e.g. pneumonia or severe tonsillitis), suspected penicillin allergy</P>
<P>
<B>Baseline characteristics -</B> balanced</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-22 21:42:33 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Tx -</B> penicillin 50 mg/mL 4 times daily; children aged 1 to 2 years: 10 mL daily, children between 3 and 5 years: 20 mL daily, children between 6 and 10 years: 30 mL daily for 7 days; N = ? (N = 72 included in analysis)<BR/>
<B>C -</B> placebo for 7 days; N = ? (N = 77 included in analysis)<BR/>
<B>Use of additional medication - </B>acetylsalicylic acid tablets (maximum of 50 mg/kg/day for 3 days) were supplied as the only supplementary treatment permitted</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-22 08:26:45 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Main outcomes: </B>(a) mean symptoms (i.e. pain, fever) scores; (b) number of analgesic tables used; (c) contralateral otitis; (d) spontaneous perforation of tympanic membrane; (e) mean number of days of otorrhoea; (f) tympanometry results at 1 week, 4 weeks and 3 months</P>
<P>Initial visits were performed at home: otoscopy and bacterial culture from nasopharynx were performed</P>
<P>Score cards were given to parents</P>
<P>Follow-up visits at hospital at day 2 to 3, day 7, week 4 and week 12. If supplementary treatment was required at day 2 to 3, then myringotomy was performed. If supplementary treatment was required at day 7, then amoxicillin was given</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Neumark-2007">
<CHAR_METHODS MODIFIED="2012-11-27 08:18:55 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Randomised -</B> yes, Internet-based random number generator</P>
<P>
<B>Concealment of allocation -</B> unclear; method not described<BR/>
<B>Double-blind -</B> no, open-label trial</P>
<P>
<B>Intention-to-treat (ITT) -</B> unclear</P>
<P>
<B>Loss to follow-up - </B>reasons described, unclear from which treatment group patients were excluded</P>
<P>
<B>Design -</B> parallel</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>N - </B>186 children (N = 179 patients were included in analysis; 7 patients were excluded due to non-compliance with protocol)</P>
<P>
<B>Age - </B>between 2 and 16 years</P>
<P>
<B>Setting - </B>general practice: 32 healthcare centres and 72 general practitioners in Sweden</P>
<P>
<B>Inclusion criteria - </B>acute otitis media (AOM) was based on direct inspection of the eardrum by pneumatic otoscope or preferably an aural microscope. Findings had to include a bulging, red eardrum displaying reduced mobility</P>
<P>
<B>Exclusion criteria - </B>perforation of the eardrum, chronic ear conditions or impaired hearing, previous adverse reactions to penicillin, concurrent disease that should be treated with antibiotics, recurrent AOM (3 or more AOM episodes during the past 6 months), children with immunosuppressive conditions, genetic disorders and mental disease or retardation</P>
<P>
<B>Baseline characteristics - </B>balanced</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-22 21:43:18 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Tx -</B> immediate treatment with antibiotics: phenoxymethylpenicillin 25 mg/kg twice daily for 5 days; N = 92<BR/>
<B>C -</B> expectant observation: no immediate antibiotics; N = 87</P>
<P>The guardians received written information about how to act if the condition did not improve or got worse within 3 days after randomisation<BR/>
<B>Use of additional medication - </B>symptomatic treatment with paracetamol or non-steroidal anti-inflammatory drugs (NSAIDs), drugs reducing the swelling of the nasal mucosa (e.g. decongestive nose drops) and nasal steroids were allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-22 21:07:16 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcomes - </B>(a) pain at day 0, 1, 2 and 3 to 7; (b) use of analgesics at day 0, 1, 2, 3, 4 to 7; (c) fever &gt; 38 °C at day 0, 1, 2 and 3 to 7; (d) subjective recovery at day 14 and 3 months; (e) perforations at 3 months; (f) serous otitis media at 3 months</P>
<P>All participants were asked to complete a symptom diary for 7 days; a nurse telephoned all participants after approximately 14 days to supplement the information in the diary and to register all acute contacts that had occurred during the first week of treatment; the final follow-up was performed after 3 months to register perforations and serous otitis media</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-11-22 21:07:19 +1000" MODIFIED_BY="[Empty name]">
<P>Open-label trial comparing immediate antibiotic prescribing versus expectant observation (no prescription provided but advice on what to do if symptoms did not improve or worsened)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Spiro-2006">
<CHAR_METHODS MODIFIED="2012-11-27 08:15:41 +1000" MODIFIED_BY="Roderick P. Venekamp">
<P>
<B>Randomised -</B> yes, computer-assisted randomisation</P>
<P>
<B>Concealment of allocation -</B> adequate<BR/>
<B>Double-blind -</B> no, open-label study, investigators blinded</P>
<P>
<B>Intention-to-treat (ITT) -</B> yes</P>
<P>
<B>Loss to follow-up - </B>described</P>
<P>
<B>Design -</B> parallel</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>N - </B>283 children (N = 265 children included in analysis at days 4 to 6)</P>
<P>
<B>Age - </B>between 6 months and 12 years</P>
<P>
<B>Setting - </B>secondary care: paediatric emergency department of Yale-New Haven Hospital in New Haven (USA)</P>
<P>
<B>Inclusion criteria - </B>the diagnosis of acute otitis media (AOM) was made at the discretion of the clinician according to the diagnostic criteria in the evidence-based guideline published in <I>Pediatrics</I> 2004</P>
<P>
<B>Exclusion criteria - </B>presence of additional intercurrent bacterial infection such as pneumonia, if the patient appeared to be "toxic" as determined by the clinician, hospitalisation, immunocompromised children, antibiotic treatment &lt; 1 week prior to randomisation, children who had either myringotomy or a perforated tympanic membrane, uncertain access to medical care (e.g. no telephone access), primary language of parents was neither English nor Spanish, previous enrolment in the study</P>
<P>
<B>Baseline characteristics - </B>balanced</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-22 21:18:25 +1000" MODIFIED_BY="Roderick P. Venekamp">
<P>
<B>Tx -</B> immediate treatment with antibiotics; N = 145 (N = 133 included in analysis at days 4 to 6)<BR/>
<B>C -</B> participants randomised to delayed prescription were given written and verbal instructions "not to fill the antibiotic prescription unless your child either is not better or is worse 48 hours (2 days) after today's visit"; N = 138 (N = 132 included in analysis at days 4 to 6)<BR/>
<B>Use of additional medication - </B>all participants received complimentary bottles of ibuprofen suspension (100 mg/5 mL) and analgesic ear drops<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-22 21:20:37 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcome -</B> proportion of each group that filled the prescription for an antibiotic. This was defined by whether the parent filled the prescription within 3 days of enrolment and was determined by the response to this question at the interview at day 4 to 6</P>
<P>
<B>Secondary outcomes -</B> (a) clinical course of the illness; (b) adverse effects of medications; (c) days of school or work missed; (d) unscheduled medical visits; (e) comfort of parents with management of AOM without antibiotics for future episodes</P>
<P>2 trained research assistants blinded to group assignment conducted standardised, structured telephone interviews with the parents at day 4 to 6, day 11 to 14, day 30 and day 40 after enrolment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-11-22 21:20:46 +1000" MODIFIED_BY="[Empty name]">
<P>Investigator-blinded study comparing immediate versus delayed antibiotic prescribing (prescription provided and advised to fill only if symptoms worsen or do not improve)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tapiainen-2014">
<CHAR_METHODS MODIFIED="2015-01-19 12:04:07 +1000" MODIFIED_BY="Liz  Dooley">
<P>
<B>Randomised -</B> yes, block randomisation, computerised randomisation list</P>
<P>
<B>Concealment of allocation -</B> adequate<BR/>
<B>Double-blind -</B> yes</P>
<P>
<B>Intention-to-treat (ITT) -</B> yes</P>
<P>
<B>Loss to follow-up - </B>described</P>
<P>
<B>Design -</B> parallel</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>N - </B>84 children (N = 84 children included in analysis at 8 weeks)</P>
<P>
<B>Age - </B>between 6 months and 15 years</P>
<P>
<B>Setting - </B>primary and secondary care: children in day care centres attending an AOM prevention trial at the Department of Pediatrics, Oulu University Hospital and children visiting the City of Oulu Health Care Center and Mehiläinen Pediatric Private Practice, Oulu (Finland)</P>
<P>
<B>Inclusion criteria - </B>acute symptoms of respiratory infection and/or ear-related symptoms and signs of tympanic membrane inflammation together with middle-ear effusion at pneumatic otoscopy performed by a study physician</P>
<P>
<B>Exclusion criteria - </B>ventilation tubes (grommets), AOM complication, amoxicillin allergy, Down syndrome, congenital craniofacial abnormality and immunodeficiency</P>
<P>
<B>Baseline characteristics - </B>balanced</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-21 16:47:39 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Tx -</B> amoxicillin-clavulanate for 7 days (amoxicillin 40 mg/kg/day divided into 2 daily doses); N = 42 (N = 42 included in analysis)<BR/>
<B>C -</B> matching placebo in 2 doses for 7 days; N = 42 (N = 42 included in analysis)<BR/>
<B>Use of additional medication - </B>not described</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcome -</B> time middle-ear effusion disappearance defined as a normal tympanogram finding (A curve) from both ears on 2 consecutive measurement days (either at home or at the study clinic)</P>
<P>
<B>Secondary outcomes -</B> (a) time to improved tympanogram findings (i.e. A or C curve) from both ears; (b) time to normal pneumatic otoscopy or otomicroscopy findings from both ears; (c) proportions of children with persistent middle-ear effusion on days 7, 14 and 60; (d) disappearance of pain; (e) disappearance of fever; (f) use of pain medication; (g) possible adverse effects of antimicrobial treatment</P>
<P>Children were examined by the study physician with pneumatic otoscopy or otomicroscopy and tympanometry at study entry, after 3 and 7 days, and then weekly until both ears were healthy according to pneumatic otoscopy or otomicroscopy</P>
<P>Families were trained to perform tympanometry using a handheld tympanometer for daily follow-up at home<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Thalin-1985">
<CHAR_METHODS MODIFIED="2012-11-22 21:49:44 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Randomised -</B> yes, block randomisation, method of random sequence generation not described</P>
<P>
<B>Concealment of allocation -</B> adequate<BR/>
<B>Double-blind -</B> yes</P>
<P>
<B>Intention-to-treat (ITT) -</B> unclear</P>
<P>
<B>Loss to follow-up - </B>described</P>
<P>
<B>Design -</B> parallel</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-11-22 21:50:38 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>N - </B>293 children (N = 293 children included in analysis)</P>
<P>
<B>Age - </B>between 2 and 15 years</P>
<P>
<B>Setting - </B>secondary care: department of otorhinolaryngology in Halmstad (Sweden)</P>
<P>
<B>Inclusion criteria - </B>purulent acute otitis media (AOM) (no further criteria described)</P>
<P>
<B>Exclusion criteria - </B>antibiotic treatment or AOM episode &lt; 4 weeks prior to randomisation, suspected penicillin allergy, presence of ventilation tubes, sensorineural hearing loss, existence of concomitant infection for which antibiotic treatment was required and chronic diseases</P>
<P>
<B>Baseline characteristics - </B>not described</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-22 21:21:37 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Tx -</B> phenoxymethyl penicillin 50 mg/kg/day twice daily for 7 days; N = 159 (N = 159 included in analysis)<BR/>
<B>C -</B> matching placebo in 2 doses for 7 days; N = 158 (N = 158 included in analysis)<BR/>
<B>Use of additional medication - </B>all children were given nose drops containing oxymetazoline chloride and, if needed, analgesics (paracetamol)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-22 21:22:57 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcome -</B> treatment failure (defined as remaining non-negligible symptoms such as pain and fever, insufficient resolution of infectious signs during treatment period of 7 days, or both</P>
<P>
<B>Secondary outcomes -</B> (a) resolution of symptoms over time; (b) AOM relapses; (c) tympanometry, audiometry, or both, results at 4 weeks</P>
<P>The children were examined at day 0, days 3 to 4, days 8 to 10 and at 4 weeks</P>
<P>Parents were instructed to record symptoms (i.e. temperature, otalgia, discharge from ear and consumption of supplied symptomatic drugs)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-T_x00e4_htinen-2011">
<CHAR_METHODS MODIFIED="2015-01-19 11:52:14 +1000" MODIFIED_BY="Liz  Dooley">
<P>
<B>Randomised -</B> yes, computerised random number generator with block length of 10</P>
<P>
<B>Concealment of allocation -</B> adequate<BR/>
<B>Double-blind -</B> yes</P>
<P>
<B>Intention-to-treat (ITT) -</B> yes</P>
<P>
<B>Loss to follow-up - </B>described</P>
<P>
<B>Design -</B> parallel</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>N -</B> 322 children (N = 319 children were included in analysis)<BR/>
<B>Age -</B> between 6 months and 3 years</P>
<P>
<B>Setting -</B> general practice: healthcare centre of Turku (Finland)</P>
<P>
<B>Inclusion criteria -</B> acute otitis media (AOM) based on 3 criteria: (a) middle-ear fluid had to be detected by means of pneumatic otoscopic examination that showed at least 2 of the following tympanic membrane findings: bulging position, decreased or absent mobility, abnormal colour or opacity not due to scarring, or air fluid interfaces; (b) at least 1 of the following acute inflammatory signs in the tympanic membrane had to be present: distinct erythematous patches or streaks or increased vascularity over full, bulging, or yellow tympanic membrane; (c) presence of acute symptoms such as fever, otalgia or respiratory symptoms</P>
<P>
<B>Exclusion criteria -</B> ongoing antibiotic treatment; AOM with spontaneous perforation of the tympanic membrane; systemic or nasal steroid therapy within 3 preceding days; antihistamine, oseltamivir or a combination therapy within 3 preceding days; contraindication to penicillin or amoxicillin; presence of ventilation tube; severe infection requiring antibiotic treatment; documented Epstein-Barr virus infection within 7 preceding days; Down's syndrome or other condition affecting middle-ear diseases; known immunodeficiency</P>
<P>
<B>Baseline characteristics -</B> balanced</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Tx -</B> amoxicillin-clavulanate 40-5.7 mg/kg daily in 2 doses for 7 days; N = 162 (N = 161 included in analysis)<BR/>
<B>C -</B> matching placebo in 2 doses for 7 days; N = 160 (N = 158 included in analysis)<BR/>
<B>Use of additional medication - </B>the use of analgesics and antipyretic agents was encouraged and the use of analgesic ear drops and decongestive nose drops or sprays was allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcome -</B> time to treatment failure (i.e. a composite endpoint consisting of 6 independent components: (a) no improvement in overall condition at day 2, (b) worsening of the child's overall condition at any time, (c) no improvement in otoscopic signs at day 7, (d) perforation of tympanic membrane at any time, (e) severe infection (e.g. mastoiditis or pneumonia) necessitating systemic open-label antimicrobial treatment at any time, (f) any other reason for stopping the study drug at any time</P>
<P>
<B>Secondary outcomes -</B> assessed by study physician - (a) time to the initiation of rescue treatment; (b) time to development of contralateral AOM; - diary symptom assessment; (c) resolution of symptoms; (d) use of analgesics</P>
<P>Parents were given a diary to record symptoms, doses of study drugs and any other medications and adverse events</P>
<P>First visit after enrolment (= day 0) was scheduled at day 2. End-of-treatment visit was scheduled at day 7</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-van-Buchem-1981a">
<CHAR_METHODS MODIFIED="2012-11-22 21:49:51 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Randomised -</B> yes, method of randomisation not described</P>
<P>
<B>Concealment of allocation -</B> adequate<BR/>
<B>Double-blind -</B> yes</P>
<P>
<B>Intention-to-treat (ITT) -</B> unclear</P>
<P>
<B>Loss to follow-up - </B>reasons not described, unclear from which treatment group patients were excluded</P>
<P>
<B>Design -</B> 2 x 2 factorial design</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>N - </B>202 children (N = 171 children included in analysis; N = 31 were excluded from the study)</P>
<P>
<B>Age - </B>between 2 and 12 years</P>
<P>
<B>Setting - </B>both general practice and secondary care: 12 general practitioners in or near Tilburg (the Netherlands) recruited patients and referred them to 1 of the 3 otorhinolaryngologists, which excluded those cases where there was disagreement with the diagnosis</P>
<P>
<B>Inclusion criteria - </B>acute otitis media (AOM) was based on history and clinical picture (i.e. diffuse redness, bulging of the eardrum, or both)</P>
<P>
<B>Exclusion criteria - </B>antibiotic treatment &lt; 2 weeks prior to randomisation, chronic otitis or otitis media serosa, contraindication for antibiotic treatment</P>
<P>
<B>Baseline characteristics - </B>balanced</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-23 00:38:37 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Tx -</B> sham myringotomy and amoxicillin 250 mg 3 times daily for 7 days; N = 47<BR/>
<B>C -</B> sham myringotomy and matching placebo for 7 days; N = 40<BR/>
<B>Use of additional medication - </B>all participants were allowed to use decongestive nose drops and analgesic suppositories (i.e. children aged 2 to 7 years: acetylsalicylic acid 50 mg, phenacetin 50 mg, phenobarbitone 15 mg, codeine phosphate 2.5 mg, caffeine 1.25 mg; children aged 8 to 12 years: acetylsalicylic acid 100 mg, phenacetin 100 mg, phenobarbitone 30 mg, codeine phosphate 5 mg, caffeine 2.5 mg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-11-22 21:33:06 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Main outcomes -</B> (a) parent report of pain at day 0, 1 and 7; (b) otoscopic findings at day 0, 1 and 7; (c) discharge from ear at day 1, 7 and 14; (d) mean temperature at day 0, 1 and 7; (e) AOM relapses at 6 months; (f) audiogram findings after 4 and 8 weeks</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<P>van Buchem 1981a is the 2 arms without myringotomy</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-van-Buchem-1981b">
<CHAR_METHODS MODIFIED="2012-11-22 21:49:55 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Randomised -</B> yes, method of randomisation not described</P>
<P>
<B>Concealment of allocation -</B> adequate<BR/>
<B>Double-blind -</B> yes</P>
<P>
<B>Intention-to-treat (ITT) -</B> unclear</P>
<P>
<B>Loss to follow-up - </B>reasons not described, unclear from which treatment group patients were excluded</P>
<P>
<B>Design -</B> 2 x 2 factorial design</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>N - </B>202 children (N = 171 children included in analysis; N = 31 were excluded from the study)</P>
<P>
<B>Age - </B>between 2 and 12 years</P>
<P>
<B>Setting - </B>both general practice and secondary care: 12 general practitioners in or near Tilburg (the Netherlands) recruited patients and referred them to 1 of the 3 otorhinolaryngologists who excluded those cases where there was disagreement with the diagnosis</P>
<P>
<B>Inclusion criteria - </B>acute otitis media (AOM) was based on history and clinical picture (i.e. diffuse redness, bulging of the eardrum, or both)</P>
<P>
<B>Exclusion criteria - </B>antibiotic treatment &lt; 2 weeks prior to randomisation, chronic otitis or otitis media serosa, contraindication for antibiotic treatment</P>
<P>
<B>Baseline characteristics - </B>balanced</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-11-23 00:38:41 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Tx -</B> myringotomy and amoxicillin 250 mg 3 times daily for 7 days; N = 48<BR/>
<B>C -</B> myringotomy and matching placebo for 7 days; N = 36<BR/>
<B>Use of additional medication - </B>all participants were allowed to use decongestive nose drops and analgesic suppositories (i.e. children aged 2 to 7 years: acetylsalicylic acid 50 mg, phenacetin 50 mg, phenobarbitone 15 mg, codeine phosphate 2.5 mg, caffeine 1.25 mg; children aged 8 to 12 years: acetylsalicylic acid 100 mg, phenacetin 100 mg, phenobarbitone 30 mg, codeine phosphate 5 mg, caffeine 2.5 mg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Main outcomes -</B> (a) parent report of pain at day 0, 1 and 7; (b) otoscopic findings at day 0, 1 and 7; (c) discharge from ear at day 1, 7 and 14; (d) mean temperature at day 0, 1 and 7; (e) AOM relapses at 6 months; (f) audiogram findings after 4 and 8 weeks</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<P>van Buchem 1981b is the 2 arms with myringotomy</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>AOM: acute otitis media<BR/>AOM-SOS: otitis media - severity of symptoms<BR/>C: control<BR/>ITT: intention-to-treat<BR/>Tx: treatment<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Arguedas-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<P>No comparison of antibiotic to placebo or expectant observation: trial comparing single-dose, extended-release azithromycin versus a 10-day regimen of amoxicillin/clavulanate</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Casey-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<P>No comparison of antibiotic to placebo or expectant observation: trial comparing high-dose amoxicillin/clavulanate versus cefdinir</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chaput-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Short versus long course of therapy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-07 12:48:19 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Engelhard-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-07 12:48:19 +1000" MODIFIED_BY="[Empty name]">
<P>No comparison of antibiotic to placebo; the 3 arms were Augmentin, myringotomy, or both</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<P>No comparison of antibiotic to placebo or expectant observation: trial comparing single oral doses azithromycin in extended-release versus immediate-release formulations</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ostfeld-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomised study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rudberg-1954">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<P>Non-randomised study: assigned "randomly" based on case number but then allowed to change groups</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-09-14 01:30:39 +1000" MODIFIED_BY="Roderick P. Venekamp" STUDY_ID="STD-Ruohola-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-09-14 01:30:39 +1000" MODIFIED_BY="Roderick P. Venekamp">
<P>Conducted in children with ventilation tubes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-02-22 02:44:38 +1000" MODIFIED_BY="Roderick P. Venekamp" STUDY_ID="STD-Sarrell-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-02-22 02:44:38 +1000" MODIFIED_BY="Roderick P. Venekamp">
<P>No comparison of antibiotic to placebo. Method of randomisation not provided and groups appear to be unbalanced at baseline</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-T_x00e4_htinen-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<P>Secondary analysis of placebo-controlled trial. This study included the total group of children allocated to immediate antimicrobial treatment (N = 161) and a subgroup of children from the placebo group that received delayed antibiotics (N = 53). As a consequence, comparability of prognosis achieved through randomisation is violated, producing groups of children that are incomparable, which may lead to biased effect estimates<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-van-Buchem-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomised study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ACTRN12608000424303">
<CHAR_STUDY_NAME MODIFIED="2015-06-19 18:17:49 +1000" MODIFIED_BY="[Empty name]">
<P>Antibiotics for asymptomatic acute otitis media</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2015-01-11 16:22:37 +1000" MODIFIED_BY="[Empty name]">
<P>Double-blind, placebo-controlled randomised clinical trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-11 16:22:40 +1000" MODIFIED_BY="[Empty name]">
<P>Aboriginal children aged between 6 and 30 months diagnosed with asymptomatic acute otitis media defined as a bulging tympanic membrane without associated symptoms (including ear pain, fever or ear discharge) at the time of diagnosis<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<P>Azithromycin 30 mg/kg divided into 2 doses or placebo for 7 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcome -</B> proportion of children with a bulging tympanic membrane or ear discharge or withdrawn due to complications or side effects at 14 days (all children who are lost to follow-up are considered clinical failures)</P>
<P>
<B>Secondary outcomes - </B>(a) proportion of children with unresolved bulging at 7 and 30 days; (b) proportion of children with a bulging tympanic membrane or ear discharge or withdrawn due to complications or side effects at 7, 14 and 30 days (not including children who are lost to follow-up); (c) proportion of children who develop an illness requiring additional medical treatment at 7, 14 and 30 days; (d) proportion of children who develop an illness requiring cessation of prescribed antibiotics at 30 days; (e) proportion of children who have no improvement in other conditions recorded, like skin sores and rhinosinusitis, at 7, 14 and 30 days; (f) microbiological outcomes including carriage and antibiotic resistance of <I>Streptococcus pneumoniae</I> and <I>Haemophilus influenzae</I> at 7, 14 and 30 days</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2015-01-11 16:22:49 +1000" MODIFIED_BY="[Empty name]">
<P>March 2007</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<P>Menzies School of Health Research, PO Box 41096, Casuarina NT 0811, Australia</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2015-01-11 16:22:55 +1000" MODIFIED_BY="[Empty name]">
<P>ACTRN12608000424303</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-22 07:27:06 +1000" MODIFIED_BY="Roderick P. Venekamp" RESULT="YES" STUDY_ID="STD-Appelman-1991">
<DESCRIPTION>
<P>Computer-generated random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-22 07:32:06 +1000" MODIFIED_BY="Roderick P. Venekamp" RESULT="YES" STUDY_ID="STD-Burke-1991">
<DESCRIPTION>
<P>Computer-generated random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-07 08:44:35 +1000" MODIFIED_BY="Roderick P. Venekamp" RESULT="YES" STUDY_ID="STD-Damoiseaux-2000">
<DESCRIPTION>
<P>Computerised 2 block randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Halsted-1968">
<DESCRIPTION>
<P>Pre-determined code, which was unknown to physician; method of random sequence generation unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-22 07:42:48 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hoberman-2011">
<DESCRIPTION>
<P>Stratified block randomisation with computer-generated randomisation lists</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-28 07:12:31 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Howie-1972">
<DESCRIPTION>
<P>Method of randomisation not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-28 07:13:05 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kaleida-1991">
<DESCRIPTION>
<P>Method of randomisation not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-28 07:13:20 +1000" MODIFIED_BY="Roderick P. Venekamp" RESULT="UNKNOWN" STUDY_ID="STD-Laxdal-1970">
<DESCRIPTION>
<P>Method of randomisation not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-22 07:54:49 +1000" MODIFIED_BY="Roderick P. Venekamp" RESULT="YES" STUDY_ID="STD-Le-Saux-2005">
<DESCRIPTION>
<P>Computer-generated randomisation sequence stratified by study centre and age using random-permuted blocks of sizes 4 and 6</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-27 08:07:36 +1000" MODIFIED_BY="Roderick P. Venekamp" RESULT="UNKNOWN" STUDY_ID="STD-Little-2001">
<DESCRIPTION>
<P>Method of randomisation not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-22 08:24:40 +1000" MODIFIED_BY="Roderick P. Venekamp" RESULT="YES" STUDY_ID="STD-McCormick-2005">
<DESCRIPTION>
<P>Computer-generated randomisation sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-28 07:14:03 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mygind-1981">
<DESCRIPTION>
<P>Method of randomisation not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-28 07:14:01 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Neumark-2007">
<DESCRIPTION>
<P>Internet-based random number generator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-27 08:16:16 +1000" MODIFIED_BY="Roderick P. Venekamp" RESULT="YES" STUDY_ID="STD-Spiro-2006">
<DESCRIPTION>
<P>Computer-assisted randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 12:04:09 +1000" MODIFIED_BY="Liz  Dooley" RESULT="YES" STUDY_ID="STD-Tapiainen-2014">
<DESCRIPTION>
<P>Block randomisation, computerised randomisation list</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-28 07:14:01 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Thalin-1985">
<DESCRIPTION>
<P>Block randomisation, method of random sequence generation not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-28 07:13:59 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-T_x00e4_htinen-2011">
<DESCRIPTION>
<P>Computerised random number generator with block length of 10</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-28 07:13:58 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-van-Buchem-1981a">
<DESCRIPTION>
<P>Method of randomisation not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-28 07:13:57 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-van-Buchem-1981b">
<DESCRIPTION>
<P>Method of randomisation not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-07 12:41:00 +1000" MODIFIED_BY="Roderick P. Venekamp" RESULT="YES" STUDY_ID="STD-Appelman-1991">
<DESCRIPTION>
<P>Treatment allocated by otolaryngologist (independent to trial personnel); treatment code placed in sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-07 08:42:56 +1000" MODIFIED_BY="Roderick P. Venekamp" RESULT="YES" STUDY_ID="STD-Burke-1991">
<DESCRIPTION>
<P>Randomisation was carried out independently of the investigators; randomisation code was kept sealed and was unknown to any of the participants in the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-07 08:44:38 +1000" MODIFIED_BY="Roderick P. Venekamp" RESULT="YES" STUDY_ID="STD-Damoiseaux-2000">
<DESCRIPTION>
<P>Randomisation was carried out independently of the investigators; randomisation code was kept in pharmacy of the University Medical Centre Utrecht</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-28 07:12:32 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Halsted-1968">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hoberman-2011">
<DESCRIPTION>
<P>A pharmacist (independent of the trial team) provided masked study medication bottles with amoxicillin/clavulanate or placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-07 12:43:40 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Howie-1972">
<DESCRIPTION>
<P>Randomisation was performed by a collaborating pharmacist</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-28 07:13:05 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kaleida-1991">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-27 08:05:09 +1000" MODIFIED_BY="Roderick P. Venekamp" RESULT="UNKNOWN" STUDY_ID="STD-Laxdal-1970">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Le-Saux-2005">
<DESCRIPTION>
<P>Randomisation sequence was kept under secure conditions and was accessible only by the trial pharmacist</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Little-2001">
<DESCRIPTION>
<P>Sealed, numbered, opaque envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-27 08:13:33 +1000" MODIFIED_BY="Roderick P. Venekamp" RESULT="UNKNOWN" STUDY_ID="STD-McCormick-2005">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-28 07:14:03 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mygind-1981">
<DESCRIPTION>
<P>Randomisation performed by pharmaceutical company. Penicillin and placebo were supplied in coded bottles to study personnel</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-27 08:19:07 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Neumark-2007">
<DESCRIPTION>
<P>Method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Spiro-2006">
<DESCRIPTION>
<P>Sealed, opaque envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-11 16:21:39 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tapiainen-2014">
<DESCRIPTION>
<P>Randomisation list was kept in the pharmacy, which delivered the study drugs to the families according to the consecutive study number</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-28 07:14:01 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Thalin-1985">
<DESCRIPTION>
<P>Randomisation list was kept by the clinical pharmacologist of the hospital and not disclosed to the investigators until the clinical trial was completed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-23 06:00:03 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-T_x00e4_htinen-2011">
<DESCRIPTION>
<P>Concealment of allocation by the pharmacist (independent to trial team) by labelling the identical opaque study drug containers with allocation numbers; allocation list was kept at the paediatric infectious disease ward behind locked doors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-22 21:33:38 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-Buchem-1981a">
<DESCRIPTION>
<P>Randomisation performed by otorhinolaryngologists; general practitioner and parent/child were outcome assessors and remained blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-22 21:35:40 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-Buchem-1981b">
<DESCRIPTION>
<P>Randomisation performed by otorhinolaryngologists; general practitioner and parent/child were outcome assessors and remained blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2012-02-22 00:27:43 +1000" MODIFIED_BY="Roderick P. Venekamp" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2012-02-22 00:27:43 +1000" MODIFIED_BY="Roderick P. Venekamp" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2012-02-22 00:27:43 +1000" MODIFIED_BY="Roderick P. Venekamp" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2015-01-11 16:21:42 +1000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-28 07:12:34 +1000" MODIFIED_BY="Roderick P. Venekamp" RESULT="UNKNOWN" STUDY_ID="STD-Appelman-1991">
<DESCRIPTION>
<P>ITT analysis - unclear, baseline characteristics - balanced</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-07 08:43:00 +1000" MODIFIED_BY="Roderick P. Venekamp" RESULT="UNKNOWN" STUDY_ID="STD-Burke-1991">
<DESCRIPTION>
<P>ITT analysis - yes; baseline characteristics - imbalance for gender and crying</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-07 08:44:47 +1000" MODIFIED_BY="Roderick P. Venekamp" RESULT="YES" STUDY_ID="STD-Damoiseaux-2000">
<DESCRIPTION>
<P>ITT analysis - yes, baseline characteristics - slight imbalance, logistic regression was used to adjust for imbalances in prognostic factors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-22 07:37:06 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Halsted-1968">
<DESCRIPTION>
<P>ITT analysis - unclear, baseline characteristics - not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-07 08:48:11 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hoberman-2011">
<DESCRIPTION>
<P>ITT analysis - yes, baseline characteristics - balanced</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-22 07:45:12 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Howie-1972">
<DESCRIPTION>
<P>ITT analysis - unclear, baseline characteristics - not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-07 09:14:42 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kaleida-1991">
<DESCRIPTION>
<P>ITT analysis - yes, baseline characteristics - balanced</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-04 07:48:39 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Laxdal-1970">
<DESCRIPTION>
<P>ITT analysis - unclear, baseline characteristics - not described, high risk of detection bias due to different follow-up strategies between treatment groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-22 07:54:58 +1000" MODIFIED_BY="Roderick P. Venekamp" RESULT="YES" STUDY_ID="STD-Le-Saux-2005">
<DESCRIPTION>
<P>ITT analysis - yes, baseline characteristics - balanced</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-07 09:17:49 +1000" MODIFIED_BY="Roderick P. Venekamp" RESULT="YES" STUDY_ID="STD-Little-2001">
<DESCRIPTION>
<P>ITT analysis - yes, baseline characteristics - balanced</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-07 09:19:34 +1000" MODIFIED_BY="Roderick P. Venekamp" RESULT="YES" STUDY_ID="STD-McCormick-2005">
<DESCRIPTION>
<P>ITT analysis - yes, baseline characteristics - balanced</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-07 09:20:45 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mygind-1981">
<DESCRIPTION>
<P>ITT analysis - unclear, baseline characteristics - balanced</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-07 09:21:41 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Neumark-2007">
<DESCRIPTION>
<P>ITT analysis - unclear, baseline characteristics - balanced</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-07 09:23:38 +1000" MODIFIED_BY="Roderick P. Venekamp" RESULT="YES" STUDY_ID="STD-Spiro-2006">
<DESCRIPTION>
<P>ITT analysis - yes, baseline characteristics - balanced</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-11 16:21:42 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tapiainen-2014">
<DESCRIPTION>
<P>ITT analysis - yes, baseline characteristics - balanced</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-07 09:24:37 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Thalin-1985">
<DESCRIPTION>
<P>ITT analysis - unclear; baseline characteristics - not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-07 09:25:37 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-T_x00e4_htinen-2011">
<DESCRIPTION>
<P>ITT analysis - yes, baseline characteristics - balanced</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-22 21:33:42 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-van-Buchem-1981a">
<DESCRIPTION>
<P>ITT analysis - unclear, baseline characteristics - balanced</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-22 21:35:50 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-van-Buchem-1981b">
<DESCRIPTION>
<P>ITT analysis - unclear, baseline characteristics - balanced</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2012-02-22 00:27:43 +1000" MODIFIED_BY="Roderick P. Venekamp" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2012-02-22 00:27:43 +1000" MODIFIED_BY="Roderick P. Venekamp" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="STUDY" MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Appelman-1991">
<DESCRIPTION>
<P>Identical taste and appearance to amoxicillin/clavulanate and placebo not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-28 07:12:33 +1000" MODIFIED_BY="Roderick P. Venekamp" RESULT="YES" STUDY_ID="STD-Burke-1991">
<DESCRIPTION>
<P>Each bottle was identified only by number</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Damoiseaux-2000">
<DESCRIPTION>
<P>Placebo suspension with same taste and appearance as amoxicillin</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Halsted-1968">
<DESCRIPTION>
<P>Identical taste and appearance to antibiotics and placebo not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hoberman-2011">
<DESCRIPTION>
<P>Placebo with same taste and appearance as amoxicillin-clavulanate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Howie-1972">
<DESCRIPTION>
<P>Identical taste and appearance to amoxicillin/clavulanate and placebo not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kaleida-1991">
<DESCRIPTION>
<P>Identical taste and appearance to amoxicillin and placebo not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-27 08:08:04 +1000" MODIFIED_BY="Roderick P. Venekamp" RESULT="UNKNOWN" STUDY_ID="STD-Laxdal-1970">
<DESCRIPTION>
<P>Open-label trial, outcome assessment not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Le-Saux-2005">
<DESCRIPTION>
<P>Placebo was similar to amoxicillin with regard to appearance and taste and was dispensed in identical opaque bottles, which were numbered sequentially</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-22 08:17:51 +1000" MODIFIED_BY="Roderick P. Venekamp" RESULT="UNKNOWN" STUDY_ID="STD-Little-2001">
<DESCRIPTION>
<P>Open-label trial, outcome assessment not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-27 08:20:13 +1000" MODIFIED_BY="Roderick P. Venekamp" RESULT="UNKNOWN" STUDY_ID="STD-McCormick-2005">
<DESCRIPTION>
<P>Investigator-blinded study, parents not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mygind-1981">
<DESCRIPTION>
<P>Identical taste and appearance to amoxicillin and placebo not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-22 21:16:22 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Neumark-2007">
<DESCRIPTION>
<P>Open-label trial, outcome assessment not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-27 08:16:31 +1000" MODIFIED_BY="Roderick P. Venekamp" RESULT="UNKNOWN" STUDY_ID="STD-Spiro-2006">
<DESCRIPTION>
<P>Investigator-blinded study, parents not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 11:50:36 +1000" MODIFIED_BY="Liz  Dooley" RESULT="YES" STUDY_ID="STD-Tapiainen-2014">
<DESCRIPTION>
<P>Bottles containing amoxicillin-clavulanate or placebo were indistinguishable, dosing was similar in both groups and placebo mixture was flavoured and sweetened to resemble the taste of amoxicillin-clavulanate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Thalin-1985">
<DESCRIPTION>
<P>Placebo with same taste and appearance as penicillin</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-T_x00e4_htinen-2011">
<DESCRIPTION>
<P>Placebo with same taste and appearance as amoxicillin-clavulanate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-28 07:13:57 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-Buchem-1981a">
<DESCRIPTION>
<P>Sham myringotomy and placebo was similar with amoxicillin with regard to appearance and taste</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-28 07:13:57 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-Buchem-1981b">
<DESCRIPTION>
<P>Sham myringotomy and placebo was similar with amoxicillin with regard to appearance and taste</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-10" LEVEL="STUDY" MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]" NO="10">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-22 21:37:22 +1000" MODIFIED_BY="Roderick P. Venekamp" RESULT="YES" STUDY_ID="STD-Appelman-1991">
<DESCRIPTION>
<P>Loss to follow-up - treatment: N = 3 (4%) and placebo: N = 2 (4%) due to loss of their registration forms</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-22 07:32:14 +1000" MODIFIED_BY="Roderick P. Venekamp" RESULT="UNKNOWN" STUDY_ID="STD-Burke-1991">
<DESCRIPTION>
<P>Loss to follow-up - not described; all randomised patients included in short-outcome analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-22 21:38:04 +1000" MODIFIED_BY="Roderick P. Venekamp" RESULT="UNKNOWN" STUDY_ID="STD-Damoiseaux-2000">
<DESCRIPTION>
<P>Loss to follow-up/exclusion from analysis (received other antibiotics or had grommets inserted) - treatment: N = 10 (9%) and placebo: N = 18 (15%). However, for primary analysis of symptoms at day 4 all randomised patients were included</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-28 07:12:32 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Halsted-1968">
<DESCRIPTION>
<P>Reasons described, unclear from which treatment group patients were excluded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-22 21:38:55 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hoberman-2011">
<DESCRIPTION>
<P>Children not assessed at day 4 to 5 - treatment: N = 5 (3%) and placebo: N = 5 (3%). All randomised patients included in analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-22 07:45:18 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Howie-1972">
<DESCRIPTION>
<P>Loss to follow-up - not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-22 21:39:41 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kaleida-1991">
<DESCRIPTION>
<P>Follow-up/exclusion of non-severe episodes for short-term outcome - treatment: N = 34 (7%) and placebo: N = 35 (7%). Reasons not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-22 21:40:20 +1000" MODIFIED_BY="Roderick P. Venekamp" RESULT="UNKNOWN" STUDY_ID="STD-Laxdal-1970">
<DESCRIPTION>
<P>Loss to follow-up - not described for short-term outcome. Loss to follow-up for long-term outcome (acute otitis media (AOM) relapses) - N = 16 (11%), no crude numbers of separate treatment groups provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-22 21:40:53 +1000" MODIFIED_BY="Roderick P. Venekamp" RESULT="YES" STUDY_ID="STD-Le-Saux-2005">
<DESCRIPTION>
<P>Loss to follow-up at day 3 - treatment: N = 5 (2%) and placebo: N = 8 (3%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Little-2001">
<DESCRIPTION>
<P>Loss to follow-up/exclusion from analysis (intervention ineffective, did not use antibiotics or did not delay) - treatment: N = 16 (12%) and placebo: N = 14 (9%); comparison of the baseline information for the 3 types of responders (those who provided diaries, those who gave information by telephone and those from whom no diary information could be collected) revealed no evidence of significant bias between treatment groups or between patients by age or severity of symptoms</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-22 21:42:18 +1000" MODIFIED_BY="Roderick P. Venekamp" RESULT="YES" STUDY_ID="STD-McCormick-2005">
<DESCRIPTION>
<P>Loss to follow-up at day 12 - treatment: N = 2 (2%) and expectant observation: N = 3 (3%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-13 15:54:04 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mygind-1981">
<DESCRIPTION>
<P>Patients not included in analysis - N = 9 (6%). Reasons described, unclear from which treatment group patients were excluded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-13 09:12:12 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Neumark-2007">
<DESCRIPTION>
<P>Patients not included in analysis - N = 7 (4%). Reasons described, unclear from which treatment group patients were excluded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-22 21:43:51 +1000" MODIFIED_BY="Roderick P. Venekamp" RESULT="UNKNOWN" STUDY_ID="STD-Spiro-2006">
<DESCRIPTION>
<P>Loss to follow-up at day 4 to 6 treatment: N = 12 (8%) and expectant observation: N = 6 (4%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-11 16:21:55 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tapiainen-2014">
<DESCRIPTION>
<P>All children were included in the analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-01 20:24:57 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Thalin-1985">
<DESCRIPTION>
<P>No children lost to follow-up for primary analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-22 21:45:12 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-T_x00e4_htinen-2011">
<DESCRIPTION>
<P>Loss to follow-up - treatment: N = 1 (1%) and placebo: N = 2 (1%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-22 21:33:49 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-van-Buchem-1981a">
<DESCRIPTION>
<P>Loss to follow-up/exclusions - N = 31 (15%). Reasons not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-22 21:35:56 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-van-Buchem-1981b">
<DESCRIPTION>
<P>Loss to follow-up/exclusions - N = 31 (15%). Reasons not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2015-06-19 19:37:40 +1000" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2015-06-19 19:37:40 +1000" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2014-12-15 20:08:19 +1000" MODIFIED_BY="Grade Profiler">Antibiotics versus placebo for acute otitis media in children</TITLE>
<TABLE COLS="7" ROWS="21">
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="BOTTOM">
<P>
<B>Antibiotics versus placebo for acute otitis media in children</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="BOTTOM">
<P>
<B>Patient or population:</B> children with acute otitis media<BR/>
<B>Settings: </B>primary care and secondary care<BR/>
<B>Intervention:</B> antibiotics versus placebo<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="BOTTOM">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Antibiotics versus placebo</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>Pain - pain at 24 hours</B>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 0.89 </B>
<BR/>(0.78 to 1.01)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>1394<BR/>(5 studies)<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>426 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>379 per 1000</B>
<BR/>(332 to 431)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>Pain - pain at 2 to 3 days</B>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 0.70 </B>
<BR/>(0.57 to 0.86)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>2320<BR/>(7 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>159 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>111 per 1000</B>
<BR/>(90 to 137)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>Pain - pain at 4 to 7 days</B>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 0.76 </B>
<BR/>(0.63 to 0.91)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>1347<BR/>(7 studies)<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>241 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>183 per 1000</B>
<BR/>(152 to 220)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>Pain - pain at 10 to 12 days</B>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 0.33 </B>
<BR/>(0.17 to 0.66)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>278<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>216 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>71 per 1000</B>
<BR/>(37 to 142)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>Abnormal tympanometry - 2 to 4 weeks</B>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 0.82 </B>
<BR/>(0.74 to 0.90)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>2138<BR/>(7 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>481 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>395 per 1000</B>
<BR/>(356 to 433)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>Abnormal tympanometry - 3 months</B>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 0.97 </B>
<BR/>(0.76 to 1.24)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>809<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>241 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>234 per 1000</B>
<BR/>(183 to 299)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>Vomiting, diarrhoea or rash</B>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 1.38 </B>
<BR/>(1.19 to 1.59)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>2107<BR/>(8 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>196 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>270 per 1000</B>
<BR/>(233 to 311)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="TOP">
<P>*The basis for the <B>assumed risk</B> for &#8216;Study population&#8217; was the average risk in the control groups (i.e. total number of participants with events divided by total number of participants included in the meta-analysis). The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>RR:</B> risk ratio</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="TOP">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>The number of studies reported in the 'Summary of findings' table for the outcomes 'Pain at 24 hours' and 'Pain at 4 to 7 days' differ slightly from those reported in the Data Analysis Table 1 - Antibiotics versus placebo (five versus six studies and seven versus eight studies, respectively). This is due to the van Buchem trial. This trial is included as one study in our review (and in the 'Summary of findings' table), but we included data from two different comparisons from this 2 x 2 factorial design trial in our analyses (<LINK REF="STD-van-Buchem-1981a" TYPE="STUDY">van Buchem 1981a</LINK>; <LINK REF="STD-van-Buchem-1981b" TYPE="STUDY">van Buchem 1981b</LINK>).</P>
<P>
<SUP>2</SUP>We downgraded the evidence for pain at days 10 to 12 from high quality as this outcome was not specified a priori in this trial (secondary analysis).</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2014-12-17 17:49:42 +1000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2014-12-17 17:49:27 +1000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Antibiotics versus placebo</NAME>
<DICH_OUTCOME CHI2="31.68072939957718" CI_END="0.8576398215068529" CI_START="0.7123144456606398" CI_STUDY="95" CI_TOTAL="95" DF="21" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7816068282922969" ESTIMABLE="YES" EVENTS_1="534" EVENTS_2="663" I2="33.71364738754951" I2_Q="72.5096890415817" ID="CMP-001.01" LOG_CI_END="-0.0666950622371473" LOG_CI_START="-0.14732824812056033" LOG_EFFECT_SIZE="-0.1070116551788538" METHOD="MH" MODIFIED="2014-12-15 20:59:55 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.06305127750274475" P_Q="0.012206140920038688" P_Z="1.9683770268730645E-7" Q="10.912935850517604" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="2714" TOTAL_2="2625" WEIGHT="400.0" Z="5.202299469596374">
<NAME>Pain</NAME>
<GROUP_LABEL_1>Antibiotics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Antibiotics better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo better</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.748425086428327" CI_END="1.009738938003654" CI_START="0.7821042564996317" DF="5" EFFECT_SIZE="0.888662546395467" ESTIMABLE="YES" EVENTS_1="267" EVENTS_2="292" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="0.0042091040403053484" LOG_CI_START="-0.1067353505149342" LOG_EFFECT_SIZE="-0.05126312323731441" MODIFIED="2012-02-28 01:36:25 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4473476899889113" P_Z="0.0701027093535429" STUDIES="6" TAU2="0.0" TOTAL_1="709" TOTAL_2="685" WEIGHT="100.00000000000003" Z="1.8112464599147389">
<NAME>Pain at 24 hours</NAME>
<DICH_DATA CI_END="1.2976379270372893" CI_START="0.7532824213720684" EFFECT_SIZE="0.9886798469387755" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="56" LOG_CI_END="0.11315353050325132" LOG_CI_START="-0.12304216716211396" LOG_EFFECT_SIZE="-0.00494431832943133" ORDER="353" O_E="0.0" SE="0.1387425219961954" STUDY_ID="STD-Burke-1991" TOTAL_1="112" TOTAL_2="117" VAR="0.01924948740986477" WEIGHT="18.534716639358045"/>
<DICH_DATA CI_END="0.9589012336843334" CI_START="0.6048812439319357" EFFECT_SIZE="0.7615913412315343" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="106" LOG_CI_END="-0.018226122625820674" LOG_CI_START="-0.2183298818228706" LOG_EFFECT_SIZE="-0.11827800222434567" ORDER="354" O_E="0.0" SE="0.11754193868193023" STUDY_ID="STD-Le-Saux-2005" TOTAL_1="258" TOTAL_2="254" VAR="0.013816107349106647" WEIGHT="36.14689468681943"/>
<DICH_DATA CI_END="1.3078219766389205" CI_START="0.7550423197374997" EFFECT_SIZE="0.9937106918238994" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="62" LOG_CI_END="0.11654863097201378" LOG_CI_START="-0.12202870570407151" LOG_EFFECT_SIZE="-0.002740037366028859" MODIFIED="2012-02-28 01:36:25 +1000" MODIFIED_BY="[Empty name]" ORDER="355" O_E="0.0" SE="0.1401415085403956" STUDY_ID="STD-Thalin-1985" TOTAL_1="159" TOTAL_2="158" VAR="0.019639642415977772" WEIGHT="21.044806414393587"/>
<DICH_DATA CI_END="1.0713241593637073" CI_START="0.5988878337149535" EFFECT_SIZE="0.8010012515644556" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="47" LOG_CI_END="0.029920898770409585" LOG_CI_START="-0.22265450943061804" LOG_EFFECT_SIZE="-0.09636680533010422" MODIFIED="2012-02-24 04:45:25 +1000" MODIFIED_BY="[Empty name]" ORDER="174" O_E="0.0" SE="0.14836404504571823" STUDY_ID="STD-T_x00e4_htinen-2011" TOTAL_1="85" TOTAL_2="80" VAR="0.022011889862327907" WEIGHT="16.38506705231515"/>
<DICH_DATA CI_END="1.9919695354978704" CI_START="0.5078587143287873" EFFECT_SIZE="1.0058027079303675" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="11" LOG_CI_END="0.29928269218690673" LOG_CI_START="-0.2942570911051935" LOG_EFFECT_SIZE="0.0025128005408566623" ORDER="356" O_E="0.0" SE="0.34864820677509156" STUDY_ID="STD-van-Buchem-1981a" TOTAL_1="47" TOTAL_2="40" VAR="0.12155557208748699" WEIGHT="4.021487045294387"/>
<DICH_DATA CI_END="2.4439608790941616" CI_START="0.6651599924964948" EFFECT_SIZE="1.275" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="10" LOG_CI_END="0.3880942497990302" LOG_CI_START="-0.1770738802590824" LOG_EFFECT_SIZE="0.10551018476997394" ORDER="357" O_E="0.0" SE="0.3319825572234987" STUDY_ID="STD-van-Buchem-1981b" TOTAL_1="48" TOTAL_2="36" VAR="0.11021241830065358" WEIGHT="3.867028161819417"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.824885673813311" CI_END="0.8634955528148966" CI_START="0.5736270992305611" DF="6" EFFECT_SIZE="0.7037929021805341" ESTIMABLE="YES" EVENTS_1="138" EVENTS_2="180" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="-0.0637398947993874" LOG_CI_START="-0.24137033996177631" LOG_EFFECT_SIZE="-0.15255511738058186" MODIFIED="2012-06-07 09:33:51 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5664612767062189" P_Z="7.6109661300562E-4" STUDIES="7" TAU2="0.0" TOTAL_1="1186" TOTAL_2="1134" WEIGHT="99.99999999999999" Z="3.366568556982157">
<NAME>Pain at 2 to 3 days</NAME>
<DICH_DATA CI_END="1.9296762837667214" CI_START="0.4073228982564409" EFFECT_SIZE="0.8865671641791045" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.2854844592847354" LOG_CI_START="-0.39006117472400115" LOG_EFFECT_SIZE="-0.05228835771963286" MODIFIED="2012-02-24 05:00:09 +1000" MODIFIED_BY="[Empty name]" ORDER="189" O_E="0.0" SE="0.3968188494215516" STUDY_ID="STD-Appelman-1991" TOTAL_1="67" TOTAL_2="54" VAR="0.15746519925624405" WEIGHT="6.01650262731022"/>
<DICH_DATA CI_END="2.2508965599886683" CI_START="0.4969244601766916" EFFECT_SIZE="1.0576036866359446" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="7" LOG_CI_END="0.352355537444615" LOG_CI_START="-0.30370962539511404" LOG_EFFECT_SIZE="0.0243229560247505" MODIFIED="2012-02-24 05:00:15 +1000" MODIFIED_BY="[Empty name]" ORDER="190" O_E="0.0" SE="0.3853759242269891" STUDY_ID="STD-Halsted-1968" TOTAL_1="62" TOTAL_2="27" VAR="0.14851460297380603" WEIGHT="5.298517842873871"/>
<DICH_DATA CI_END="0.8618219922740964" CI_START="0.29485805594873077" EFFECT_SIZE="0.5040983606557377" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="38" LOG_CI_END="-0.06458242762822765" LOG_CI_START="-0.5303870021704354" LOG_EFFECT_SIZE="-0.29748471489933154" MODIFIED="2012-02-24 05:00:28 +1000" MODIFIED_BY="[Empty name]" ORDER="191" O_E="0.0" SE="0.27361591285592385" STUDY_ID="STD-Kaleida-1991" TOTAL_1="488" TOTAL_2="492" VAR="0.07486566776798052" WEIGHT="20.56042185687135"/>
<DICH_DATA CI_END="1.1329369746380311" CI_START="0.5492987277138428" EFFECT_SIZE="0.7888731449026773" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="53" LOG_CI_END="0.05420575070342372" LOG_CI_START="-0.26019140689070624" LOG_EFFECT_SIZE="-0.10299282809364128" MODIFIED="2012-02-24 05:00:42 +1000" MODIFIED_BY="[Empty name]" ORDER="192" O_E="0.0" SE="0.18467844666182157" STUDY_ID="STD-Le-Saux-2005" TOTAL_1="253" TOTAL_2="246" VAR="0.03410612866142328" WEIGHT="29.197826492632824"/>
<DICH_DATA CI_END="0.9436933335703992" CI_START="0.3242441077218504" EFFECT_SIZE="0.5531609195402298" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="29" LOG_CI_END="-0.025169112879631708" LOG_CI_START="-0.48912790732449124" LOG_EFFECT_SIZE="-0.25714851010206147" MODIFIED="2012-02-24 05:01:10 +1000" MODIFIED_BY="[Empty name]" ORDER="193" O_E="0.0" SE="0.2725316924899826" STUDY_ID="STD-Mygind-1981" TOTAL_1="72" TOTAL_2="77" VAR="0.07427352341145443" WEIGHT="15.226458537360237"/>
<DICH_DATA CI_END="1.1445436032781806" CI_START="0.3533845276618802" EFFECT_SIZE="0.6359748427672955" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="25" LOG_CI_END="0.05863234249102517" LOG_CI_START="-0.45175246925530865" LOG_EFFECT_SIZE="-0.19656006338214171" MODIFIED="2012-02-24 05:01:29 +1000" MODIFIED_BY="[Empty name]" ORDER="195" O_E="0.0" SE="0.2998025648653606" STUDY_ID="STD-Thalin-1985" TOTAL_1="159" TOTAL_2="158" VAR="0.08988157789984874" WEIGHT="13.624875705873784"/>
<DICH_DATA CI_END="1.600921934797659" CI_START="0.4935427765814123" EFFECT_SIZE="0.8888888888888888" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="18" LOG_CI_END="0.20437015508407239" LOG_CI_START="-0.30667519997883497" LOG_EFFECT_SIZE="-0.05115252244738131" MODIFIED="2012-02-24 05:02:15 +1000" MODIFIED_BY="[Empty name]" ORDER="194" O_E="0.0" SE="0.3001905712792581" STUDY_ID="STD-T_x00e4_htinen-2011" TOTAL_1="85" TOTAL_2="80" VAR="0.09011437908496732" WEIGHT="10.075396937077713"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="11.651378210827207" CI_END="0.9053848728786034" CI_START="0.6334426812941137" DF="7" EFFECT_SIZE="0.7573040482391157" ESTIMABLE="YES" EVENTS_1="119" EVENTS_2="161" I2="39.9212704854508" ID="CMP-001.01.03" LOG_CI_END="-0.04316676594882022" LOG_CI_START="-0.19829267726657787" LOG_EFFECT_SIZE="-0.12072972160769904" MODIFIED="2014-12-02 02:02:03 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.11262232851740561" P_Z="0.0022826350574834957" STUDIES="8" TAU2="0.0" TOTAL_1="680" TOTAL_2="667" WEIGHT="99.99999999999997" Z="3.0507592729616415">
<NAME>Pain at 4 to 7 days</NAME>
<DICH_DATA CI_END="1.1750358054651018" CI_START="0.4269496285791863" EFFECT_SIZE="0.7082945013979497" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="29" LOG_CI_END="0.07005110054732376" LOG_CI_START="-0.36962335991764317" LOG_EFFECT_SIZE="-0.14978612968515972" MODIFIED="2012-02-24 05:06:19 +1000" MODIFIED_BY="[Empty name]" ORDER="196" O_E="0.0" SE="0.25826695450080184" STUDY_ID="STD-Burke-1991" TOTAL_1="111" TOTAL_2="114" VAR="0.06670181978711924" WEIGHT="17.978017052371882"/>
<DICH_DATA CI_END="0.9821134193410253" CI_START="0.676386642465475" EFFECT_SIZE="0.8150388936905791" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="89" LOG_CI_END="-0.007838354830571222" LOG_CI_START="-0.1698049775982711" LOG_EFFECT_SIZE="-0.08882166621442115" MODIFIED="2012-02-24 04:53:18 +1000" MODIFIED_BY="[Empty name]" ORDER="183" O_E="0.0" SE="0.09513999596146" STUDY_ID="STD-Damoiseaux-2000" TOTAL_1="117" TOTAL_2="123" VAR="0.009051618831546626" WEIGHT="54.521520143973795"/>
<DICH_DATA CI_END="0.8656468615298497" CI_START="0.229378767714683" EFFECT_SIZE="0.44560185185185186" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="24" LOG_CI_END="-0.06265924120128734" LOG_CI_START="-0.6394467847394978" LOG_EFFECT_SIZE="-0.3510530129703926" MODIFIED="2012-02-28 00:12:54 +1000" MODIFIED_BY="[Empty name]" ORDER="184" O_E="0.0" SE="0.33880785821873255" STUDY_ID="STD-Mygind-1981" TOTAL_1="72" TOTAL_2="77" VAR="0.11479076479076478" WEIGHT="14.573397111450651"/>
<DICH_DATA CI_END="1.1312028987903366" CI_START="0.003928954256744883" EFFECT_SIZE="0.06666666666666667" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="7" LOG_CI_END="0.05354050936569048" LOG_CI_START="-2.405723027477053" LOG_EFFECT_SIZE="-1.1760912590556813" MODIFIED="2014-12-02 02:02:03 +1000" MODIFIED_BY="[Empty name]" ORDER="72" O_E="0.0" SE="1.4445835750922673" STUDY_ID="STD-Tapiainen-2014" TOTAL_1="42" TOTAL_2="42" VAR="2.0868217054263565" WEIGHT="4.712318076402229"/>
<DICH_DATA CI_END="12.615899430930323" CI_START="0.48919467873222977" EFFECT_SIZE="2.4842767295597485" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.1009182183070467" LOG_CI_START="-0.31051827569502927" LOG_EFFECT_SIZE="0.39519997130600876" MODIFIED="2012-02-28 00:12:44 +1000" MODIFIED_BY="[Empty name]" ORDER="186" O_E="0.0" SE="0.8290847833001451" STUDY_ID="STD-Thalin-1985" TOTAL_1="159" TOTAL_2="158" VAR="0.6873815778998487" WEIGHT="1.260582248829366"/>
<DICH_DATA CI_END="15.38914996645967" CI_START="0.705120886879025" EFFECT_SIZE="3.2941176470588234" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.1872146318476329" LOG_CI_START="-0.1517364205917799" LOG_EFFECT_SIZE="0.5177391056279265" MODIFIED="2012-02-24 05:04:43 +1000" MODIFIED_BY="[Empty name]" ORDER="185" O_E="0.0" SE="0.7865064761175142" STUDY_ID="STD-T_x00e4_htinen-2011" TOTAL_1="85" TOTAL_2="80" VAR="0.6185924369747899" WEIGHT="1.2946974916983902"/>
<DICH_DATA CI_END="2.599257233396786" CI_START="0.1476810581380948" EFFECT_SIZE="0.6195652173913043" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.41484926123118127" LOG_CI_START="-0.830675204577309" LOG_EFFECT_SIZE="-0.20791297167306388" MODIFIED="2012-02-24 05:04:53 +1000" MODIFIED_BY="[Empty name]" ORDER="187" O_E="0.0" SE="0.731627236661448" STUDY_ID="STD-van-Buchem-1981a" TOTAL_1="46" TOTAL_2="38" VAR="0.5352784134248665" WEIGHT="2.7525921462159055"/>
<DICH_DATA CI_END="3.15126083449925" CI_START="0.2636266361412729" EFFECT_SIZE="0.9114583333333334" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.4984843518555137" LOG_CI_START="-0.5790107118900241" LOG_EFFECT_SIZE="-0.04026318001725515" MODIFIED="2012-02-24 05:05:33 +1000" MODIFIED_BY="[Empty name]" ORDER="188" O_E="0.0" SE="0.632925934130715" STUDY_ID="STD-van-Buchem-1981b" TOTAL_1="48" TOTAL_2="35" VAR="0.4005952380952381" WEIGHT="2.9068757290577607"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.6553063535705279" CI_START="0.1695559802002632" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="30" I2="0.0" ID="CMP-001.01.04" LOG_CI_END="-0.18355562128963576" LOG_CI_START="-0.7706868881496891" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2014-12-12 02:15:51 +1000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.0014452596533227119" STUDIES="1" TAU2="0.0" TOTAL_1="139" TOTAL_2="139" WEIGHT="100.0" Z="3.185456228588135">
<NAME>Pain at 10 to 12 days</NAME>
<DICH_DATA CI_END="0.6553063535705279" CI_START="0.1695559802002632" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="30" LOG_CI_END="-0.18355562128963576" LOG_CI_START="-0.7706868881496891" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2014-12-09 02:01:40 +1000" MODIFIED_BY="[Empty name]" ORDER="70" O_E="0.0" SE="0.3448838125002393" STUDY_ID="STD-Hoberman-2011" TOTAL_1="139" TOTAL_2="139" VAR="0.11894484412470023" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.161452620125221" CI_END="1.5874513709069682" CI_START="1.191282796564089" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3751739920982908" ESTIMABLE="YES" EVENTS_1="283" EVENTS_2="208" I2="14.230954637428269" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.20070043023472858" LOG_CI_START="0.07601487013808839" LOG_EFFECT_SIZE="0.13835765018640847" METHOD="MH" MODIFIED="2014-12-17 17:49:27 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.318572972603977" P_Q="1.0" P_Z="1.3628780072384364E-5" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1044" TOTAL_2="1063" WEIGHT="99.99999999999999" Z="4.349758081702026">
<NAME>Vomiting, diarrhoea or rash</NAME>
<GROUP_LABEL_1>Antibiotics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Antibiotics better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo better</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.1325498459377243" CI_START="1.0889347532772238" EFFECT_SIZE="1.523879142300195" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="36" LOG_CI_END="0.32889919109991256" LOG_CI_START="0.03700185850639655" LOG_EFFECT_SIZE="0.18295052480315457" MODIFIED="2012-02-24 05:35:00 +1000" MODIFIED_BY="[Empty name]" ORDER="377" O_E="0.0" SE="0.17146193808053092" STUDY_ID="STD-Burke-1991" TOTAL_1="114" TOTAL_2="118" VAR="0.029399196210331817" WEIGHT="17.102231373227198"/>
<DICH_DATA CI_END="3.4221235759301813" CI_START="0.8970988715256613" EFFECT_SIZE="1.7521367521367521" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="12" LOG_CI_END="0.5342956882487858" LOG_CI_START="-0.047159689629600536" LOG_EFFECT_SIZE="0.24356799930959266" MODIFIED="2012-02-24 05:35:28 +1000" MODIFIED_BY="[Empty name]" ORDER="378" O_E="0.0" SE="0.3415497672163045" STUDY_ID="STD-Damoiseaux-2000" TOTAL_1="117" TOTAL_2="123" VAR="0.11665624348551178" WEIGHT="5.6557379190409245"/>
<DICH_DATA CI_END="1.9989951570126636" CI_START="0.9657953317656909" EFFECT_SIZE="1.3894675925925926" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="36" LOG_CI_END="0.3008117419494206" LOG_CI_START="-0.01511489812111496" LOG_EFFECT_SIZE="0.14284842191415284" MODIFIED="2012-02-24 05:35:44 +1000" MODIFIED_BY="[Empty name]" ORDER="206" O_E="0.0" SE="0.18557687223952254" STUDY_ID="STD-Hoberman-2011" TOTAL_1="144" TOTAL_2="147" VAR="0.03443877551020407" WEIGHT="17.222865669402974"/>
<DICH_DATA CI_END="1.3560185110806857" CI_START="0.6438168457724942" EFFECT_SIZE="0.9343594386600271" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="47" LOG_CI_END="0.1322656181485397" LOG_CI_START="-0.19123766398106207" LOG_EFFECT_SIZE="-0.0294860229162612" MODIFIED="2012-02-24 05:35:57 +1000" MODIFIED_BY="[Empty name]" ORDER="379" O_E="0.0" SE="0.19002742929000116" STUDY_ID="STD-Le-Saux-2005" TOTAL_1="235" TOTAL_2="240" VAR="0.03611042388256639" WEIGHT="22.480476946759158"/>
<DICH_DATA CI_END="30.144354386030557" CI_START="0.34147033457608006" EFFECT_SIZE="3.2083333333333335" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4792059868383949" LOG_CI_START="-0.46664701991664315" LOG_EFFECT_SIZE="0.5062794834608759" ORDER="380" O_E="0.0" SE="1.1430036882956378" STUDY_ID="STD-Mygind-1981" TOTAL_1="72" TOTAL_2="77" VAR="1.3064574314574315" WEIGHT="0.467175047520159"/>
<DICH_DATA CI_END="19.596404129266862" CI_START="1.0333528471050977" EFFECT_SIZE="4.5" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="1.2921763871682903" LOG_CI_START="0.014248640382397135" LOG_EFFECT_SIZE="0.6532125137753437" MODIFIED="2014-12-02 02:21:22 +1000" MODIFIED_BY="[Empty name]" ORDER="74" O_E="0.0" SE="0.7506610843064022" STUDY_ID="STD-Tapiainen-2014" TOTAL_1="42" TOTAL_2="42" VAR="0.5634920634920635" WEIGHT="0.9667928066736623"/>
<DICH_DATA CI_END="15.748430101857245" CI_START="0.06270218254508299" EFFECT_SIZE="0.9937106918238994" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.19723726719976" LOG_CI_START="-1.2027173419318176" LOG_EFFECT_SIZE="-0.002740037366028859" ORDER="381" O_E="0.0" SE="1.4097452173708016" STUDY_ID="STD-Thalin-1985" TOTAL_1="159" TOTAL_2="158" VAR="1.9873815778998487" WEIGHT="0.48492131312653725"/>
<DICH_DATA CI_END="1.7285149125124026" CI_START="1.1527155957979782" EFFECT_SIZE="1.4115544967242406" ESTIMABLE="YES" EVENTS_1="105" EVENTS_2="73" LOG_CI_END="0.23767313070741636" LOG_CI_START="0.06172216903669386" LOG_EFFECT_SIZE="0.14969764987205508" MODIFIED="2012-02-24 05:38:17 +1000" MODIFIED_BY="[Empty name]" ORDER="207" O_E="0.0" SE="0.10335446585668949" STUDY_ID="STD-T_x00e4_htinen-2011" TOTAL_1="161" TOTAL_2="158" VAR="0.010682145612521593" WEIGHT="35.61979892424938"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="21.66909684751096" CI_END="0.9175671332824851" CI_START="0.7924788654248848" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8527324086340731" ESTIMABLE="YES" EVENTS_1="737" EVENTS_2="859" I2="44.62159597861417" I2_Q="8.282276566331412" ID="CMP-001.03" LOG_CI_END="-0.037362151002268404" LOG_CI_START="-0.10101231113133519" LOG_EFFECT_SIZE="-0.0691872310668018" METHOD="MH" MODIFIED="2014-12-17 17:49:27 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.04140023426766071" P_Q="0.33611527887531334" P_Z="2.0357677187652452E-5" Q="2.1806036228607715" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1959" TOTAL_2="1941" WEIGHT="300.0" Z="4.2609313411312675">
<NAME>Abnormal tympanometry</NAME>
<GROUP_LABEL_1>Antibiotics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Antibiotics better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo better</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="10.009946981092657" CI_END="0.8971918946588213" CI_START="0.7408921677177642" DF="6" EFFECT_SIZE="0.8153051255159519" ESTIMABLE="YES" EVENTS_1="419" EVENTS_2="514" I2="40.05962258008826" ID="CMP-001.03.01" LOG_CI_END="-0.04711465854075102" LOG_CI_START="-0.1302449963026687" LOG_EFFECT_SIZE="-0.08867982742170985" MODIFIED="2014-12-02 01:54:34 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.1242338374713785" P_Z="2.8945393019093146E-5" STUDIES="7" TAU2="0.0" TOTAL_1="1070" TOTAL_2="1068" WEIGHT="100.00000000000001" Z="4.181608605983592">
<NAME>2 to 4 weeks</NAME>
<DICH_DATA CI_END="1.1273656463576387" CI_START="0.48727984778362066" EFFECT_SIZE="0.7411764705882353" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="25" LOG_CI_END="0.05206479665001353" LOG_CI_START="-0.3122215491714355" LOG_EFFECT_SIZE="-0.130078376260711" MODIFIED="2014-12-02 01:51:12 +1000" MODIFIED_BY="[Empty name]" ORDER="62" O_E="0.0" SE="0.2139836027820134" STUDY_ID="STD-Appelman-1991" TOTAL_1="51" TOTAL_2="45" VAR="0.045788982259570496" WEIGHT="5.169164911883915"/>
<DICH_DATA CI_END="1.4644257534049974" CI_START="0.732508342699153" EFFECT_SIZE="1.0357142857142858" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="41" LOG_CI_END="0.16566735778347194" LOG_CI_START="-0.1351874246699982" LOG_EFFECT_SIZE="0.015239966556736905" MODIFIED="2014-12-02 01:51:12 +1000" MODIFIED_BY="[Empty name]" ORDER="63" O_E="0.0" SE="0.17672358846835987" STUDY_ID="STD-Burke-1991" TOTAL_1="112" TOTAL_2="116" VAR="0.031231226721134212" WEIGHT="7.838779863899587"/>
<DICH_DATA CI_END="0.8529514763874081" CI_START="0.659694089925637" EFFECT_SIZE="0.7501246882793018" ESTIMABLE="YES" EVENTS_1="188" EVENTS_2="255" LOG_CI_END="-0.06907567473705638" LOG_CI_START="-0.1806574066640989" LOG_EFFECT_SIZE="-0.12486654070057765" MODIFIED="2014-12-02 01:51:32 +1000" MODIFIED_BY="[Empty name]" ORDER="64" O_E="0.0" SE="0.0655436616724258" STUDY_ID="STD-Kaleida-1991" TOTAL_1="401" TOTAL_2="408" VAR="0.0042959715854294185" WEIGHT="49.19460381900697"/>
<DICH_DATA CI_END="1.1016037627621373" CI_START="0.6426952220007988" EFFECT_SIZE="0.8414246697508501" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="77" LOG_CI_END="0.04202541067664692" LOG_CI_START="-0.19199492875989865" LOG_EFFECT_SIZE="-0.07498475904162587" MODIFIED="2014-12-02 01:51:22 +1000" MODIFIED_BY="[Empty name]" ORDER="65" O_E="0.0" SE="0.13746470580438977" STUDY_ID="STD-Le-Saux-2005" TOTAL_1="233" TOTAL_2="222" VAR="0.01889654534188743" WEIGHT="15.346759435767282"/>
<DICH_DATA CI_END="1.5684025713050485" CI_START="0.6172122919140082" EFFECT_SIZE="0.9838888888888889" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="25" LOG_CI_END="0.19545754562936682" LOG_CI_START="-0.20956543345582934" LOG_EFFECT_SIZE="-0.007053943913231304" MODIFIED="2014-12-02 01:51:22 +1000" MODIFIED_BY="[Empty name]" ORDER="66" O_E="0.0" SE="0.23791250281072523" STUDY_ID="STD-Mygind-1981" TOTAL_1="72" TOTAL_2="77" VAR="0.05660235899366334" WEIGHT="4.70183811961332"/>
<DICH_DATA CI_END="0.8328240575302264" CI_START="0.3001834514019506" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="26" LOG_CI_END="-0.07944673798633" LOG_CI_START="-0.5226132533416324" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2014-12-02 01:54:34 +1000" MODIFIED_BY="[Empty name]" ORDER="71" O_E="0.0" SE="0.2603182048293353" STUDY_ID="STD-Tapiainen-2014" TOTAL_1="42" TOTAL_2="42" VAR="0.06776556776556777" WEIGHT="5.059700243161667"/>
<DICH_DATA CI_END="1.294011205064642" CI_START="0.7631007638730644" EFFECT_SIZE="0.9937106918238994" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="65" LOG_CI_END="0.11193803697926137" LOG_CI_START="-0.11741811171131905" LOG_EFFECT_SIZE="-0.002740037366028859" MODIFIED="2014-12-02 01:51:22 +1000" MODIFIED_BY="[Empty name]" ORDER="67" O_E="0.0" SE="0.13472493707209335" STUDY_ID="STD-Thalin-1985" TOTAL_1="159" TOTAL_2="158" VAR="0.01815080866907951" WEIGHT="12.689153606667274"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.812600135674427" CI_END="1.0022282382916492" CI_START="0.7810748606395908" DF="2" EFFECT_SIZE="0.8847684903706238" ESTIMABLE="YES" EVENTS_1="222" EVENTS_2="249" I2="58.4424231472178" ID="CMP-001.03.02" LOG_CI_END="9.666350473195158E-4" LOG_CI_START="-0.1073073399964107" LOG_EFFECT_SIZE="-0.05317035247454556" MODIFIED="2014-12-02 01:55:23 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.09014826312368085" P_Z="0.05423334485155984" STUDIES="3" TAU2="0.0" TOTAL_1="478" TOTAL_2="475" WEIGHT="100.00000000000001" Z="1.9249681348323975">
<NAME>6 to 8 weeks</NAME>
<DICH_DATA CI_END="1.1756768402810904" CI_START="0.7958389326362578" EFFECT_SIZE="0.9672897196261683" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="70" LOG_CI_END="0.07028796309255783" LOG_CI_START="-0.09917481887710398" LOG_EFFECT_SIZE="-0.01444342789227306" MODIFIED="2014-12-02 01:53:17 +1000" MODIFIED_BY="[Empty name]" ORDER="68" O_E="0.0" SE="0.09954327698327899" STUDY_ID="STD-Damoiseaux-2000" TOTAL_1="107" TOTAL_2="105" VAR="0.009908863992569801" WEIGHT="28.273469065535053"/>
<DICH_DATA CI_END="1.0426465703017915" CI_START="0.7610255854934014" EFFECT_SIZE="0.8907753457671624" ESTIMABLE="YES" EVENTS_1="151" EVENTS_2="169" LOG_CI_END="0.018137118992493928" LOG_CI_START="-0.1186007421100926" LOG_EFFECT_SIZE="-0.05023181155879933" MODIFIED="2014-12-02 01:53:17 +1000" MODIFIED_BY="[Empty name]" ORDER="69" O_E="0.0" SE="0.08032049647498807" STUDY_ID="STD-Kaleida-1991" TOTAL_1="329" TOTAL_2="328" VAR="0.006451382153988571" WEIGHT="67.72521221490993"/>
<DICH_DATA CI_END="0.8583469349203022" CI_START="0.04660120328118142" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="10" LOG_CI_END="-0.06633713934552508" LOG_CI_START="-1.3316028693265125" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2014-12-02 01:55:23 +1000" MODIFIED_BY="[Empty name]" ORDER="70" O_E="0.0" SE="0.7432233529572064" STUDY_ID="STD-Tapiainen-2014" TOTAL_1="42" TOTAL_2="42" VAR="0.5523809523809523" WEIGHT="4.0013187195550275"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.558382099198743" CI_END="1.2407579386370566" CI_START="0.7553225804639614" DF="2" EFFECT_SIZE="0.9680766952790916" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="96" I2="43.79468128365559" ID="CMP-001.03.03" LOG_CI_END="0.09368706258806976" LOG_CI_START="-0.12186753182036003" LOG_EFFECT_SIZE="-0.014090234616145128" MODIFIED="2014-12-15 21:06:00 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.1687746778670144" P_Z="0.7977691222436324" STUDIES="3" TAU2="0.0" TOTAL_1="411" TOTAL_2="398" WEIGHT="99.99999999999997" Z="0.256235339888297">
<NAME>3 months</NAME>
<DICH_DATA CI_END="1.0602556913480348" CI_START="0.39257802992926005" EFFECT_SIZE="0.6451612903225806" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="31" LOG_CI_END="0.025410612387971796" LOG_CI_START="-0.40607400872855487" LOG_EFFECT_SIZE="-0.1903316981702915" MODIFIED="2012-02-24 05:23:14 +1000" MODIFIED_BY="[Empty name]" ORDER="372" O_E="0.0" SE="0.25345620232716937" STUDY_ID="STD-Burke-1991" TOTAL_1="111" TOTAL_2="111" VAR="0.064240046498111" WEIGHT="31.851230504302247"/>
<DICH_DATA CI_END="1.5903438101375877" CI_START="0.8123405709108877" EFFECT_SIZE="1.1366181410974243" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="47" LOG_CI_END="0.20149102287675377" LOG_CI_START="-0.09026185615538321" LOG_EFFECT_SIZE="0.05561458336068526" ORDER="373" O_E="0.0" SE="0.17137708534352022" STUDY_ID="STD-Le-Saux-2005" TOTAL_1="228" TOTAL_2="210" VAR="0.02937010538084021" WEIGHT="50.27511947033479"/>
<DICH_DATA CI_END="1.8888828703489002" CI_START="0.6054962103297747" EFFECT_SIZE="1.0694444444444444" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="18" LOG_CI_END="0.2762050281503706" LOG_CI_START="-0.21788857066794382" LOG_EFFECT_SIZE="0.0291582287412134" ORDER="374" O_E="0.0" SE="0.2902330257486374" STUDY_ID="STD-Mygind-1981" TOTAL_1="72" TOTAL_2="77" VAR="0.08423520923520922" WEIGHT="17.87365002536294"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.594163057919654" CI_END="0.7635272843239266" CI_START="0.1835488785301846" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.37435888765308367" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="26" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-0.11717543900100592" LOG_CI_START="-0.7362482646584437" LOG_EFFECT_SIZE="-0.4267118518297248" METHOD="MH" MODIFIED="2014-12-17 17:49:22 +1000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.45851380157544297" P_Q="1.0" P_Z="0.006894219876409064" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="EFFECT_SIZE" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="533" TOTAL_2="542" WEIGHT="100.0" Z="2.7019110731422704">
<NAME>Tympanic membrane perforation</NAME>
<GROUP_LABEL_1>Antibiotics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Antibiotics better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo better</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-02 02:13:40 +1000" MODIFIED_BY="[Empty name]" ORDER="73" O_E="0.0" SE="0.0" STUDY_ID="STD-Tapiainen-2014" TOTAL_1="42" TOTAL_2="42" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.1704154465314736" CI_START="0.018170779592953035" EFFECT_SIZE="0.14583333333333334" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.06834004474671163" LOG_CI_START="-1.7406264394693722" LOG_EFFECT_SIZE="-0.8361431973613304" MODIFIED="2012-02-24 05:28:25 +1000" MODIFIED_BY="[Empty name]" ORDER="204" O_E="0.0" SE="1.0625958673570413" STUDY_ID="STD-Hoberman-2011" TOTAL_1="144" TOTAL_2="147" VAR="1.129109977324263" WEIGHT="26.615385296700495"/>
<DICH_DATA CI_END="1.661195883156519" CI_START="0.02319004369915685" EFFECT_SIZE="0.19627329192546583" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.22042084615285254" LOG_CI_START="-1.6346984329797443" LOG_EFFECT_SIZE="-0.7071387934134459" MODIFIED="2012-02-24 05:28:45 +1000" MODIFIED_BY="[Empty name]" ORDER="205" O_E="0.0" SE="1.0897062475510204" STUDY_ID="STD-T_x00e4_htinen-2011" TOTAL_1="161" TOTAL_2="158" VAR="1.1874597059517258" WEIGHT="19.389669735155042"/>
<DICH_DATA CI_END="4.264311964377157" CI_START="0.010044059217092251" EFFECT_SIZE="0.20695652173913043" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6298489688730212" LOG_CI_START="-1.9980907354672208" LOG_EFFECT_SIZE="-0.6841208832970997" ORDER="375" O_E="0.0" SE="1.543664790840793" STUDY_ID="STD-Burke-1991" TOTAL_1="114" TOTAL_2="118" VAR="2.382900986481549" WEIGHT="9.440330655547099"/>
<DICH_DATA CI_END="1.4965494266728119" CI_START="0.26005127087441865" EFFECT_SIZE="0.6238425925925926" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="0.17509106489607776" LOG_CI_START="-0.5849410194803871" LOG_EFFECT_SIZE="-0.20492497729215461" ORDER="376" O_E="0.0" SE="0.44644660858222934" STUDY_ID="STD-Mygind-1981" TOTAL_1="72" TOTAL_2="77" VAR="0.19931457431457428" WEIGHT="44.55461431259737"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.790714926180728" CI_END="0.9467471512127451" CI_START="0.24954553241266655" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4860622613509094" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="85" I2="65.87308284716043" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="-0.02376599300876941" LOG_CI_START="-0.6028502008565415" LOG_EFFECT_SIZE="-0.3133080969326555" METHOD="MH" MODIFIED="2014-12-17 17:49:20 +1000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.03220692780188861" P_Q="1.0" P_Z="0.033935237194021556" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.2758160812342478" TOTALS="YES" TOTAL_1="453" TOTAL_2="453" WEIGHT="100.0" Z="2.1208403811772207">
<NAME>Contralateral otitis (in unilateral cases)</NAME>
<GROUP_LABEL_1>Antibiotics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Antibiotics better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo better</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3847739609990364" CI_START="0.6041397612613693" EFFECT_SIZE="0.9146567717996289" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="33" LOG_CI_END="0.14137888856118902" LOG_CI_START="-0.2188625803802064" LOG_EFFECT_SIZE="-0.03874184590950871" MODIFIED="2012-02-24 05:40:29 +1000" MODIFIED_BY="[Empty name]" ORDER="382" O_E="0.0" SE="0.2116076220802064" STUDY_ID="STD-Burke-1991" TOTAL_1="98" TOTAL_2="102" VAR="0.04477778572243945" WEIGHT="36.09137575319007"/>
<DICH_DATA CI_END="0.8147398177049494" CI_START="0.23753859815253092" EFFECT_SIZE="0.43992289569500964" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="29" LOG_CI_END="-0.08898105846906108" LOG_CI_START="-0.6242658108700319" LOG_EFFECT_SIZE="-0.3566234346695464" MODIFIED="2012-02-24 05:40:40 +1000" MODIFIED_BY="[Empty name]" ORDER="208" O_E="0.0" SE="0.3144289132625884" STUDY_ID="STD-Hoberman-2011" TOTAL_1="161" TOTAL_2="158" VAR="0.09886554149549234" WEIGHT="30.88134836238823"/>
<DICH_DATA CI_END="1.564679540132893" CI_START="0.06881026616853161" EFFECT_SIZE="0.328125" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.194425403733588" LOG_CI_START="-1.1623467622335237" LOG_EFFECT_SIZE="-0.4839606792499679" MODIFIED="2012-02-28 00:36:12 +1000" MODIFIED_BY="[Empty name]" ORDER="383" O_E="0.0" SE="0.7969746864196194" STUDY_ID="STD-Mygind-1981" TOTAL_1="64" TOTAL_2="63" VAR="0.6351686507936507" WEIGHT="12.701281711654063"/>
<DICH_DATA CI_END="0.6803101723212099" CI_START="0.08137952959075856" EFFECT_SIZE="0.23529411764705882" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="17" LOG_CI_END="-0.1672930352132661" LOG_CI_START="-1.089484824887357" LOG_EFFECT_SIZE="-0.6283889300503115" ORDER="384" O_E="0.0" SE="0.5417000221775419" STUDY_ID="STD-Thalin-1985" TOTAL_1="130" TOTAL_2="130" VAR="0.2934389140271494" WEIGHT="20.32599417276763"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.5998273571082087" CI_END="1.0951078043457625" CI_START="0.782993186588879" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9259924132427" ESTIMABLE="YES" EVENTS_1="208" EVENTS_2="213" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.039456873996182765" LOG_CI_START="-0.10624201704771066" LOG_EFFECT_SIZE="-0.03339257152576392" METHOD="MH" MODIFIED="2014-12-17 17:49:17 +1000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.6083393865284547" P_Q="1.0" P_Z="0.36897018336164245" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1138" TOTAL_2="1062" WEIGHT="100.00000000000001" Z="0.8984040588470641">
<NAME>Late AOM recurrences</NAME>
<GROUP_LABEL_1>Antibiotics</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Antibioitics better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo better</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6316299810780124" CI_START="0.45300289523635134" EFFECT_SIZE="0.8597285067873304" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="13" LOG_CI_END="0.2126216768467701" LOG_CI_START="-0.3438990223113335" LOG_EFFECT_SIZE="-0.0656386727322817" MODIFIED="2012-02-24 05:44:48 +1000" MODIFIED_BY="[Empty name]" ORDER="209" O_E="0.0" SE="0.32690301350736006" STUDY_ID="STD-Hoberman-2011" TOTAL_1="119" TOTAL_2="70" VAR="0.10686558024019324" WEIGHT="7.511141767231531"/>
<DICH_DATA CI_END="1.2501414006766656" CI_START="0.8187745871407714" EFFECT_SIZE="1.011723286875726" ESTIMABLE="YES" EVENTS_1="125" EVENTS_2="123" LOG_CI_END="0.09695913785648466" LOG_CI_START="-0.08683564529117188" LOG_EFFECT_SIZE="0.0050617462826563885" MODIFIED="2012-02-24 05:45:13 +1000" MODIFIED_BY="[Empty name]" ORDER="385" O_E="0.0" SE="0.1079619654197831" STUDY_ID="STD-Kaleida-1991" TOTAL_1="448" TOTAL_2="446" VAR="0.011655785977302442" WEIGHT="56.56177842439395"/>
<DICH_DATA CI_END="1.040657046213588" CI_START="0.41707228311486055" EFFECT_SIZE="0.6588089330024814" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="39" LOG_CI_END="0.017307629148634523" LOG_CI_START="-0.3797886705958776" LOG_EFFECT_SIZE="-0.18124052072362154" ORDER="387" O_E="0.0" SE="0.23325633212831184" STUDY_ID="STD-Le-Saux-2005" TOTAL_1="248" TOTAL_2="236" VAR="0.05440851647795332" WEIGHT="18.33784830094154"/>
<DICH_DATA CI_END="1.6453717840627267" CI_START="0.5690114746761468" EFFECT_SIZE="0.9675925925925926" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="21" LOG_CI_END="0.21626404546140626" LOG_CI_START="-0.24487897554116017" LOG_EFFECT_SIZE="-0.01430746503987691" ORDER="388" O_E="0.0" SE="0.2708776932316763" STUDY_ID="STD-Mygind-1981" TOTAL_1="72" TOTAL_2="77" VAR="0.07337472469051415" WEIGHT="9.312000106455102"/>
<DICH_DATA CI_END="3.346396130533874" CI_START="0.48778845222169603" EFFECT_SIZE="1.2776280323450135" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.5245773493944845" LOG_CI_START="-0.3117684852764061" LOG_EFFECT_SIZE="0.10640443205903921" ORDER="389" O_E="0.0" SE="0.49127368326433146" STUDY_ID="STD-Thalin-1985" TOTAL_1="159" TOTAL_2="158" VAR="0.2413498318681027" WEIGHT="3.2219096057078485"/>
<DICH_DATA CI_END="1.7120439454810088" CI_START="0.31442493718679776" EFFECT_SIZE="0.7336956521739131" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.23351490814192882" LOG_CI_START="-0.5024830171709895" LOG_EFFECT_SIZE="-0.13448405451453033" MODIFIED="2012-02-24 05:45:51 +1000" MODIFIED_BY="[Empty name]" ORDER="390" O_E="0.0" SE="0.4323288245772961" STUDY_ID="STD-van-Buchem-1981a" TOTAL_1="92" TOTAL_2="75" VAR="0.18690821256038648" WEIGHT="5.055321795270036"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2014-12-17 17:49:42 +1000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Immediate antibiotics versus expectant observation</NAME>
<DICH_OUTCOME CHI2="9.856965368587955" CI_END="1.0435885952858655" CI_START="0.74197636147456" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8799534469541861" ESTIMABLE="YES" EVENTS_1="216" EVENTS_2="254" I2="59.419559160194005" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.018529324326726344" LOG_CI_START="-0.12960993063025866" LOG_EFFECT_SIZE="-0.055540303151766175" METHOD="MH" MODIFIED="2014-12-15 21:05:15 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.04290731815875326" P_Q="0.38880497810405845" P_Z="0.14165450094576704" Q="0.7426761830606035" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.03347118937542024" TOTALS="SUB" TOTAL_1="601" TOTAL_2="605" WEIGHT="200.0" Z="1.4696576393543603">
<NAME>Pain</NAME>
<GROUP_LABEL_1>Antibiotics</GROUP_LABEL_1>
<GROUP_LABEL_2>Expectant observation</GROUP_LABEL_2>
<GRAPH_LABEL_1>Immediate ab better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Expectant obs better</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="10.282305733189466" CI_END="1.1235826747144753" CI_START="0.4980433874679091" DF="3" EFFECT_SIZE="0.7480594370870881" ESTIMABLE="YES" EVENTS_1="141" EVENTS_2="171" I2="70.82366467360983" ID="CMP-002.01.01" LOG_CI_END="0.05060503389914581" LOG_CI_START="-0.302732821663749" LOG_EFFECT_SIZE="-0.12606389388230158" MODIFIED="2014-12-14 21:02:46 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.01631280914864086" P_Z="0.1619473527747108" STUDIES="4" TAU2="0.10438044173902838" TOTAL_1="478" TOTAL_2="481" WEIGHT="100.0" Z="1.3985520536234166">
<NAME>Pain at 3 to 7 days</NAME>
<DICH_DATA CI_END="0.9880634473421149" CI_START="0.41686008359384047" EFFECT_SIZE="0.641782059000602" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="44" LOG_CI_END="-0.005215166803209583" LOG_CI_START="-0.38000968871847246" LOG_EFFECT_SIZE="-0.19261242776084103" MODIFIED="2014-12-04 07:08:45 +1000" MODIFIED_BY="[Empty name]" ORDER="68" O_E="0.0" SE="0.2201561574358302" STUDY_ID="STD-Little-2001" TOTAL_1="151" TOTAL_2="164" VAR="0.04846873365691005" WEIGHT="28.183338823488473"/>
<DICH_DATA CI_END="0.932165079235086" CI_START="0.39501561957065146" EFFECT_SIZE="0.6068111455108359" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="38" LOG_CI_END="-0.03050717063704703" LOG_CI_START="-0.4033857313122066" LOG_EFFECT_SIZE="-0.21694645097462684" MODIFIED="2014-12-04 07:08:45 +1000" MODIFIED_BY="[Empty name]" ORDER="69" O_E="0.0" SE="0.21903071231923243" STUDY_ID="STD-McCormick-2005" TOTAL_1="102" TOTAL_2="98" VAR="0.04797445293907036" WEIGHT="28.274773240309973"/>
<DICH_DATA CI_END="2.5164592850730187" CI_START="0.0888409003208368" EFFECT_SIZE="0.47282608695652173" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4007899081441803" LOG_CI_START="-1.0513870489260162" LOG_EFFECT_SIZE="-0.325298570390918" MODIFIED="2014-12-04 07:08:45 +1000" MODIFIED_BY="[Empty name]" ORDER="70" O_E="0.0" SE="0.8530159329749037" STUDY_ID="STD-Neumark-2007" TOTAL_1="92" TOTAL_2="87" VAR="0.7276361819090454" WEIGHT="5.177540900789337"/>
<DICH_DATA CI_END="1.2370266420528462" CI_START="0.872986824384753" EFFECT_SIZE="1.039186200796108" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="85" LOG_CI_END="0.09237905320384895" LOG_CI_START="-0.058992310865080715" LOG_EFFECT_SIZE="0.016693371169384123" MODIFIED="2014-12-04 07:08:45 +1000" MODIFIED_BY="[Empty name]" ORDER="71" O_E="0.0" SE="0.08891628855442595" STUDY_ID="STD-Spiro-2006" TOTAL_1="133" TOTAL_2="132" VAR="0.007906106370293937" WEIGHT="38.364347035412216"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0992237619642176" CI_START="0.7549416422035974" DF="0" EFFECT_SIZE="0.910960916838084" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="83" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="0.04108610797820946" LOG_CI_START="-0.12208661850128293" LOG_EFFECT_SIZE="-0.04050025526153674" MODIFIED="2014-12-12 02:16:06 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.33058066577988365" STUDIES="1" TAU2="0.0" TOTAL_1="123" TOTAL_2="124" WEIGHT="100.0" Z="0.9729449692962903">
<NAME>Pain at 11 to 14 days</NAME>
<DICH_DATA CI_END="1.0992237619642176" CI_START="0.7549416422035974" EFFECT_SIZE="0.910960916838084" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="83" LOG_CI_END="0.04108610797820946" LOG_CI_START="-0.12208661850128293" LOG_EFFECT_SIZE="-0.04050025526153674" MODIFIED="2014-12-04 07:11:09 +1000" MODIFIED_BY="[Empty name]" ORDER="72" O_E="0.0" SE="0.0958484672520766" STUDY_ID="STD-Spiro-2006" TOTAL_1="123" TOTAL_2="124" VAR="0.009186928674572402" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.21492639139140074" CI_END="2.3554129950357816" CI_START="1.2384901907230264" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.707968351420295" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="47" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.37206706676838497" LOG_CI_START="0.0928925711707602" LOG_EFFECT_SIZE="0.23247981896957262" METHOD="MH" MODIFIED="2014-12-17 17:49:42 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6429332630108799" P_Q="1.0" P_Z="0.0010974206741986633" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="EFFECT_SIZE" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="268" TOTAL_2="282" WEIGHT="100.0" Z="3.2642815120868853">
<NAME>Vomiting, diarrhoea or rash</NAME>
<GROUP_LABEL_1>Antibiotics</GROUP_LABEL_1>
<GROUP_LABEL_2>Expectant observation</GROUP_LABEL_2>
<GRAPH_LABEL_1>Immediate ab better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Expectant obs better</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.567003074587193" CI_START="0.954919184106435" EFFECT_SIZE="1.5656565656565657" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="22" LOG_CI_END="0.4094263888410781" LOG_CI_START="-0.020033381695594897" LOG_EFFECT_SIZE="0.1946965035727416" MODIFIED="2012-11-13 19:13:29 +1000" MODIFIED_BY="Roderick P. Venekamp" ORDER="63" O_E="0.0" SE="0.25226679507339134" STUDY_ID="STD-Little-2001" TOTAL_1="135" TOTAL_2="150" VAR="0.06363853589660041" WEIGHT="45.37161139694755"/>
<DICH_DATA CI_END="2.788541648960298" CI_START="1.1959226496870166" EFFECT_SIZE="1.8261654135338345" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="25" LOG_CI_END="0.4453771353897299" LOG_CI_START="0.0777030911068713" LOG_EFFECT_SIZE="0.2615401132483005" MODIFIED="2012-11-13 19:13:29 +1000" MODIFIED_BY="Roderick P. Venekamp" ORDER="62" O_E="0.0" SE="0.2159735536276232" STUDY_ID="STD-Spiro-2006" TOTAL_1="133" TOTAL_2="132" VAR="0.04664457586654383" WEIGHT="54.62838860305244"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3502532145047514" CI_START="0.784044797263536" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0289115646258504" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="49" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.13041521986547985" LOG_CI_START="-0.10565912271281894" LOG_EFFECT_SIZE="0.012378048576330434" METHOD="MH" MODIFIED="2014-12-17 17:49:42 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.8371557481605024" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="108" TOTAL_2="99" WEIGHT="100.0" Z="0.20553296172326269">
<NAME>Abnormal tympanometry at 4 weeks</NAME>
<GROUP_LABEL_1>Antibiotics</GROUP_LABEL_1>
<GROUP_LABEL_2>Expectant observation</GROUP_LABEL_2>
<GRAPH_LABEL_1>Immediate ab better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Expectant obs better</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3502532145047514" CI_START="0.784044797263536" EFFECT_SIZE="1.0289115646258504" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="49" LOG_CI_END="0.13041521986547985" LOG_CI_START="-0.10565912271281894" LOG_EFFECT_SIZE="0.012378048576330434" MODIFIED="2014-12-13 21:05:15 +1000" MODIFIED_BY="[Empty name]" ORDER="69" O_E="0.0" SE="0.1386712374173352" STUDY_ID="STD-McCormick-2005" TOTAL_1="108" TOTAL_2="99" VAR="0.019229712086854943" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-12-17 17:49:40 +1000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="92" TOTAL_2="87" WEIGHT="0.0" Z="0.0">
<NAME>Tympanic membrane perforation</NAME>
<GROUP_LABEL_1>Antibiotics</GROUP_LABEL_1>
<GROUP_LABEL_2>Expectant observation</GROUP_LABEL_2>
<GRAPH_LABEL_1>Immediate ab better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Expectant obs better</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-05-24 02:19:02 +1000" MODIFIED_BY="Roderick P. Venekamp" ORDER="62" O_E="0.0" SE="0.0" STUDY_ID="STD-Neumark-2007" TOTAL_1="92" TOTAL_2="87" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.685764708534082" CI_START="0.7417410726885736" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4114326040931546" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="0.42906796281473475" LOG_CI_START="-0.12974767198169307" LOG_EFFECT_SIZE="0.1496601454165208" METHOD="MH" MODIFIED="2014-12-17 17:49:38 +1000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.2937999387376322" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="109" TOTAL_2="100" WEIGHT="100.0" Z="1.049822076092289">
<NAME>AOM recurrences</NAME>
<GROUP_LABEL_1>Antibiotics</GROUP_LABEL_1>
<GROUP_LABEL_2>Expectant observation</GROUP_LABEL_2>
<GRAPH_LABEL_1>Immediate ab better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Expectant obs better</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.685764708534082" CI_START="0.7417410726885736" EFFECT_SIZE="1.4114326040931546" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="13" LOG_CI_END="0.42906796281473475" LOG_CI_START="-0.12974767198169307" LOG_EFFECT_SIZE="0.1496601454165208" MODIFIED="2012-05-24 01:30:53 +1000" MODIFIED_BY="Roderick P. Venekamp" ORDER="59" O_E="0.0" SE="0.32825107006142634" STUDY_ID="STD-McCormick-2005" TOTAL_1="109" TOTAL_2="100" VAR="0.10774876499647142" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2015-06-19 18:50:32 +1000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2015-06-19 18:50:32 +1000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAARkAAAOPCAIAAABw0iI3AAAoWUlEQVR42u3dv44kRdbG4ZKQEEYb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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2015-06-19 18:50:32 +1000" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAADOCAMAAADYBvzeAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD/gADAwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID///8AAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///9BjlLGAAAWPUlEQVR42u1da2wc13U+pDiv3SW5MyRh0aoFUWTbH/pTuLBqyaIS
L62mapLaCRDAcJzEyQ/GLyQIWiC1CxgJClhSGqEwXKO26kKVa7UuZBhV0lSKJW1gr5QHXajoDwVB
wlfkiCtD5Awpcjm7O8tl72Oey11yudxdDuXz8TEzd86558zsN/femb1nDgAC0TC0gIonAdEgGK14
DhCNA9ILgfRCIL0QCKQXAumFQHohEEgvxKahDU9BfWHgKfA9qUd63an9web5UcDOEYFjLwTSC4FA
eiGQXgik15aB3nRFRIPolSAQI+myuzbr2HZUsK3G1vCwgmKivPSyhjRqeOuVTCZvCv2hOrZ9xKty
bZP529oUnSMt2S6Y2No1o3PUJgoAPYookcs5EZdFshiJSPQRrhUVoxYtlMSTpiykmLgpSHKK7hNi
FpWU1QRvGsifHpGiOlOQTLJPplXaZcBqjRMhK8Zr7Twsmm49iU7Z9iHBfmg5l3LsnjG7wBQlhdkW
qQ64dVnykKcYkSKeD8yuwmoC6FZEmRxXShTlbhAW+5FHzRh77RYA5qP5aIasF6diZJGQ00tko+ts
XuyihelLT/dO3R5i0h2x3IWHyL5Ri+5L/HjK1wjsnMudV5nCbCfAg8qk6ZUB3Cemi7RWIy/RWuH0
pQ63Htg2BQvR/GyGtDKsnek6y8vBsfuty8z2u9T2LPeL1UXX4sr/LTqKqpSTd7o+MLs3Rrl0Rs9H
FgGGYvkLCwCX88ijRtOLjr0KswDZadAfINuTGl0URrUZspG7F8ayZDmjDe4b15QDTEOyUntyZF8v
6GRh7dF8XyYUBBhUWC1UuDDWa3plAMo4r1VgmjChDQ669cCoBuY0KA84VT1q255w7C7tIbbz3LZd
A1szctTSdNb1YQxGC64PFIbWy6VNhR2kkOveQ8T3FJBHFVCvSKFEEkztNmm9ZnYXivuSdJv+iXm2
oFtk1S5kf4RQ8S+e6rjFukNy/QuWK0kXvNDZSjpDat5QDJ9whcTzZVRmdi8tcR9sZSnns0t9orbb
p306Pm3wKfqcBl9Net9SYX8SZnZaLZO93B8HBn7nWFAbcTIU6S/J/8dh+raPvTrQsc0VvczNvpA5
GpknHyq5KSAf+EEuaT8WuMILbVxhyl7ZG1yWap53hS57Ko/DLe/m8DKxvey3O6hz2wv+Km3tFp+b
1OnBgMcW6F+xby3F92mPmrmpPE4cPoXNVBM4Pvs6GS1fumB2eUXZfuim/eAA9Mul4nJK+wEZmMk9
oEYBPlCY5BVTp9wnbdlJxZVsG0grrMzklZi7oYsMoGQLLka86ng9FJemzZzLSrnU9s+vkUKT2ZbS
jg6pSyV1/by/R2aMpD4oMPCLgMedoLzFVoq/Gn2IH8EPySFfw2knTWlC5w7pMHew11fnB3m5hY65
cmJ+plS6/ZDIejJTzBLyTHZLVHK2c/u/0Jv/TvEprxGcXewjH3gyLqrzvM3NSdTGTFw4HnWF7HqY
H+3Mh7btUM62SEZS7Rq3/fuODqnrflLXT8zbhGTiXewBRJdoBh9CzMk9vKbI15iB2CFpaA7ggIg8
avDYq14DuKofgphmrVb0L77ZVU+vrb84reHYq/zYaxso4aHX1FJ1cn/1P9uW3vunWq0cm8n8tJ5e
d6a/69vKtoSm4dgsFBXfycB3TNQVOBnaNxnawFFpo04tAnBCDgLphUB6IRBIL0QzgUN7vHNs4O0N
0gv7g3q7j2G0CLzWEEgvBALphUB6IZBejYa++VVjYNnWpZeWoDO1EhXDa3dsLPB2Nd0X+MJ8aQ2d
F9YVRhszkUbhoVd+pHvV/avHsG4Iv+Rtk7pvbbl1hNFeV7G1Cw29dMsouB+HziNVLYXGwaYVUb7o
xLDqEVHR3WhcYOG5pheP26mIKUfPLutRJImLJlRp2DRlwfRF2lL5BG94rkp7QZNExWTxuBHujB4V
6VpakUwv/la043JFHn8LPRHmk2vLFAUlBZqIYbSV0PTZqt+JLcl/I0DfBP19RVpo/34eOsXZzgL8
8mpr+xuFib4k3XO0PdNB9vTd+PDVDJvD2spkVCETVXLQl75+OFG09VQD2r/xUyjG5hdal1jFN373
dFv8+p//xxJ8+wLEyD4uT6smeOe/T0Ixkuk4NAr//pNXbx9vYfYWIfmHLfD9WKRlyXaB2IowWx9S
WwR9H14/8QKTtm1FI4vzZwpw8ZTlHV9oZqvWiDq475ut2vTW64QIohsWaI3CKPlo8uNCFuCcAsZ+
Z488xvbY0bgEjzGZ3BiMe5GzXI/Gwr7M4nedcNcZbXrfuDZItl4WwHjZled4bA9Am26OniP294LC
o4gUHqP79fFbOUcuaAvY2i0ubdv6u4Jp0jBaC5upimRt7vRK/QvLAFfS2opIVbJr1xMn9idXi2GF
kuJAeK3VXTiYS/pCcSuF49IwWv33lpY7b5WE0aastcNoeYFta+STBUgeYLG1Lgz8zrExYbRVQflZ
Mpncds3eopGqLU5A4o7WN+ddOXsP+AuAx8SuKOMRsJ0w/YMV5i4HwnG95w7aYjp22x9GS9csJ8LR
1l0R+9vt+GTb2rt4MzqEzzFCNLSnUaogX7W3vncNBgQAYbdFiovCKJ2/kRqhe2gMq+BX5DLyAOyW
S8t4NG0hEL/r9LGWG1tLCcN6MZF0goc1dhcgjIBmd3c8blfstyRH7hsBW+yJBvwBfwOFbUvRtCnS
GCs47SQs9CqMkn+j37Yv+C99SspeB/hNLnYBILrw1/Qzl9gA6noX2+OBy0zkhq2ZkrKZuPBZQqG5
N3rfWWFuJj6c9QK5BfZqgP+8C+ADU8jMEisPSo/ZkbmdEo3bNcxnZh25IznBCsb+jiomn85l23rX
FONE9K6zyKOQjL1CAL03tbee9VmxdBjDaEMx9vo4xjlquUw9q3vpu/7BF9Lr406vhgInQ2MYbTNO
LQJwQg4C6YVAeiEQSC9EM4FDe7xzbODtDdLrDuoPNs904L1/y9g5InDshUB6IRBILwTSC4H0+lgA
Z6AivRoA7TCLUIO7KwTkVgilRSC9qkB68fm8rnYD7F9dLomnCum1fmxXBkFRsjyOVpVo/lov5y2T
sGQ7I20qIspxllNX6cYTh/SqBvIY+TeW5wlpl9I0f22bkT/HstyeZhKvT53nESN/+uM87Ua/Gcu9
+3k8cRWAs1WDQyvW6/GcoIm3NbqgQYy04G02oT5xdK8XmUkXMTi3xzfVflMnQ4flSyE1DCcjjGBx
js5dI2fNA4lEYtndgr1OnPxIZ4yGqRmQ6MXOETvHqpCjbyPpDwRYlkTi9jjsO9gi0hg2YeEjmtcW
gfRaGzfNFKTM3wBccd8bIVvwvhcqCRm4JvEugEf92nltEWURqnyOm4/j89PXTxsvEda0LfVNAH0b
zkIcpqYX6RpF35v/+m/GNrrVufeZf7w2AWpr66nkSa+GzXxDzuaZDiQrB8zn2DDg0B6H9ogmAWer
1hvFj6VppFdzgGMNvHNEIL0QSC8EAumFwKH9HQEMo8Uw2ju0PwhJV4TZaBE49kIgvRAIpBcC6YVA
elUNvU4yiDuDXolEQqBBVSsyxSZWjRvVpOWy5f5I1ErqO1b3bgPRqraqFi2zz6zgcXVVljr1koY0
qqr1SiY/kvm88RVhoqvEjWZmy8+S3O/TqqS+r8GHpy9+WKa0M7qReZ2lx7JvEdvgKjtHzfiy217F
5WGW63VYcwokyaR5YuWL/ALmuWQTD3yaaZjD0RmAnmdFmqc1ER+2c7qy/K5M3WSZX1Ms5ywkLsp2
flhTFJ/l2V57npW4rm1Het9uLt7nOWujw1GeoJbo/BnVmYmK1Cavy9WLOhlmCa6KGjEsRiy3nKgn
DvwRzXbLt4YhoQ5LWmqYJrbtVqRhlclQRyz231dfWonwbLS2HM9pu1e8ijyqcux18Yy7ujz1pU6A
58SjTt6mYnqWFOwSp87z7Z1yTtrJI04J5KPCEYD5t/JR2gC2HLXLj0gd9ncEclomay++m1eIHJyf
mhtiup3R/B8fYgLzb+WYLrejymkngd5n0hLR7Jo9Ie2iLk8RnfNUp0/MC25drt5s7pVdzjE8/BGl
7U2pzStvmaJWd76SJ75TPwmBjs5mP310juguvJvbRxPCFKeiZBF/qWMxUN/xG5GdbMWWy0Ty+ucB
PnoEeVQNvcjg60VvVDLB87mOac7XaJMaTcGaH9eO8G1rFMa8RKyGNs5zwuo0pdmYMyB5bfwWT1IH
BW1UBjg3CAa18bxm544Vv5N6mEs4utyOMqo9b9cxo40RzUcF0B8lW6MaCFyH5ot92avL1hPgq27g
mGUyz8Ykr5x7Zj3Mfadbhqbcz3Wzg/BVXhPNgVv4AnXdV98RbZofry3XpmvmOTKUw2y0leAP5aCh
x90LWV8yVvJHc7cGCgSrTGpYd8PqseycsD4tNxUs0dV3Df/Dfr+AFbdaJnvZR+7mky1vh6xeYfHT
YKn5lvbpMrlpS/PK0hBrukbDrL3ylalm7T+rp1AIOGeP5FNW8HhtOX1HETpu8fy27lWG3zmuko12
+sslBU+U5mRt1cG+WoMZY8nGE2TUvFySE9bL70oEiLUdLX/7fkBAyNz8UR8fcQd0PTtkSTVpwlg7
q7CwcPNHpBsd0Ms82bDzynJ8hUdd66XlK7PdMnQs35oAv0xQL8388OQ0Mx35HD5dWQfh46dLz/hu
2BUokHbDc5f5h3zWH9C8C652BHLC2rlf+3skR+AsWSuK5n0+8lk0DlXiMQiFi/58stIZeM5efQ76
TZYwVrXjWW2dDqU0Xyy4eWU5Tg8AnR/SL5WUl/juYGnaPO5ttZ2luXN9egNwzfTLHTa1llOkWEQe
VTf2EqzZEoEj1vC2QMFkTnqdX/fXnxFzXsbYbcIjZKw0d9DNCctzuirZz9lVviM9O0lzzm73PSci
Mu2qOHSJbcx9wp9PdvJb8uv26j9LeTL+K8TF7BgvaFclqnOkpzRfLLh5ZTnO0skhmkilAuXU92C2
W4ZL7b2ve1uzT81HAnoR5VOGX+55TchEiWMC8qiKsVfV0Exz5TPHtd6olqj5lWu1a4J+97yQaPC7
3kYOToUkG234xl7rp9fy10+13l55vQ6fWENPytXqbu2a5K7uxDf9A+9GIHbL/x4FpBdmo20gcDI0
ZqNtxqlFAE7IQSC9EEgvBALphWgmcGiPd44NvL1Bem3p/iCUnQ+G0SJw7IVAeiEQSC8E0guB9Go2
9Jp2rVdF9+/C6af1QpNnTFQ998oTlLMVhRRz3bUFVVR3QjQpjyw6smSjnKNeGrQAlrv8dDTwwURh
K6VNWCUvbA1BuAEVPVvwld/P15JsY5XLoHRXwcTWLjz0t6NdR3ikaoTHtr4mDmkpVp4whyIj/MOP
SFGdRdqOREW7zJGn9bCfnsMii/XlGWPjkngyxWJq7RyywPbRlD89Co3vpSrdsiTx66tfELxyVl9c
suslFkZsW9xfihHFzkTbrYhDpIqUKMrdICz2I4/C07ryaNcHlUmT5hPOyTQydfjmf+U+w8rhrjMS
j/XYOZc7r7JI2/s+zM88xHszW95uRpJg/iwTB+g6mxe7WNWXnv7s1KUhUmLkJR4X0iXefIIsFqL5
2QxTWbiQm82wXXnRV87Cft9O2/VS/tq2uL8U992Y5nVm9Pz/Eu+HYvkLC4S5eeRReOjFI1YLY70m
/Q+jtJH5QFP+ZIIHw/KYWWAREoN8mrGsgcI/QkfehTUu5ACy98JYlukO7htn0b85AXQ+hzrH44DN
aVAeYAXZQbAjeAu/9pdT3OubNe/YmnQCfmm8La/TVEAnnbaQS+0hZn9dQB5VQJMT7vVNQN+TbPGJ
J+n2wSfh2LYl6HsenPK+63CstUjXDvb19f12icmStcmiX57nwnOrIf+PtS1RXbd6onKd5elqexGO
kYKZ19ra7mEqVtex9+5h4YytR8BX7vnGfx1bvAx41W3MuP6q0EqUbv79yeO/O878ddHchHstYeRU
0Uu4t2lDeztGVQd9MLjDAp1Hvl1x08C2uJGsnjwfi9lRuuS/Hnynki+HrM5k74HpGN/uKHbYgWWt
ur+8jIclvlnOI4sdINJY4K7MTeVxcGJrESG6s20bSBOSCwoM/CK4owv6eViqwONXL1twcQQ0fkXY
8pc1/SHOKnG3JZHecwD6g/G0MtHiMbfSVaCyhWkzxzmzNPOwHa3bds1fnnJvADlnv7fCt05QeEhw
8VejdHyopLQfktuIazjtJHT0ml3sIx9isks0S270W6X8JB+5d4pPvccibY1PSiZvcGz5WKaXtnDi
djCysYukh8uJ+WA87UxcOM7fHDfziERl59p76bEK22kMrH3U4gF/ubTdURbZ2r4uMRv0bU7u4a5F
v9ZL7z2jh6ShOYADGKVdufMOWWhLo4NeA8+97r7RtfFaZnZsXhht2B+rho5eG4mZXTe0/MLGK4kJ
/hmqSC8/vUI3bGgmu+rz5WIJQ5uaErYI4QaOSusMDKMNfeuKQHohEEgvBNILgfRCIJBeCKQXAumF
QCC9wgVjk/XDVQHSC4GtFwLphUCUAF88HrKx150AfPF4E85tjfTc6OUeggqwc0Tg2AuB9EIgcGiP
2Iz7HBzaN+LeUWULtfphsqvDlutS9YbTam22veG4WrUHfJfndSWjSK+6s4ufZPZbNbucD0a1t6pX
Ddyw1mLbUzegWg+MkiOtaBTHXiF6mFH7IwFDrdt1UVdr2Ho1uCGrpV+tQdUofeC2fttq1R6oVR8w
0qtRDZJBf42q75ycvpEs16sKrmaNtlfUU5MH5XSQXo3s8OyRyTr7yBpU1Q3b3qgH5XVw7BWOvtHY
YNe28X5Z3fhobqUO0itETKz96/B6fZFe7y/k8bFq/anif0pQ3en1PXVar2rQ6AYqUNfjfLnnXmV0
DKQXooFXGnaOiAYC6YVAeiGQXggE0guB9ELcEfB9KYQxLog6QS1DL3wChqgPDOwcETj2QiC9EAik
FwLphbiz0Lb6yH/r3VOi76GnV2mbVtzCR7SlEhGXJJddxs4RgUB6IUJOL6PKvSvkDMMr3aQvnoyy
xo0tcTyu75VcCvOpr1cg2lqvI9hqY9UQHo+6BU/9+jtHw7CvJPfKMNiPvcd/xXFJo+RKssU86aY2
Y45x/9E4CyPUx8NtQcD/sJ/6dbde5d5EYKjBPf5t560WboBl8MUXTeeX6v2udMbzNZzHQ+0EjIf9
1NfYOaqG/VPS7qor2uQVbbO6qe21Wta2GlyG63iMkjO/0sHwnvo6vgRA9b2kau3TpRqhGImtMu4N
y/FUEWEb2lPfVt/zQK+eNV5NYPheUrb5/FIDPm3Z4wmrq7U+91LZe1TUWp5c+G4Kmnb2jRUdh7HG
U4uwHo+xkYdGTT/1bes8MLVyy+rt4bwLSqqGu5PvaWrnWGLN7wxds30K/fGU9TPMp973EgDv6i6N
3S5upa+FS79z3Eq+l37nqK71MCukx6FW+DAQ4f7cYIvNokB6bSVsuQk65elV3MIfQWEL+758p10P
bXfERYK+hxQ4IQeB9EIgvRAIpBcC6YVAeiEQq8P/YALfwIRoHL3w/UsI7BwRSC8EAumFQHohkF4I
BNILgfRCIBCItfH/5QN4zPUFoaoAAAAASUVORK5CYII=
</FILE>
</FIGURE>
<FIGURE FILENAME="Cochrane_L'Abbe plot at 24 hours.JPG" FILE_TYPE="JPG" ID="FIG-03" MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>L'Abbé plot of the rates of pain at 24 hours for the placebo (control) versus antibiotic (experimental) group.</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Cochrane_L'Abbe plot at 2-3 days.JPG" FILE_TYPE="JPG" ID="FIG-04" MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]" NO="4" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>L'Abbé plot of the rates of pain at two to three days for the placebo (control) versus antibiotic (experimental) group.</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2014-12-15 20:59:56 +1000" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-001.01" SETTINGS="SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;SHOW_CI_LINES:YES;DISTINGUISH_SUBGROUPS:YES;SHOW_STUDY_NAMES:NO;SHOW_EFFECT_ESTIMATE:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 1 Antibiotic versus placebo, outcome: 1.1 Pain.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGsCAMAAAA2Uyl8AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.jpg" FILE_TYPE="JPG" ID="FIG-06" MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]" NO="6" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Percentage with pain based on the subset of six studies included in the IPD meta-analysis (<LINK REF="REF-Rovers-2006" TYPE="REFERENCE">Rovers 2006</LINK>).</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2015-06-19 19:38:54 +1000" MODIFIED_BY="[Empty name]">
<FEEDBACK_ITEM ID="FBK-01" MODIFIED="2012-07-03 10:03:27 +1000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE>Antibiotics for AOM</TITLE>
<DATE_SUBMITTED>
<DATE DAY="22" MONTH="11" YEAR="2000"/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2012-06-07 09:47:44 +1000" MODIFIED_BY="[Empty name]">
<P>1. Types of interventions includes surgical procedures versus placebo which are not dealt with in this review and should therefore be deleted.</P>
<P>2. The authors included only six studies in the analysis but in 1994 another meta-analysis by Rosenfeld and colleagues to which the authors refer was published which included 33 randomized trials with 5400 children. Were any studies with a no-treatment control excluded and if so why?</P>
<P>3. The meta-analysis by Rosenfeld is only mentioned in the text; there is no reference to it. How many patients were included in the meta-analysis?</P>
<P>4. It is stated that trials analysed on an intention to treat basis were preferred. This indicates that other trials were excluded which does not seem reasonable?</P>
<P>5. The description of the factorial trial is unclear; I suppose the authors excluded all patients who were randomised to myringotomy?</P>
<P>6. In the trial by Laxdal the control group was more closely monitored. The trial therefore violates the principle that all other Traitement etc. should be the same in the two randomised groups and it should therefore be excluded.</P>
<P>7. The strategy described by Dickersin lacks a publication year and it is not cited in the references.</P>
<P>8. The search was done in August 1994 and the Cochrane review was published in April 1997. The search should therefore have been updated before publication since Cochrane reviews are meant to be up-to-date.</P>
<P>9. There is no information whether the original authors and the pharmaceutical industry were contacted about additional data including unpublished trials and trials not registered in Medline. Useful trial data might be expected to be available in books published in connection with symposia arranged by the drug industry for example.</P>
<P>10. What is quality methodology?</P>
<P>11. The term blinded randomisation should be avoided since it may be confused with blinded treatments; the term concealed allocation should be used.</P>
<P>12. The elaborated quality assessment scale for the trials does not appear under Results and should therefore be deleted.</P>
<P>13. The authors refer to Rosenfeld's meta-analysis when they state that 80% of the children have recovered spontaneously after 24 hours. Since such a percentage refers to untreated patients it raises the question why the authors did not use their own data? If these data are used in a meta-analysis of the risk difference the NNTB will be 23 not 12 as stated in the Cochrane review.</P>
<P>14. For several of the excluded studies the authors gave no reason for the exclusion.</P>
<P>15. There should be a cross-reference to the authors' nearly identical review in the BMJ (24 May 1997).</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2012-06-07 12:29:50 +1000" MODIFIED_BY="[Empty name]">
<P>The changes made were:</P>
<P>1. We updated the search. (see Johansen criticism 7 &amp; 8). No recent trials were found but we recognised that the Appelman trial qualifies (originally we had thought this was only prevention of recurrent otitis, rather than treatment of acute otitis in children with a recurrent episode).</P>
<P>2. We have corrected and updated the Relative Risk Reduction and consequent Number-Needed-to-Treat (see Johansen criticism 13).</P>
<P>3. We have separate the four arms of the Van Buchem factorial trial, and treated this as "two" trials (i.e., two separate strata): (a) without myringotomy - antibiotics versus placebo (b) with myringotomy - antibiotics versus placebo. (see Johansen criticism 5)</P>
<P>4. As suggested by Andrew Herxheimer, we have added several references including (a) Chris Cates BMJ, and (b) Kozrskyj's meta-analysis of short versus long duration of antibiotics (rather than just the de Saintonge paper).</P>
<P>5. We have made small text changes in response to Johansen's criticisms 5 (description added), 7 (dropped), 10 (- methodological quality), 11 (- allocation concealment), 13 (corrected in text), 14 (exclusions explained), and 15 (reference added).</P>
<P>6. As we have pointed out to Johansen in the BMJ correspondence, and point out in the discussion here, the Rosenfeld meta-analysis is largely concerned with comparison between antibiotics. (see Johansen criticism 2 &amp; 3).</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2012-07-03 10:03:09 +1000" MODIFIED_BY="[Empty name]">
<P>Helle Krogh Johansen<BR/>Peter C. Gøtzsche<BR/>
</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
<FEEDBACK_ITEM ID="FBK-02" MODIFIED="2012-06-19 14:36:19 +1000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE>Antibiotic versus placebo for acute otitis media</TITLE>
<DATE_SUBMITTED>
<DATE DAY="22" MONTH="11" YEAR="2010"/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2008-11-09 15:26:47 +1000" MODIFIED_BY="[Empty name]">
<P>This excellent and important review was completed in 1996, and I hope it will soon be updated. It is especially worth noting and<BR/>discussing the new study by Christopher Cates (BMJ 13 March 1999, p715-6), who has successfully tried a method in his general<BR/>practice of substantially reducing the use of antibiotic in children with acute otitis media. This would considerably strengthen the<BR/>'implications for practice' in the conclusion.</P>
<P>I would like to suggest that in updating this review the objectives be amended and the trial by Chaput de Saintonge et al be added,<BR/>because it contributes an important piece of evidence about the duration of amoxicillin therapy. The review concludes that some<BR/>children will benefit from antibiotic treatment, and it would be valuable to say (as a result of the Chaput trial) that the evidence<BR/>indicates that a 3-day course is no less effective than a 10-day course.</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY>
<P>Chris and I have revised the acute otitis media review. We have made a number of modest changes, though none of these change<BR/>the conclusions. However, because a new trial is included we've called it a "substantive update".</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2012-06-19 14:36:19 +1000" MODIFIED_BY="[Empty name]">
<P>Andrew Herxheimer</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
<FEEDBACK_ITEM ID="FBK-03" MODIFIED="2012-07-03 10:03:52 +1000" MODIFIED_BY="Liz Dooley" NO="3">
<TITLE MODIFIED="2012-07-03 10:03:52 +1000" MODIFIED_BY="[Empty name]">Antibiotic versus placebo for acute otitis media</TITLE>
<DATE_SUBMITTED>
<DATE DAY="22" MONTH="11" YEAR="2000"/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2012-06-07 12:29:56 +1000" MODIFIED_BY="Liz Dooley">
<P>1. I am glad to see this has been updated but the text does not explain what was updated, forcing the reader who wants to know to<BR/>compare the previous version with the new one. Is it the sentence referring to Cates 99 [in implics for practice] or other points as<BR/>well?</P>
<P>2. There are embarrassingly many typos in the refs to excluded and additional studies: Chaput de SaintoNGE, amoxyciillin, author<BR/>not in bold in the first few additional refs, below that several authors' names begin in lower case when they should all begin with a<BR/>capital.</P>
<P>3. It is implied that no comcrit was received before the final submission date for CL99 issue 3. Is this true? I think I sent one early<BR/>this year.</P>
<P>CONFLICT OF INTEREST: None.</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY>
<P>Excluded and additional references have been corrected and completed.</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2012-06-19 14:37:21 +1000" MODIFIED_BY="[Empty name]">
<P>Andrew Herxheimer<BR/>
</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
<FEEDBACK_ITEM ID="FBK-04" MODIFIED="2012-06-19 14:37:48 +1000" MODIFIED_BY="Liz Dooley" NO="4">
<TITLE>Antibiotic versus placebo for acute otitis media</TITLE>
<DATE_SUBMITTED>
<DATE DAY="22" MONTH="6" YEAR="2000"/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2012-06-07 09:47:45 +1000" MODIFIED_BY="Liz Dooley">
<P>1. The new study also reported diarrhoea and rashes. Shouldn't it be included in this outcome (side effects) also?<BR/>2. I think the methods used for calculating the NNTB should be made explicit.<BR/>3. The new trial is important because it looks at a sub-group who were believed to be a greater risk of poor outcomes. In EBM OM Rosenfeld and Bluestone review the study inclusion criteria and state that the meta-analysis 'most likely can be applied to children 2 years of age or older with non severe AOM, and most likely cannot be applied to infants with severe symptoms'. This study provides the best evidence that the conclusions of the meta-analysis do appear to apply to this group. Perhaps this point needs to be emphasised (the peak incidence of AOM is 9 months).<BR/>4. I think the comment that 80% resolve spontaneously within 2 to 7 days is now slightly misleading as about 70% of the control children were clinical failures in this new study.<BR/>5. The entry in the table 'characteristics of included studies' should be consistent with previous entries.<BR/>6. Some typographical errors and inconsistent spelling.</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2012-06-07 09:47:45 +1000" MODIFIED_BY="Liz Dooley">
<P>Thank you for your comments and suggestions.<BR/>The Absolute risk difference was used to calculate the NNTB in this systematic review. This has now been stated in the Results section of the review. A comment regarding the application of the conclusions to infants with severe symptoms has been added to the discussion section. The 70% incidence of clinical failure in the Damoiseaux, 2000 study have been included and typographical errors and inconsistencies have been corrected.</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2012-06-19 14:37:48 +1000" MODIFIED_BY="[Empty name]">
<P>Peter Morris<BR/>
</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
<FEEDBACK_ITEM ID="FBK-05" MODIFIED="2012-06-19 14:38:27 +1000" MODIFIED_BY="[Empty name]" NO="5">
<TITLE>Antibiotics for acute otitis media</TITLE>
<DATE_SUBMITTED>
<DATE DAY="19" MONTH="2" YEAR="2002"/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY>
<P>The second graph (comparison of outcome Abnormal Tympanometry) has wrong labels on the X-axis.</P>
<P>It says 'antibiotics better' (left) and 'placebo worse' (right). The second should probably be 'placebo better'.</P>
<P>The other graphs are correctly labelled.</P>
<P>I certify that I have no affiliations with or involvement in any organisation or entity with a direct financial interest in the subject matter of my<BR/>criticisms.</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY>
<P>The label on the x-axis has been corrected and now reads 'Placebo better'.</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2012-06-19 14:38:27 +1000" MODIFIED_BY="[Empty name]">
<P>Johannes C van der Wouden<BR/>
</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
<FEEDBACK_ITEM ID="FBK-06" MODIFIED="2012-06-19 14:39:20 +1000" MODIFIED_BY="[Empty name]" NO="6">
<TITLE>Antibiotics reduce the risk of mastoiditis?</TITLE>
<DATE_SUBMITTED>
<DATE DAY="26" MONTH="8" YEAR="2002"/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY>
<P>I agree with other commentators that this is a very good and important review. However, I would like some more clarity concerning one statement in your conclusions: Antibiotic treatment may play an important role in reducing the risk of mastoiditis in populations where it is more common.</P>
<P>What is the basis for this statement? In the included studies with more than 2000 children only one mastoiditis case occurred in a patient in a penicillin treated group. In the review you mention two articles concerning the mastoiditis. Firstly, the study of Rudberg (1954), which was excluded since it was not properly randomised. Even if it were, the rate of 17 % of mastoiditis cases is in these times highly unlikely, as is shown in the included studies. The second article by Berman (1995) is a literature review, where only the available literature concerning developing countries were reviewed. The goal of this review was to determine the extent to which otitis media impacts mortality and morbidity in developing countries, not to study the effect of antibiotics on (acute) otitis media or mastoiditis. </P>
<P>In neither of these studies evidence is shown that antibiotic treatment reduces the risk of mastoiditis, certainly not in developed countries. Since I think the rest of the review is excellent, I wonder if you could explain to me the reasons for including this statement in the conclusions.</P>
<P>I certify that I have no affiliations with or involvement in any organisation or entity with a direct financial interest in the subject matter of my criticisms.</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2008-11-09 15:27:00 +1000" MODIFIED_BY="[Empty name]">
<P>Dear Markus,</P>
<P>We included the caveat about mastoiditis because we, and the reviewers, were concerned about misinterpretation of the results in situations with high rates of mastoiditis. We were mindful that "an absence of evidence is not equal to evidence of absence". Since the trials we analysed did not include high rates of mastoiditis, we can use them as the sole basis. Given that we have two weaker pieces of evidence:</P>
<P>1. The trials do show a modest reduction in other infective complications</P>
<P>2. The excluded Rudberg trial did show dramatic effects that we don't think explicable from the potential biases of that study.</P>
<P>Prudence would then suggest that antibiotics are advisable if there is a substantial risk of mastoiditis,</P>
<P>Regards,</P>
<P>Paul Glasziou</P>
<P>I certify that I have no affiliations with or involvement in any organisation or entity with a direct financial interest in the subject matter of my criticisms.</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2012-06-19 14:39:20 +1000" MODIFIED_BY="[Empty name]">
<P>Markus Oei (ENT surgeon)<BR/>
</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
<FEEDBACK_ITEM ID="FBK-07" MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]" NO="7">
<TITLE MODIFIED="2012-06-07 09:47:58 +1000" MODIFIED_BY="Liz Dooley">Incorrect NNTB</TITLE>
<DATE_SUBMITTED>
<DATE DAY="19" MONTH="6" YEAR="2005"/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2012-06-07 09:48:06 +1000" MODIFIED_BY="Liz Dooley">
<P>I am a bit troubled by the way the conclusions of this review are written. By combining results of treatment at Days 2 to 7 in arriving at a NNTB of 15 one is going to underestimate treatment benefit after 2 days. In your abstract though you say the ARR is 7% and NNTB 15 for some pain after two days. This is simply not correct. If one carefully looks at trials that record pain at the end of day 2 the ARR is in fact 20% giving a NNTB of 5. Clearly acute otitis media is an acute condition and the main benefit of antibiotics is pain control and symptom relief. If this is measured at the end of 2 days the benefits are greater than one would surmise just from reading the review. It would be absurd to do a review of pain relief for biliary colic treated with pethidine and measuring the outcome 7 days later. For acute conditions symptom control in the first few days should be the outcome of interest. NNTB are meaningless unless giving a time period at which they apply. I think the review needs correcting. This is not just of academic interest but of direct relevance to parents and doctors faced with a child with AOM in pain. Unfortunately your review gets quoted uncritically and invariably the NNTB of 15 is given for symptom control after 2 days. I am currently trying to correct a brochure produced here in New Zealand for GPs to give to parents of children with AOM and it uncritically repeats this misleading information. If you want to comment on symptom control after Day 2 DO NOT pool it with data from Day 7 or later!</P>
<P>I certify that I have no affiliations with or involvement in any organisation or entity with a direct financial interest in the subject matter of my criticisms.</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<P>Thank you for your comment. We agree that we should be clearer about the time frame to which the ARR 7% and NNTB 15 applies. With the availability of results of the individual patient data meta-analysis (Rovers 2006) we are able to obtain a clearer indication of the recovery pattern over time. We have reported this in the text and included an extra figure.</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2012-06-19 14:39:47 +1000" MODIFIED_BY="[Empty name]">
<P>Paul Corwin</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
<FEEDBACK_ITEM ID="FBK-08" MODIFIED="2015-06-19 19:38:54 +1000" MODIFIED_BY="[Empty name]" NO="8">
<TITLE>Comment on two of the meta-analyses</TITLE>
<DATE_SUBMITTED>
<DATE DAY="9" MONTH="6" YEAR="2007"/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2012-06-07 12:28:48 +1000" MODIFIED_BY="[Empty name]">
<P>Summary<BR/>Feedback: This is a comment on two of the meta-analyses in the Cochrane Review, Glasziou et al. (2004). These analyses are for the outcomes "Vomiting, Diarrhea or Rash" and "Contralateral AOM."</P>
<P>1) Vomiting, Diarrhea or Rash</P>
<P>First we consider the meta-analysis relating possible adverse effects of treatment. In Glasziou et al. (2004), this is done using the composite outcome "Vomiting, Diarrhea or Rash." The data used for this meta-analysis are reproduced in the table below.</P>
<P>Outcome: Vomiting, Diarrhea or Rash<BR/>Study Treatment Control<BR/>Thalin et al. (1985) 1/159 1/158<BR/>Burke et al. (1991) 53/114 36/116<BR/>Mygind et al. (1981) 3/72 1/77<BR/>Damoiseaux et al. (2000) 20 12</P>
<P>We noted five major problems with this meta-analysis. The first relates to clinical heterogeneity. This was manifested in variations in terms of the types of adverse effects recorded, who recorded them (parent or physician) and the time period over which they were recorded (from 3-4 days to 21 days). In Thalin et al. (1985), the effects were recorded by an ENT physician on days 3-4 or days 8-10. In Burke et al. (1991), they were recorded by a parent in a 21-day diary. In Mygind et al. (1981), it was done with 7 day parental score card. And in Damoiseaux et al. (2000), this was done by a physician on day 4 and day 11.</P>
<P>Another related problem is the use of the outcome "Vomiting, Diarrhea or Rash" as an entity. Vomiting is only reported in Burke et al. (1991). It is not clear whether it was not observed, or observed but not reported in the other studies. Also, in Burkeat al. (1991), as noted, such effects were recorded over a 21-day period while the maximum recording period for the other studies was 11 days. The totals then gave a much higher weight to Burke et al. (1991) than may be appropriate.</P>
<P>A third problem is possible double or triple counting with the use of the composite outcome. For Burke et al. (1991), the group numerator is the sum of the cases for each effect. A number of children may well have had two or three of these effects at the same time.</P>
<P>A fourth problem is also with the numbers used. Damoiseaux et al. (2000) gives two sets of numbers for "de novo diarrhoea," for day 4 and for day 11. Glasziou et al. (2004) uses the day 4 numbers only. The reason for this choice is not clear. It may be better to use the sums of the numbers for the two days (provided this does not involve double counting.)</P>
<P>Further, the group denominators used for Burke et al. (1991) are perhaps not what they should be. In this study, the adverse effects were recorded by parents. Only 220 (treatment = 107, control = 113) out of a total of 232 (treatment = 114, control = 118) diaries were collected. Using the total group size in the numerator (also done in Burke at al. (1991)) is thus not appropriate.</P>
<P>Finally, it is not clear if the numbers for adverse effects in Burke et al. (1991) and Damoiseaux et al. (2000) included the cases known or suspected to have dropped out of the study due to an adverse effect.</P>
<P>In our view, this meta-analysis should be modified as follows: First, do not use the data on vomiting until it is reported in at least one other study. Second, do not use a composite adverse effect outcome. Instead, perform separate meta-analyses for diarrhoea and rash. Third, for Damoiseaux et al. (2000), use the total numbers for day 4 and day 11, with the above noted qualification in mind. Fourth, for Burke et al. (1991) change the denominators as noted above. Finally, include drop outs due to side effects in the meta-analyses. The table below gives the possible numerators to be used for these meta-analysis.</P>
<P>Separated Data on Side Effects<BR/>Vomiting Diarrhea Rash<BR/>Study T C T C T C<BR/>Thalin et al. (1985) ? ? 0 0 1 1<BR/>Burke et al. (1991)+ 20 14 24 16 16 9<BR/>Mygind et al. (1981) ? ? 2 1 1/2? 0<BR/>Damoiseaux et al. (2000)*,+ ? ? 20 12 0 3<BR/>Damoiseaux et al. (2000)? ? ? 34 22 0 3<BR/>Note: ? Unclear if vomiting not observed or not reported.<BR/>Note: ? = 2 if a dropout was not counted; else = 1.<BR/>* Day 4; ? Day 4 and Day 11; + unclear if dropouts counted.</P>
<P>2) Contralateral AOM</P>
<P>The occurrence of contralateral AOM, as is made clear in Glasziou et al. (2004), is relevant for only the cases with unilateral AOM at the outset. This numbers in the table below are used for the meta-analysis of this outcome in Glasziou et al. (2004).</P>
<P>Outcome: Contralateral AOM<BR/>Study Treatment Control<BR/>Thalin et al. (1985) 4/159 17/158<BR/>Burke et al. (1991) 29/98 33/102<BR/>Mygind et al. (1981) 2/72 6/77<BR/>Overall 35/329 56/337</P>
<P>The first problem is clinical heterogeneity, as noted in the table below. The issues in that respect are similar to those stated for the meta-analysis of adverse effect.</P>
<P>Clinical Heterogeneity: Contralateral AOM<BR/>Study Time Period Evaluator(s)<BR/>Thalin et al. (1985) day 8-10 or day 30 ENT Physician<BR/>Burke et al. (1991) 21 days Parent<BR/>Mygind et al. (1981) 1 week Physician</P>
<P>A further problem with this meta-analysis is the denominators used. Consider this issue for each study.</P>
<P>Thalin et al. (1985): The denominators in Glasziou et al. (2004) include unilateral and bilateral cases. Only 82% of the episodes were unilateral at the start but the breakdown by group is not given in the paper. We obtained adjusted denominators as follows. Treatment: 0.82?159 = 130; Control: 0.82?158 = 130. The bias now remains the same but the precision level is now corrected.</P>
<P>Burke et al. (1991): The denominators represent the total unilateral cases for each group. The study authors used these denominators. Completed 21-day diaries, the source of data on contralateral otitis, were, however, available only for 107 (of 114) in the treatment group and 113 (of 118) in the control group. So either one assumes that only the bilateral cases had missing diaries (which is unlikely) or that the rate of missingness in each group was not affected by laterality. In the latter case, the adjusted denominators are: Treatment: (98?107)/114 = 92; Control: (102?113)/118 = 98. The level of bias remains unknown but the precision level is possibly better.</P>
<P>Mygind et al. (1991): The denominators used include unilateral and bilateral cases. But there were 8 bilateral cases in the placebo group and 14 in the control group. So the appropriate denominators are Treatment: 72 - 8 = 64; Control: 77 - 14 = 65. The bias and precision levels are now corrected.</P>
<P>The appropriately adjusted data for this meta analysis are given below.</P>
<P>Contralateral AOM: Adjusted Data<BR/>Study Treatment Control<BR/>Thalin et al. (1985) 4/130 17/130<BR/>Burke et al. (1991) 29/92 33/98<BR/>Mygind et al. (1981) 2/64 6/65<BR/>Overall 35/286 56/294</P>
<P>References</P>
<P>1. Burke P, Bain J, Robinson D and Dunleavey J (1991) Acute red ear in children: Controlled trial of non-antibiotic treatment in general practice, British Medical Journal, 303, 558?562.</P>
<P>2. Damoiseaux RAMJ, van Balen FAM, Hoes AW, Verheij TJM and de Melker RA (2000) Primary care based randomised, double blind trial of amoxicillin versus placebo for acute otitis media in children aged under 2 years, British Medical Journal, 320: 330?334.</P>
<P>3. Glasziou PP, Del Mar CB, HayemMand Sanders SL (2004) Antibiotics for acute otitis media in children, Cochrane Database of Systematic Reviews, 2004; (1): CD000219. Art. No: CD000219, DOI: 10.1002/14651858.CD000219.pub2 (21pages)</P>
<P>4. Mygind N, Meistrup-Larsen K-I, Thomsen J, Thomsen VF, Josefsson K and Sorenson H (1981) Penicillin in acute otitis media: a double-blind placebo-controlled trial, Clinical Otolaryngology, 6: 5?13.</P>
<P>5. Thalin A, Densert O, Larsson A, Lyden E and Ripa T (1986) Is penicillin necessary in the treatment of acute otitis media? In: Proceedings of the International Conference on Acute and Secretory Otitis Media, Amsterdam, The Netherlands, Kegler Publications, pages 441?446.</P>
<P>Submitter agrees with default conflict of interest statement:<BR/>I certify that I have no affiliations with or involvement in any organization or entity with a financial interest in the subject matter of my feedback.</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2015-06-19 19:38:54 +1000" MODIFIED_BY="[Empty name]">
<P>1) We acknowledge the variation in methods of collecting and recording information on adverse events and in the types of adverse events reported in the included trials. We contend however, that considering vomiting, diarrhoea or rash as an entity is justified by the easier interpretation it provides. Though the events are biologically very different, they are of similar seriousness; irritating and difficult to manage but minor in nature. Also, as pointed out in the above comments, dividing the adverse events into each type would not be helpful as they are infrequently reported (i.e. vomiting is only reported in one study). We recognise that 'lumping' the adverse events together is a crude approach but believe the benefits in continuing to do so outweigh the drawbacks. In the discussion section of this update we have made reference to the results of the individual patient data meta analysis (Rovers 2006) (which included a subset [n = 6 ] of the trials included in this review [n = 10]) which reports separately on the frequency of diarrhoea and rash in the treatment and control groups. We appreciate your consideration and suggestions related to the inclusion of drop outs due to side effects in the Burke and Damoiseaux studies. Corrections to the data have been incorporated.<BR/>2) Thank you for pointing out the numerical errors in the meta analysis of contralateral AOM. We have corrected the analysis as suggested. This results in a minor changed to the pooled random effects OR (OR 0.44 95% CI 0.16, 1.26 versus 0.45 95% CI 0.16, 1.23) with antibiotics appearing to reduce contralateral AOM though the effect was not significant with the random effects model.</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2012-06-19 14:40:24 +1000" MODIFIED_BY="[Empty name]">
<P>Karim F. Hirji, D.Sc<BR/>Peter C. Gøtzsche<BR/>
</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
<FEEDBACK_ITEM ID="FBK-09" MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]" NO="9">
<TITLE MODIFIED="2012-06-19 14:33:14 +1000" MODIFIED_BY="[Empty name]">Antibiotics for acute otitis media in children</TITLE>
<DATE_SUBMITTED>
<DATE DAY="8" MONTH="3" YEAR="2011"/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<P>The title and conclusion of the review need revising as it is just reviewing the effect of penicillin family antibiotic on the AOM and not other antibiotics. It is suggesting to changed the title to "Usage of penicillin family Antibiotics for acute otitis media in children". </P>
<P>Warm regards.</P>
<P>PS: The only included trials were too old and they just used the publish data:</P>
<P>Halsted 1968 ampicillin 100 mg/kg/day or phenethicillin 30 mg/kg/day plus sulphisoxazole 150 mg/kg/day<BR/>Howie 1973 one of erythromycin, ampicillin, or triple sulphonamide plus erythromycin </P>
<P>Submitter agrees with default conflict of interest statement: I certify that I have no affiliations with or involvement in any organization or entity with a financial interest in the subject matter of my feedback.</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2012-06-19 14:41:26 +1000" MODIFIED_BY="[Empty name]">
<P>The title is our intention. However, as you point out, it just so happens that most (but not all) antibiotics trialled against placebo for acute otitis media were from the penicillin group. Moreover more trials might be undertaken using non-penicillin antibiotics. So it is appropriate to retain the original title.</P>
<P>Chris Del Mar, 19 June, 2012</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2012-06-19 14:35:03 +1000" MODIFIED_BY="[Empty name]">
<P>Amirkambiz Hamedanizadeh, Medical Doctor</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2011-01-25 11:58:15 +1000" MODIFIED_BY="[Empty name]">Previous search</TITLE>
<APPENDIX_BODY MODIFIED="2015-06-19 18:50:27 +1000" MODIFIED_BY="[Empty name]">
<P>Several electronic databases were used to compile relevant published RCTs of antibiotic treatment of AOM in children. The Cochrane Controlled Trials Register, MEDLINE and Current Contents were searched from 1966 to January 2000 by an expert librarian in conjunction with one researcher, using combinations of "OTITIS MEDIA" and a search strategy described by (<LINK REF="REF-Dickersin-1994" TYPE="REFERENCE">Dickersin 1994</LINK>) for optimally identifying controlled trials. In addition, titles in Index Medicus were checked from 1958 to 1965. The references of all relevant retrieved trials were checked to identify other articles.</P>
<P>The search was updated in March 2003, and again in July 2008. We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I>, 2008, Issue 2), which contains the ARI Group's Specialized Register; MEDLINE (1966 to June week 4 2008); OLDMEDLINE (1958 to 1965); EMBASE (January 1990 to July 2008); and Current Contents (1966 to July 2008). The bibliographies of relevant articles were checked. A forward search of relevant articles was conducted in Web of Science®.</P>
<P>The following search strategy was run on MEDLINE (Ovid) combined with terms from Phase 1 and 2 of the Cochrane highly sensitive search strategy for identifying reports of RCTs (<LINK REF="REF-Lefebvre-2011" TYPE="REFERENCE">Lefebvre 2011</LINK>). Modified terms were used to search the other databases:</P>
<SUBSECTION>
<HEADING LEVEL="4">MEDLINE (Ovid)</HEADING>
<P>#1 exp Otitis Media/<BR/>#2 exp Otitis Media with Effusion/<BR/>#3 exp Otitis Media, Suppurative/<BR/>#4 glue ear.mp.<BR/>#5 otitis media.mp.<BR/>#6 OME.mp.<BR/>#7 AOM.mp.<BR/>#8 #1 or #2 or #3 or #4 or #5 or #6 or #7<BR/>#9 exp Anti-Bacterial Agents/<BR/>#10 exp Drug Therapy/<BR/>#11 exp Anti-Infective Agents/<BR/>#12 antibiotic$.mp.<BR/>#13 #9 or #10 or #11 or #12<BR/>#14 #8 and #13</P>
<P>There were no language or publication restrictions.</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2014-11-11 16:19:23 +1000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2014-11-11 16:18:37 +1000" MODIFIED_BY="[Empty name]">MEDLINE (Ovid) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-11-11 16:18:59 +1000" MODIFIED_BY="[Empty name]">
<P>1 exp Otitis Media/<BR/>2 otitis media.tw.<BR/>3 glue ear*.tw.<BR/>4 (middle ear adj5 (infect* or inflam*)).tw.<BR/>5 (ome or aom).tw.<BR/>6 or/1-5<BR/>7 exp Anti-Bacterial Agents/<BR/>8 Drug Therapy/<BR/>9 Anti-Infective Agents/<BR/>10 antibiotic*.tw.<BR/>11 antibacterial*.tw.<BR/>12 exp Ampicillin/<BR/>13 exp Cephalosporins/<BR/>14 exp Macrolides/<BR/>15 exp Penicillins/<BR/>16 (ampicillin* or cephalosporin* or macrolide* or penicillin* or amoxicillin* or amoxycillin* or cefdinir or cefpodoxime or cefuroxime or azithromycin or clarithromycin or erythromycin*).tw,nm.<BR/>17 or/7-16<BR/>18 6 and 17</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2014-11-11 16:19:23 +1000" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2011-01-25 12:13:12 +1000" MODIFIED_BY="[Empty name]">Embase.com search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-11-08 13:16:38 +1000" MODIFIED_BY="[Empty name]">
<P>18 #14 AND #17 <BR/>17 #15 OR #16 <BR/>16 random*:ab,ti OR placebo*:ab,ti OR factorial*:ab,ti OR crossover*:ab,ti OR 'cross-over':ab,ti OR 'cross over':ab,ti OR volunteer*:ab,ti OR assign*:ab,ti OR allocat*:ab,ti <BR/>15 'randomized controlled trial'/exp OR 'single blind procedure'/exp OR 'double blind procedure'/exp OR 'crossover procedure'/exp <BR/>14 #4 AND #13 <BR/>13 #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 <BR/>12 ampicillin*:ab,ti OR cephalosporin*:ab,ti OR macrolide*:ab,ti OR penicillin*:ab,ti OR amoxycillin*:ab,ti OR amoxicillin*:ab,ti OR cefdinir*:ab,ti OR cefpodoxime*:ab,ti OR cefuroxime*:ab,ti OR<BR/>azithromycin*:ab,ti OR clarithromycin*:ab,ti OR erythromycin*:ab,ti <BR/>11 'penicillin g'/exp <BR/>10 'macrolide'/exp <BR/>9 'cephalosporin derivative'/exp <BR/>8 'ampicillin'/exp <BR/>7 antibiotic*:ab,ti OR antibacterial*:ab,ti <BR/>6 'drug therapy'/de OR 'antiinfective agent'/de <BR/>5 'antibiotic agent'/exp <BR/>4 #1 OR #2 OR #3 <BR/>3 ('middle ear' NEAR/5 (inflam* OR infect*)):ab,ti <BR/>2 'otitis media':ab,ti OR 'glue ear':ab,ti OR 'glue ears':ab,ti OR ome:ab,ti OR aom:ab,ti <BR/>1 'otitis media'/exp </P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2014-11-11 16:19:20 +1000" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2011-01-25 12:18:35 +1000" MODIFIED_BY="[Empty name]">Current Contents search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-11-08 13:14:47 +1000" MODIFIED_BY="[Empty name]">
<TABLE COLS="3" ROWS="5">
<TR>
<TD VALIGN="TOP">
<P># 3</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=CCC&amp;doc=1&amp;qid=3&amp;SID=P24KlCB8gCi1HLCJik8&amp;search_mode=CombineSearches">578</A>
 
</P>
</TD>
<TD VALIGN="TOP">
<P>#2 AND #1</P>
<P>
<I>Databases=CM, LS Timespan=All Years</I>
</P>
<P>
<I>Lemmatization=On   </I>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P># 2</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=CCC&amp;doc=1&amp;qid=2&amp;SID=P24KlCB8gCi1HLCJik8&amp;search_mode=GeneralSearch">528,401</A>
 
</P>
</TD>
<TD VALIGN="TOP">
<P>Topic=(random* or placebo* or crossover* or "cross over" or allocat* or ((doubl* or singl*) NEAR/1 blind*)) OR Title=(trial)</P>
<P>
<I>Databases=CM, LS Timespan=All Years</I>
</P>
<P>
<I>Lemmatization=On   </I>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P># 1</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=CCC&amp;doc=1&amp;qid=1&amp;SID=P24KlCB8gCi1HLCJik8&amp;search_mode=GeneralSearch">2,624</A>
 
</P>
</TD>
<TD VALIGN="TOP">
<P>Topic=(otitis or "glue ear" or ("middle ear" NEAR/3 (infect* or inflam*)) or ome or aom) AND Topic=(antibiotic* or antibacterial* or antiinfective* or ampicillin* or cephalosporin* or macrolide* or amoxicillin* or amoxycillin* or penicillin* or cefdinir* or cefpodoxime* or cefuroxime* or azithromycin* or clarithromycin* or erythromycin*)</P>
<P>
<I>Databases=CM, LS Timespan=All Years</I>
</P>
<P>
<I>Lemmatization=On   </I>
</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2014-11-11 16:19:17 +1000" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2011-01-25 12:19:41 +1000" MODIFIED_BY="[Empty name]">CINAHL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2011-01-25 12:23:44 +1000" MODIFIED_BY="[Empty name]">
<P>S30 S19 and S29 <BR/>S29 S20 or S21 or S22 or S23 or S24 or S25 or S26 or S27 or S28 <BR/>S28 (MH "Quantitative Studies") <BR/>S27 TI placebo* or AB placebo* <BR/>S26 (MH "Placebos") <BR/>S25 TI random* or AB random* <BR/>S24 (MH "Random Assignment") <BR/>S23 TI (singl* blind* or doubl* blind* or tripl* blind* or trebl* blind* or singl* mask* or doubl* mask* or tripl* mask* or trebl* mask*) or AB (singl* blind* or doubl* blind* or tripl* blind* or trebl* blind* or singl* mask* or doubl* mask* or tripl* mask* or trebl* mask*) <BR/>S22 TI clinic* N1 trial* or AB clinic* N1 trial* <BR/>S21 PT clinical trial <BR/>S20 (MH "Clinical Trials+") <BR/>S19 S7 and S18 <BR/>S18 S8 or S9 or S10 or S11 or S12 or S13 or S14 or S15 or S16 or S17<BR/>S17 TI ( ampicillin* or cephalosporin* or macrolide* or amoxicillin* or amoxycillin* or penicillin* or cefdinir* or cefpodoxime* or cefuroxime* or azithromycin* or clarithromycin* or erythromycin* ) or AB ( ampicillin* or cephalosporin* or macrolide* or amoxicillin* or amoxycillin* or penicillin* or cefdinir* or cefpodoxime* or cefuroxime* or azithromycin* or clarithromycin* or erythromycin* ) <BR/>S16 (MH "Penicillins+") <BR/>S15 (MH "Antibiotics, Macrolide+") <BR/>S14 (MH "Cephalosporins+") <BR/>S13 (MH "Ampicillin+") <BR/>S12 TI antibacterial* or AB antibacterial* <BR/>S11 TI antibiotic* or AB antibiotic* <BR/>S10 (MH "Antiinfective Agents") <BR/>S9 (MH "Drug Therapy") <BR/>S8 (MH "Antibiotics+") <BR/>S7 S1 or S2 or S3 or S4 or S5 or S6 <BR/>S6 TI ( aom or ome ) or AB ( aom or ome ) <BR/>S5 TI middle ear inflam* or AB middle ear inflam* <BR/>S4 TI middle ear infect* or AB middle ear infect* <BR/>S3 AB glue ear* or TI glue ear* <BR/>S2 TI otitis media or AB otitis media <BR/>S1 (MH "Otitis Media+") <BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2014-11-11 16:19:14 +1000" MODIFIED_BY="[Empty name]" NO="6">
<TITLE MODIFIED="2011-01-25 12:24:23 +1000" MODIFIED_BY="[Empty name]">LILACS search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-02-22 12:37:19 +1000" MODIFIED_BY="[Empty name]">
<P>&gt; Search &gt; (MH:"otitis media" OR "otitis media" OR "Otite Média" OR MH:C09.218.705.633$) AND (MH:"Anti-Bacterial Agents" OR antibiotic$ OR Antibacterianos OR Antibióticos OR MH:"Drug Therapy" OR Quimioterapia OR "Terapia por Drogas" OR Farmacoterapia OR MH:"Anti-Infective Agents" OR Antiinfecciosos OR MH:ampicillin OR Ampicilina OR ampicillin$ OR MH:D02.065.589.099.750.750.050$ OR MH:D02.886.108.750.750.050$ OR MH:D03.438.460.825.750.050$ OR MH:D03.605.084.737.750.050$ OR D04.075.080.875.099.221.750.750.050$ OR MH:cephalosporins OR cephalosporin$ OR Cefalosporinas OR MH:D02.065.589.099.249$ OR D02.886.665.074$ OR D04.075.080.875.099.221.249$ OR MH:macrolides OR macrolide$ OR Macrólidos OR Macrolídeos OR D02.540.505$ OR D02.540.576.500$ OR D04.345.674.500$ OR MH:penicillins OR penicillin$ OR Penicilinas OR MH:D02.065.589.099.750$ OR D02.886.108.750$ OR D03.438.260.825$ OR D03.605.084.737$ OR D04.075.080.875.099.221.750$ OR amoxicillin$ OR Amoxicilina OR cefdinir OR cefpodoxim$ OR cefuroxim$ OR azithromycin$ OR Azitromicina OR clarithromycin$ OR Claritromicina OR erythromycin OR Eritromicina) &gt; clinical_trials</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>